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Introduction
The lifespan of an organism is determined by a complex network of environmental-, genetic- 
and stochastic factors. Each of these components contributes to the wide variability in lifespan 
between and within species. In recent years, a central question has been to what extent the vari-
ability in human life span is related to genetic differences and whether there are common genetic 
determinants that influence lifespan. To date, we know that 20-30 % of the overall variation in 
human lifespan is accounted for by genetic factors, which become increasingly important for 
survival at oldest ages (Herskind et al., 1996; Mitchell et al., 2001; vB et al., 2006). In addition, a 
number of candidate genes have arisen for the study of longevity in humans, of which the major-
ity has emerged from studies with model organisms.
The most commonly studied model organisms are the budding yeast Saccharomyces cerevisiae, 
the nematode worm Caenorhabditis elegans, the fruit fly Drosophila melanogaster and the house mouse 
Mus musculus. These organisms have many advantages for ageing studies, most notably their 
relatively short life spans, well-characterized biology and completely sequenced genomes, which 
have allowed rapid progress in the discovery of pathways underlying longevity. The first pathway 
that was identified was the evolutionarily conserved insulin/IGF1-like signal (IIS) transduction 
pathway. In C. elegans, mutations in the daf-2 and age-1 genes, which are related to the mamma-
lian insulin receptor and to the catalytic subunit of phosphatidylinositol-3-kinase (PI-3-kinase), 
respectively, both lead to increased lifespan (Friedman and Johnson, 1988; Kenyon et al., 1993; 
Larsen et al., 1995; Morris et al., 1996). In following studies, similar effects were observed for 
other genes in the IIS pathway and in other pathways involved in metabolic- and physiologic 
processes, that regulate stress resistance, fertility and genomic maintenance (Christensen et al., 
2006; Vijg and Suh, 2005). These findings have provided evidence that individual genes can have 
major effects on lifespan, but it is largely unknown whether the same genes and processes are 
also important for the observed variation in human life span. Human genes homologous to the 
longevity genes identified in model organisms represent relevant candidate genes for the study 
of longevity in humans. 
In addition to the longevity genes identified in model organisms, other candidate genes can 
de deduced from the biology of human ageing and lifespan. A consistent feature of environmen-
tal and genetic factors that influence lifespan is their influence on stress resistance. Most types of 
stressors are perceived first by the nervous system and the responses of the whole body to such 
stressors are coordinated by the brain. In humans, the ability to cope with stress and maintain a 
good mental performance are essential for a long life. Therefore, genes involved in both central 
nervous system- and peripheral stress responses may play important roles in lifespan determi-
nation (Mattson et al., 2002). Yet another set of candidate genes can be derived from human 
premature ageing syndromes, such as Hutchinson-Gilford syndrome, Werner syndrome, Bloom 
syndrome, Cockayne’s syndrome and Xeroderma pigmentosum. It is unknown whether subtle 
variations in these genes influence ageing in the population at large. Taken together, different 
approaches have yielded a number of candidate longevity genes that await testing in humans. 
Understanding the role of specific genetic factors in the variation of lifespan among humans is 
central to the understanding of human ageing and lifespan, including exceptional longevity. 
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The candidate longevity genes 
Daf-16 - forkhead transcription factors
The main downstream target of the IIS pathway is the transcription factor dauer 
formation -16 (daf-16), which regulates the expression of numerous downstream genes that me-
diate stress resistance, innate immunity and metabolic processes (McElwee et al., 2003; Mur-
phy et al., 2003). In C. elegans, increased activity of Daf-16 has been associated with increased 
lifespan (Kenyon et al., 1993; Kimura et al., 1997). In contrast, mutations in the daf-16 gene 
have been shown to suppress the life-extending effects of decreased insulin signaling (Lin et 
al., 1997). These data indicate that daf-16 is negatively regulated by insulin signaling and is the 
major downstream effector of the IIS pathway. In mammals, the daf-16 gene homologues are 
forkhead/winged-helix transcription factors (FOXOs) of which to date, four different family 
members have been identified: FOXO1a, FOXO3a, FOXO4 and FOXO6 (Anderson et al., 1998; 
Biggs et al., 2001; Jacobs et al., 2003). From these, cellular functions have been described best 
for FOXO1a and FOXO3a. Both of these genes are involved in a variety of cellular processes, in-
cluding metabolism, cell differentiation, cell cycle arrest and DNA repair. In addition, FOXO1a 
has been specifically implicated in mediating the effects of insulin on hepatic glucose produc-
tion (Altomonte et al., 2003; Barthel et al., 2005; Nakae et al., 2002) while FOXO3a has been 
specifically implicated in female fertility through suppression of follicular activation (Castrillon 
et al., 2003). 
Daf-12 -  liver X receptors and vitamin D receptor
Dauer formation-12 (Daf-12) gene belongs to the nuclear hormone receptor (NHR) super-
family, a large and diverse family of transcription factors (Laudet,  1997), and it has been placed 
at the convergence of several signal transduction pathways, including the IIS pathway. Similar 
to other Daf proteins in C. elegans, Daf-12 regulates dauer diapause, developmental timing and 
metabolism in response to environmental signals (Rottiers and Antebi, 2006). Mutations in the 
daf-12 gene can result in dauer defective or dauer constitutive worms, which are short- and long-
lived, respectively. In addition, it has been shown that the long-lived phenotype of germline-
ablated worms depends, besides on daf-16, also on daf-12 (Hsin and Kenyon, 1999). In humans, 
the closest daf-12 homologues are the liver X receptors (LXRA and LXRB) and the vitamin 
D receptor (VDR) (Mooijaart et al., 2005). These genes belong to NHR super-family, but have 
distinct functions. The LXRs are mainly involved in lipid metabolism and -transport  (Peet et 
al., 1998; Tontonoz and Mangelsdorf, 2003), whereas the VDR is involved in diverse functions 
that include bone metabolism, cellular proliferation and differentiation, immunomodulation 
and neuroprotection (Lin and White, 2004). 
Sir2 - sirtuins
The Sirtuins represent an evolutionarily conserved family of Silent Information Regulator 2 
(Sir2) NAD-dependent protein deacetylases that interact with and influence the activity of vari-
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ous transcription factors and co-regulators (Bordone and Guarente, 2005). Increased expres-
sion of the Sir2 gene, either due to an extra copy of the gene or to caloric restriction, has been 
shown to prolong lifespan in various model organisms (Kaeberlein et al., 1999; Tissenbaum and 
Guarente, 2001; Wood et al., 2004). In mammals, there are seven Sir2 homologues (SIRT1-7 ), of 
which SIRT1 is the most closely related to Sir2 (Frye,  2000). Studies with mouse models have 
shown that in response to environmental signals, SIRT1 regulates glucose and fat metabolism, 
stress resistance and cell survival (Bordone and Guarente, 2005; Cohen et al., 2004; Picard et 
al., 2004; Yang et al., 2006). Some of the target genes through which SIRT1 exerts these effects 
include the FOXOs, p53 and PPAR-gamma (Leibiger and Berggren, 2006). 
Mineralocorticoid- and glucocorticoid receptor
The mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) genes, which belong 
to the NHR family, and are activated by cortisol to regulate metabolism, inflammation, and im-
munity (Meijer et al., 2006). Cortisol is the primary active stress hormone that mediates counter-
responses to stress, aimed to re-establish homeostasis and coordinate behavioral adaptations (de 
Kloet et al., 2005). By targeting many genes through the MR and GR, cortisol functions in a 
binary fashion, and serves as a master switch in the control of neuronal and network responses 
that underlie behavioral adaptation. Various studies have shown that stress-responsiveness is 
highly variable among human subjects, and an inadequate stress-response increases vulnerability 
for disease. Changes in the stress hormone system have been shown to play a role in cognitive 
impairment (Lupien et al., 2005) and in the development of depression (Belanoff et al., 2001; 
Holsboer,  2000). The ability to cope with stress and maintain a good mental performance are 
essential for a long life, which place the MR and GR genes on the list of candidate genes impor-
tant for human longevity. 
WRN
The WRN gene encodes a nuclear protein with both helicase and exonuclease activities (Liu 
et al., 1999; Morozov et al., 1997; Mushegian et al., 1997). The WRN protein is capable of a mul-
titude of functions and is involved in DNA replication, repair, recombination, transcription and/
or a combination of these events. Loss-of function mutations in the WRN gene lead to Werner 
syndrome (WS), which is a segmental progeroid disorder with an autosomal recessive pattern of 
inheritance. Patients with WS exhibit a number of symptoms that resemble premature ageing. 
Characteristic clinical features of the syndrome include diabetes, osteoporosis, vascular diseases 
and a high incidence of malignant neoplasms (Martin, 1978; Salk,  1982). Since mutations in the 
WRN gene lead to accelerated ageing, it has been reasoned that common polymorphism in the 
WRN gene could contribute to the differences in the prevalence of disease and lifespan in the 
general population.
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Candidate-gene-based association studies 
Candidate-gene-based association studies assess correlations between genetic variants in the 
candidate gene and differences in the trait of interest on a population scale. In analyzing the role 
of a candidate gene in humans, the association between DNA variants in, around and nearby 
the candidate gene and the trait of interest are analyzed. The DNA variants investigated most 
often are single nucleotide polymorphisms (SNPs). Until recently, there were relatively few SNPs 
available for study, but advances in the past two decades have identified millions of such poly-
morphisms. The availability of a large number of SNPs in public databases has facilitates the 
selection of genetic variants for association studies. There are two approaches that can be used 
for the identification of DNA variants related to the phenotype of interest: the direct- and the 
indirect association approach (Figure 1) (Carlson et al., 2004; Cordell and Clayton, 2005). 
Direct association studies make use of polymorphisms which are themselves putative causal 
variants (Carlson et al., 2004; Cordell and Clayton, 2005). This type of study is the easiest to ana-
lyze and the most powerful, but its difficulty is the identification of candidate polymorphisms. A 
mutation in a codon, which leads to an aminoacid change, is a candidate causal variant. However, 
it is likely that many causal variants responsible for heritability of common complex disorders 
will be non-coding. For example, such variants may cause variation in gene regulation and ex-
pression, or differential splicing. The exponential increase in annotation of common variants 
has generated a catalog of variants of which we know nothing about the function for the vast 
majority. Thus, for the direct association approach prior knowledge of functionality of the SNPs 
has to be first gained through functional studies. 
The second, indirect approach, does not rely on the functionality of the polymorphisms but 
on linkage disequilibrium (LD) between a disease susceptibility allele and either a single marker 
allele or a multilocus haplotype (Carlson et al., 2004; Cordell and Clayton, 2005; Newton-Cheh 
and Hirschhorn, 2005). Several polymorphisms are commonly selected from a candidate gene 
and the polymorphisms under study serve as surrogates for the causal locus. Much recent meth-
Figure 1. The direct- and indirect association approach 
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odological work has been conducted to optimize this indirect approach, including the investi-
gation of haplotype-block structure and techniques for selecting haplotype-tagging SNPs. The 
systematization of the indirect approach is the aim of the HapMap Project (The International 
HapMap Consortium, 2005). In this thesis, both the direct- and indirect association strategies 
were used. 
The Leiden 85-plus Study
All studies presented in this thesis were performed within the Leiden 85-plus Study. The 
Leiden 85-plus Study is a prospective population-based study, in which all 85 year old or older 
inhabitants of the city Leiden, The Netherlands, were invited to take part. The study popula-
tion consists of two cohorts, cohort ’87 and ’97. The Medical Ethical Committee of the Leiden 
University Medical Centre approved the study.
Cohort ‘87
On December 1, 1986, the community of Leiden in the Netherlands had 105 000 inhabitants, 
of whom 1258 (1.2 %) were 85 years and older. Among these oldest old, a population-based 
prospective follow-up study was initiated to assess the association of HLA antigens with human 
lifespan (Izaks et al., 1997; Lagaay et al., 1992). During an assessment, which lasted from Decem-
ber 1986 to March 1989, 221 participants died before they could be visited. From the remaining 
1037 people, 977 (94 %) agreed to participate in study (Weverling-Rijnsburger et al., 1997). All 
participants were interviewed at their place of residence by an internist experienced in geriatric 
medicine. After oral informed consent was obtained, a Mini-Mental State Examination (MMSE) 
and General Health Questionnaire (GHQ-12) were administered to detect cognitive impair-
ment. The Dutch version of the Geriatric Mental State Schedule (GMS) was used to diagnose 
psychiatric disorders according to Diagnostic and Statistical Manual of Mental Disorders III 
(DSM-III) criteria. A complete medical history was taken with special emphasis on cardiovascu-
lar disease, diabetes mellitus, and other chronic disorders together with information about the 
living situation and demography. When it was not possible to get reliable information from the 
participant, a family member or a caretaker was asked to provide the information. In addition, 
diastolic- and systolic blood pressure, and glucose levels were measured. Blood samples were 
taken at their homes, according to predefined protocols under non-fasting conditions. After 
isolation of the leucocytes for HLA typing, which was the primary goal of the study, the remain-
ing serum was available for other laboratory measurements. For DNA extraction, sufficient cell 
material was available for 682 participants. 
Cohort ‘97
Between September 1997 and September 1999, 705 inhabitants of the city Leiden, in The 
Netherlands, reached the age of 85 years, and in the month after their 85th birthday, they were 
asked to participate in the Leiden 85-plus Study. Of the 705 eligible subjects 14 died before they 
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could be enrolled and 92 refused to participate, resulting in a cohort of 599 subjects (85 %) who 
were enrolled (der Wiel et al., 2002). All the study participants were visited at their place of resi-
dence, where face-to-face interviews were conducted, cognitive testing was performed, and a ve-
nous blood sample was drawn. Of the 599 participants, a venous blood sample was available for 
563 participants. During the main interview with participants, global cognitive function was as-
sessed with the Mini-Mental State Examination (MMSE), attention with the Stroop Test (Klein 
et al., 1997), processing speed with the Letter Digit Coding Test (LDT) (Houx et al., 2002), and 
memory with the 12-Word Learning Test, which assesses immediate recall (WLTI) and delayed 
recall (WLTD)(Brand and Jolles, 1985). The prevalence of depressive symptoms was assessed 
with the 15-item Geriatric Depression Scale (GDS-15) (De Craen et al., 2003). All participants 
were visited annually for re-measurement of cognitive functioning and depressive symptoms 
during a mean follow-up period of 4.2 years. For all subjects socio-demographic characteristics 
such as gender, marital state, and type of housing were available from the municipal registry. 
Informed consent was obtained from all participants, or in case of severe cognitive impairment, 
from their guardian. 
Follow-up of mortality
All participants of the cohort ’87 and ’97 were followed for mortality until August 1 2005. 
Primary causes of death were obtained from the Dutch Central Bureau of Statistics and cat-
egorized according to the 10th International Classification of Diseases (ICD-10). At the date of 
censoring, August 1 2005, 681 (99 %) participants of the cohort ’87 and 320 (57 %) participants 
of the cohort ’97 had died. The most frequent primary cause of death in the participants of the 
Leiden 85-plus Study was death due to cardiovascular diseases (Table 1), as is the case in the 
general population. 
Table 1. The causes of death in the Leiden 85-plus Study
The Leiden 85-plus Study
Cohort ‘87
(n=682)
Cohort ‘97
(n=563)
Combined
(n=1245)
All-cause mortality* 681 (99 %) 320 (57 %) 1001 (80 %)
CVD 277 (40 %) 129 (40 %) 406 (41 %)
Cancer 101 (15 %) 61 (19 %) 162 (16 %)
Infectious disease 65 (10 %) 20 (6 %) 85 (8 %)
Other 237 (35 %) 109(34 %) 346 (35 %)
*A cause of death could not be obtained for one participant from both cohort ’87 and cohort ’97; CVD – cardiovascular disease
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Outline of the thesis 
The general objective of the thesis was to test the impact of the most prominent longevity 
candidate genes on the prevalence of age-related diseases and lifespan in a population-based 
prospective study of the oldest old. The thesis consists of ten chapters, of which in chapter 1 a 
general introduction to the thesis is given. In the following chapters, the effect of genetic vari-
ance in the evolutionarily conserved genes FOXO1 and FOXO3a (chapter 2), LXR (chapter 3), 
VDR (chapter 4) and SIRT1 (chapter 5) on the prevalence of age-related diseases and lifespan 
was examined. In chapter 6, the influence of cortisol levels and of polymorphisms in the min-
eralocorticoid receptor (MR) and glucocorticoid receptor (GR) genes on mental performance 
and on the prevalence of depressive symptoms in old age was assessed. The influence of poly-
morphisms in the GR gene and in the WRN gene on the prevalence of age-related diseases and 
lifespan were studied in chapter 7 and in chapter 8, respectively. In chapter 9, the results are 
summarized and discussed, and the main conclusions are drawn. The last chapter of the thesis, 
chapter 10, contains a summary in Dutch of the thesis. 
The research presented in this thesis was carried out within the framework of an “Innovative 
Oriented Research” (IOP) project entitled “Genetic determinants of longevity and disease in old 
age”, subsidized by the Dutch Ministry of Economic Affairs (grant number IGE010114). This 
project brought together medical doctors, evolutionary biologist, geneticists and bioinformati-
cians with the aim to identify mechanisms that determine longevity and disease in old age. In 
addition there was tight collaboration with industrial partners to maximize the opportunity to 
generate knowledge with the potential to exploite commercially.
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Abstract
Recently, the Daf-16 gene has been shown to regulate the lifespan of nematodes and flies. In 
mammals, Daf-16 homologues are forkhead (FOXO) transcription factors, of which specific 
functions have been identified for FOXO1a and FOXO3a. Despite that, their influence on hu-
man age-related trajectories and lifespan is unknown. Here, we analyzed the effect of genetic 
variance in FOXO1a and FOXO3a on metabolic profile, age-related diseases, fertility, fecundity 
and mortality. This study was carried out in the prospective population-based Leiden 85-plus 
Study, which includes 1245 participants, aged 85 years or more. The mean follow-up time was 
4.4 years. Haplotype analyses of FOXO1a revealed that carriers of haplotype 3 ‘TCA’ have higher 
HbA1c levels ( p=0.025) and a 1.14-fold higher all-cause mortality risk ( p=0.021). This increase 
in mortality was attributable to death from diabetes, for which a 2.43-fold increase was observed 
( p=0.025). The analyses with FOXO3a haplotypes revealed no differences in metabolic profile, 
fertility or fecundity. However, increased risks of stroke were observed for FOXO3a block-A 
haplotype 2 ‘GAGC’ ( p=0.007 ) and haplotype 4 ‘AAAT’ ( p=0.014) carriers. In addition, the 
haplotype 2 ‘GAGC’ carriers had a 1.13-fold increased risk for all-cause mortality ( p=0.036) 
and 1.19-fold increased risk for cardiovascular mortality ( p=0.052). In conclusion, this study 
shows that genetic variation in evolutionarily conserved FOXO1a and FOXO3a genes, influences 
lifespan in our study population.
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Introduction
Insulin signaling has emerged as a conserved mechanism that influences the lifespan of sev-
eral organisms (Guarente and Kenyon, 2000; Tatar et al., 2003). In Caenorhabditis elegans down-
regulation of the insulin/IGF-1 signalling (IIS) pathway activates Daf-16, and leads to increased 
lifespan (Ogg et al., 1997; Tissenbaum and Ruvkun, 1998). Among the genes regulated by Daf-16 
are those implicated in glucose and lipid metabolism, fertility, stress response and defense mech-
anisms (Murphy et al., 2003). In mammals, the main downstream targets of the IIS pathway are 
the forkhead box group O (FOXO) transcription factors, which are Daf-16 homologues (Lin 
et al., 1997). However, it remains to be elucidated whether FOXO proteins in mammals have a 
similar role as Daf-16 in C. elegans. 
In mammals, the FOXO family consists of FOXO1a, FOXO3a, FOXO4 and FOXO6. These 
genes are expressed in all tissues albeit at varying degrees, suggesting that their physiologi-
cal roles might be different (Anderson et al., 1998; Biggs et al., 2001; Furuyama et al., 2000). 
Distinct functions have been identified for FOXO1a and FOXO3a. Compared to other family 
members, FOXO1a seems to be the most important and functionally the most indispensable, as 
only the FOXO1a knock-out mice were not viable (Furuyama et al., 2004; Hosaka et al., 2004). 
It has been shown that FOXO1a predominantly mediates the effects of insulin on metabolism, 
including its effects on hepatic glucose production (Barthel et al., 2005). Mice over-expressing 
FOXO1a in liver and pancreatic β-cells have fasting hyperglycaemia and hepatic insulin resis-
tance leading to the development of diabetes in an age-dependent manner (Altomonte et al., 
2003; Nakae et al., 2002; Zhang et al., 2006). On the other hand, FOXO3a has been implicated 
in the suppression of follicular activation and thus in female fertility (Castrillon et al., 2003; 
Hosaka et al., 2004). These female FOXO3a knock-out mice also displayed signs of premature 
ageing. Reduced lifespan in reproductively active females has been noted for a variety of species 
over the years (Partridge et al., 2005). Hence, the phenotypes described above provide strong 
clues to the basic functions of FOXO1a and FOXO3a. Despite that, the role of FOXO proteins 
in humans has hardly been assessed. Recently, genetic variants in FOXO1a were associated 
with increased glucose levels and with a trend for early onset type-2 diabetes in a case-control 
study consisting of middle-aged participants (Karim et al., 2006). The influence of FOXO1a and 
FOXO3a on human lifespan has not been assessed yet. 
In this study, we analyzed the effect of genetic variance in FOXO1a and FOXO3a on meta-
bolic profile and mortality. In addition, associations with the prevalence of age-related diseases, 
fertility and fecundity were assessed. We used a haplotype-based approach, and the study was 
carried out in participants aged 85 years and older of the prospective population based Leiden 
85-plus Study.
Participants and methods
Participants
The Leiden 85-plus Study is a prospective population based study, in which inhabitants of 
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Leiden, The Netherlands, aged 85 years or above, were invited to take part. There were no selec-
tion criteria related to health or demographic characteristics. The study population consists of 
two cohorts, cohort ‘87 and ‘97. Cohort ‘87 includes 977 participants aged 85 years and older, 
enrolled between 1987 and 1989 (Weverling-Rijnsburger et al., 1997). Cohort ‘97 consists of 599 
subjects, all members of the 1912-1914 birth cohort, who were enrolled in the month of their 85th 
birthday between 1997 and 1999 (der Wiel et al., 2002). DNA was available for 682 participants 
from cohort ‘87 and for 563 people from cohort ‘97. All the participants of the Leiden 85-plus 
Study were followed for mortality until August 1, 2005. Primary causes of death were obtained 
from the Dutch Central Bureau of Statistics and categorized according to the 10th International 
Classification of Diseases (ICD-10). The Medical Ethical Committee of the Leiden University 
Medical Center approved the study and informed consent was obtained from all the participants. 
We also genotyped 370 blood donors from Leiden and surrounding areas (Heijmans et al., 1999), 
in order to compare allele and haplotype frequencies between the elderly and the young.
Metabolic profile and BMI at baseline in cohort ‘97
HbA1c (hemoglobin A1c), triglycerides, C-reactive protein (CRP) and high-density lipo-
protein (HDL)-cholesterol concentrations in serum were determined using fully automated 
analyzers (Hitachi 747 and 911; Hitachi, Ltd, Tokyo, Japan). Low-density lipoprotein (LDL)-
cholesterol was estimated with the Friedewald equation (Friedewald et al., 1972). Body weight 
(kg) and height (cm) were measured in all participants and body mass index (BMI, kg/m2) was 
calculated.
Diabetes and cardiovascular pathologies at baseline in cohort ‘97
Participants were classified as having diabetes when they met at least one of the following 
criteria: 1) history of diabetes obtained from the general practitioner or the subject’s treating 
physician; 2) use of sulfonylureas, biguanides, or insulin, based on information obtained from 
the subject’s pharmacist; or 3) nonfasting glucose of  11.1 mmol/l. The prevalence of and the 
number of cardiovascular pathologies were obtained from the participants’ general practitioners 
or nursing home physicians. In addition, electrocardiograms were recorded on a Siemens Siccard 
440 and transmitted by telephone to the ECG Core Lab in Glasgow for automated Minnesota 
coding (Macfarlane and Latif, 1996). Cardiovascular pathologies were classified as follows: myo-
cardial infarction, myocardial ischemia, intermittent claudication, arterial surgery and stroke 
(van Exel et al., 2002). 
Fertility and fecundity in the combined cohort
Birth dates of all the participants and their children, and the date(s) of marriage(s) were ob-
tained from the registry of births, deaths, and marriages of the municipality of Leiden and from 
the Central Bureau of Genealogy, The Netherlands. These participants were of childbearing age 
at a time of minimal fertility control for lack of modern contraceptive methods. Fertility and 
fecundity were assessed only in married female participants who were younger than 40 at the 
time of their marriage (n=701). Women older than 40 years at the time of their marriage were 
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excluded from further analyses owing to the rapid decline of fertility and fecundity that can be 
expected from that age onwards. Fertility was defined as by having children or not. Fecundity 
was defined as the calculated time interval between the date of the first marriage and the birth 
date of the firstborn child. To minimize the selection of pregnancies conceived before marriage, 
women whose children were born before marriage or within the first 36 weeks (250 days) of 
marriage were excluded from analyses (van Dunne et al., 2006).
SNP selection and genotyping
The single nucleotide polymorphisms (SNPs) from FOXO1a (GeneID 2308) and FOXO3a 
(GeneID 2309) were selected using the CEPH population (Utah residents with northern and 
western European ancestry) data from the International HapMap Project release no. 15 (The 
International HapMap Consortium,  2005). All polymorphisms were genotyped with matrix-as-
sisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS), using 
the Sequenom MassARRAYtm methodology (Sequenom Inc, San Diego, CA, USA). Amplifica-
tion reactions and parameters were based on the manufacturer’s instructions.
Statistical analysis
The program Haploview (Barrett et al., 2005) was used to estimate the allele frequencies of 
the polymorphisms, test for Hardy-Weinberg equilibrium and estimate pair-wise linkage dis-
equilibrium (LD) between the SNPs. Haplotypes and haplotype frequencies were calculated 
using SNPHAP software (http://www-gene.cimr.cam.ac.uk/clayton/software). Differences in allele 
and haplotype frequencies between the elderly and the young control group were tested using 
Fisher’s exact test. The posterior probabilities of pairs of haplotypes per subject, as estimated by 
the SNPHAP, were used as weights in all the analyses. The haplotype analyses approach used 
in this study assumes an additive effect of the haplotypes, and details of this approach have 
been described elsewhere (Wallenstein et al., 1998). Haplotypes with a frequency < 5 % were 
combined and included in the following analyses, without reporting the results. Continuous 
variables were normally distributed except for HbA1c, triglycerides and CRP levels, which were 
therefore ln-transformed. Associations between haplotypes and metabolic profiles were ana-
lyzed using a general linear model. Differences in the prevalence of cardiovascular pathologies, 
fertility and fecundity between haplotypes were tested using binary logistic regression. All-cause 
and cause-specific mortality risks with 95 % confidence intervals (CI) were calculated with Cox 
proportional hazard model, using left censoring to correct according to age for the delayed entry 
into the risk set. All analyses were sex adjusted, and clustered by the individual identification 
number to obtain robust standard errors. The common allele homozygote haplotype was used as 
the reference group. All the analyses were performed using STATA statistical software, version 
9.0 (StataCorp LP, TX, USA). 
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Results
Using HapMap data, we first examined the extent of LD in FOXO1a and FOXO3a. The poly-
morphisms of both genes were in LD (Figure 1a), which enabled us to select haplotype tagging 
SNPs (htSNPs) that would tag all haplotypes with frequencies > 1 %. From the FOXO1a gene 
three htSNPs that define one haplotype block, and from the FOXO3a gene nine htSNPs that 
define two haplotype blocks were chosen. In order to mark non-haploblock regions, one SNP 
from FOXO1a and two SNPs from FOXO3a were selected (Figure 1a).
The 1245 participants of the Leiden 85-plus Study and 370 young blood bank donors were 
genotyped for these polymorphisms. The genotype frequencies of the SNPs were in Hardy-
Weinberg equilibrium and similar between the two elderly cohorts and the young control group 
(Table 1). As expected, all the htSNPs were in strong LD and in FOXO1a gene they defined six 
haplotypes, of which four had frequencies > 5 % and described 99.6 % of the haplotype diversity 
(Figure 1b). In FOXO3a, the nine htSNPs defined two haplotype blocks. All five haplotypes in 
block-A and three haplotypes in block-B had frequencies > 5 % and described respectively 100 
% and 94.6 % of haplotype diversity (Figure 1b). The overall and individual haplotype frequen-
cies were not different between the elderly and young control group for neither of the genes 
(data not shown). 
Figure 1. FOXO1a and FOXO3a gene structure, LD and haplotypes. (a) Genomic structure of FOXO1a 
and FOXO3a genes, where exons are represented by black boxes, and introns and intragenic regions 
by lines. The long striped horizontal box indicates the extent of LD based on the Hapmap data. Long 
vertical lines show the relative position of the SNPs analyzed in this study; (b) Haplotypes  and their 
frequencies. For FOXO3a the lines between the block-A and block-B show the most common crossings 
from one block to the next, with thicker lines showing more common crossings than thinner lines. Be-
neath the crossing lines is shown the multilocus D’, which is a measure of the LD between the blocks. 
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The data on metabolic profile, BMI, prevalence of diabetes and cardiovascular diseases were 
available for 563 participants of the cohort ’97. Haplotype analyses of the FOXO1a gene revealed 
that carriers of haplotype 3 ‘TCA’ have 0.25 mmol/l higher HbA1c levels (95 % CI: 0.02-0.48, 
p=0.025) compared with the levels in the carriers of the most common haplotype 1 ‘CGA’ (Table 
2). In addition, haplotype 3 ‘TCA’ carriers had a trend for higher CRP levels and lower BMI 
(Table 2). Their risks for diabetes and myocardial infarction were also increased, although the 
association with diabetes was non-significant (OR 1.29, 95 % CI: 0.86-1.92, p=0.360) and the 
association with myocardial infarction just failed to reach significance (OR 1.41, 95 % CI: 1.00-
2.00, p=0.051) (Supplementary Table 1). No differences in metabolic profile, diabetes or cardio-
vascular diseases were observed for any other FOXO1a haplotype. 
FOXO1a haplotypes were also analyzed for association with histories of fertility and fecun-
dity in married women of the combined cohort (n=701). These analyses revealed no associations 
with FOXO1a haplotypes (Supplementary Table 2). 
Table 1. Demographic characteristics of the study participants, and minor allele frequencies of the FOXO1a 
and FOXO3a polymorphisms
Leiden 85-plus Study
Young controlCohort ‘87 Cohort ‘97
Number 682 563 370
Female (n, %) 491 (72 %) 375 (67 %) 220 (60 %)
Age (median, IQR) 89 (88-92) 85 (-) 32 (27-36)
FOXO1a1
rs2755209 (A/C) 0.385 0.398 0.376
rs2721069 (C/T) 0.321 0.310 0.292
rs4943794 (G/C) 0.229 0.218 0.181
rs7981045 (A/G) 0.229 0.263 0.260
FOXO3a1
rs9384680 (T/G) 0.029 0.039 0.036
rs9372190 (T/G) 0.072 0.087 0.074
rs2802288 (G/A) 0.365 0.341 0.354
rs2883881 (A/G) 0.073 0.087 0.069
rs12200646 (G/A) 0.113 0.109 0.128
rs13220810 (T/C) 0.291 0.290 0.271
rs12524491 (T/C) 0.300 0.270 0.290
rs3813498 (T/C) 0.193 0.163 0.171
rs9486913 (C/G) 0.166 0.136 0.142
rs7772662 (A/G) 0.104 0.103 0.116
rs2153960 (T/C) 0.293 0.262 0.281
IQR- interquartile range;  1minor allele frequencies. htSNPs are indicated in bold
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To study the role of FOXO1a further, we assessed the association between FOXO1a haplo-
types and mortality in 1245 participants of the combined cohort. During the mean follow-up 
time of 4.4 years, 1001 (80 %) of the participants had died. Of these deaths 406 (41 %) were due 
to cardiovascular causes, 162 (16 %) were due to cancer and 431 (43 %) owing to other causes. 
Causes of death could not be obtained for two participants. Mortality analyses dependent on 
FOXO1a haplotypes revealed that carriers of haplotype 3 ‘TCA’ had 1.14-fold increased all-cause 
mortality risks (95 % CI: 1.02-1.28, p=0.021) compared to the reference haplotype (Figure 2). 
This increase was not attributable to cardiovascular or cancer mortality, but to death from other 
causes (HR 1.28, 95 % CI: 1.09-1.51, p=0.002). This category also included death due to diabe-
tes (n=14), for which an association with haplotype 3 ‘TCA’ was observed (HR 2.43, 95 % CI: 
1.12-5.27, p=0.025). For the other FOXO1a haplotypes, no associations with all-cause or cause-
specific mortalities were found (Figure 2).
The analyses with FOXO3a haplotypes revealed no differences in the various parameters 
of the metabolic profile (Supplementary Table 3), fertility and fecundity (Supplementary Table 
4). In contrast, increased risks of stroke for haplotype 2 ‘GAGC’ (OR 1.92, 95 % CI: 1.19-
3.08, p=0.007 ), and for haplotype 4 ‘AAAT’ (OR 2.17, 95 % CI: 1.17-4.03, p=0.014) in FOXO3a 
block-A were observed (Table 3). In addition, the haplotype 2 ‘GAGC’ carriers had 1.13-fold in-
creased all-cause mortality (95 % CI; 1.01-1.26, p=0.036) and 1.19-fold increased cardiovascular 
mortality risks (HR 1.19, 95 % CI: 1.00-1.42, p=0.052) (Figure 3). There were no differences in 
cancer risk or in the risk from other causes of mortality in the FOXO3a haplotypes (Figure 3). 
All the above-mentioned analyses were also performed with the individual SNPs, which were 
selected to cover the non-haploblock regions of the FOXO1a and FOXO3a genes. None of these 
polymorphisms were associated with any of the phenotypes analyzed (data not shown). 
Table 2. Metabolic profile and BMI dependent on FOXO1a haplotypes in cohort ’97 (n=563)
FOXO1a
Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 4
Mean (95% CI) Dif (95% CI)1 p-value1 Dif (95% CI)1 p-value1 Dif (95% CI)1 p-value1
HbA1c 
(mmol/l)2 5.80 (5.61-5.98) -0.11  (-0.25-0.03) 0.185 +0.25 (0.02-0.48) 0.025* -0.05 (-0.24-0.14) 0.700
Triglycerides 
(mmol/l)2 1.57 (1.44-1.69) +0.07 (-0.04-0.17) 0.593 +0.09 (-0.03-0.21) 0.152 +0.04 -0.12-0.19) 0.816
CRP 
(mg/l)2 6.10 (2.99-9.21) +0.88 (-1.22-2.97) 0.803 +1.90 (-1.05-4.86) 0.070 1.56 (-2.34-5.46) 0.346
HDL 
(mmol/l) 1.42 (1.35-1.48) -0.01 (-0.06-0.04) 0.651 -0.04 (-0.10-0.01) 0.128 -0.06 (-0.13-0.01) 0.053
LDL 
(mmol/l) 3.71 (3.56-3.86) +0.12 (-0.01-0.25) 0.068 0.00 (-0.13-0.14) 0.971 +0.12 (-0.08-0.31) 0.245
BMI 
(kg/m2) 28.3 (27.5-29.1) -0.48 (1.10-0.15) 0.132 -0.57(-1.24-0.10) 0.094 -0.38 (-1.42-0.67) 0.478
HbA1c - hemoglobin A1c; CRP - C-reactive protein; HDL - high-density lipoprotein cholesterol; LDL - low-den-
sity lipoprotein cholesterol; BMI - body mass index; 1Difference compared to the most common haplotype 1; 
2Estimates presented for non-transformed and p-values for ln-transformed data; *p-value < 0.05
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Table 3. Risks of diabetes and cardiovascular disease (CVD
) dependent on FO
XO
3a haplotypes in cohort ’97 (n=563)
FO
XO
3a
Block-A
Block-B
H
aplotype 1
H
aplotype 2
H
aplotype 3
H
aplotype 4
H
aplotype 5
H
aplotype 1
H
aplotype 2
H
aplotype 3
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
D
iabetes (n=92)
1 (Ref)
1.07 (0.73-1.57)
0.93 (0.59-1.48)
1.03 (0.60-1.74)
1.18 (0.69-2.02)
1 (Ref)
0.85 (0.52-1.38)
0.83 (0.47-1.47)
CVD
 total (n=365)
1 (Ref)
1.15 (0.86-1.54)
1.09 (0.75-1.57)
1.04 (0.69-1.57)
1.38 (0.86-2.23)
1 (Ref)
1.02 (0.71-1.47)
0.88 (0.57-1.35)
M
yocardial infarction (n=137)
1 (Ref)
0.74 (0.52-1.06)
1.01 (0.67-1.52)
1.18 (0.74-1.86)
1.51 (0.94-2.40)
1 (Ref)
1.09 (0.73-1.62)
1.56 (0.98-2.49)
M
yocardial ischem
ia (n=286)
1 (Ref)
1.09 (0.82-1.45)
1.09 (0.76-1.55)
1.03 (0.69-1.55)
1.30 (0.84-2.02)
1 (Ref)
1.03 (0.73-1.46)
0.96 (0.63-1.47)
Interm
ittent claudication (n=36)
1 (Ref)
0.98 (0.56-1.73)
1.42 (0.82-2.47)
1.20 (0.50-2.85)
0.92 (0.32-2.67)
1 (Ref)
1.64 (0.92-2.90)
1.12 (0.41-3.01)
A
rterial surgery (n=37)
1 (Ref)
0.75 (0.41-1.36)
0.71 (0.37-1.36)
0.42 (0.16-1.11)
0.52 (0.20-1.37)
1 (Ref)
0.77 (0.38-1.55)
0.28 (0.07-1.14)
Stroke (n=57)
1 (Ref)
1.92 (1.19-3.08)*
1.14 (0.63-2.08)
2.17 (1.17-4.03)*
1.50 (0.72-3.12)
1 (Ref)
0.94 (0.53-1.65)
1.74 (0.95-3.18)
The m
ost com
m
on haplotype 1 w
as used as a reference group (Ref); *p-value < 0.05
Figure 2. FOXO1a, all-cause and cause-specific mortal-
ity. Mortality risks were calculated in the combined co-
hort (n=1245). Data are presented as hazard ratios (HR) 
with 95 % confidence intervals (CI). The most com-
mon haplotype 1 was used as a reference group (Ref); 
*p-value < 0.05 (see text)
Figure 3. FOXO3a, all-cause and cause-specific mortal-
ity. Mortality risks were calculated in the combined co-
hort (n=1245). Data are presented as hazard ratios (HR) 
with 95 % confidence intervals (CI). The most com-
mon haplotype 1 was used as a reference group (Ref); 
*p-value < 0.05 (see text)
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Discussion
In this study, we report for the first time associations between haplotypes in the evolution-
arily conserved FOXO1a and FOXO3a genes, and mortality in humans. For FOXO1a, haplotype 
3 ‘TCA’ was associated with higher HbA1c levels, with a trend for higher prevalence of diabetes 
and myocardial infarction, and increased mortality. Moreover, haplotype analyses of the FOX-
O3a gene revealed increased risks of stroke and mortality for haplotype 2 ’GAGC’ carriers.
FOXO transcription factors have emerged as candidate genes that are involved in lifespan 
regulation of various organisms. On the basis of the results from mouse models, it has been 
reasoned that FOXO1a influences mortality mainly by modifying the risks of diabetes (Barthel 
et al., 2005). In this study, we observed an association between FOXO1a haplotype 3 ‘TCA’ and 
HbA1c, which is the main risk factor for diabetes. In these haplotype carriers, the risks of dia-
betes and mortality were also increased. The observation that BMI was lower, suggests that the 
susceptibility to diabetes in these elderly participants was not influenced by body composition. 
In principle, all diabetes at old age is due to type-2 diabetes and is driven by insulin resistance 
and secondary exhaustion of the β-cell function. This implies that the FOXO1a transcription 
factors, which are normally downregulated by insulin signaling, are activated leading to in-
creased transcription of FOXO1a target genes. 
The role of FOXO1a in the development of diabetes has been previously assessed in a case-
control study consisting of middle-aged participants (Karim et al., 2006). In that study, haplo-
types in FOXO1a were associated with increased glucose levels, and with a trend for diabetes. 
In this study, we observed similar results, even though only one polymorphism was the same 
(rs2721069) between the studies. This difference in the analyzed polymorphisms might explain 
the stronger associations observed in this study. However, on the basis of the evidence from 
both the studies, we conclude that, in humans, FOXO1a may influence glucose metabolism 
and contribute to the predisposition to diabetes, leading to increased mortality. In contrast, we 
found no evidence for the FOXO1a involvement in female fertility and fecundity, which were 
respectively defined as the ability to have children, and the probability to conceive within a spe-
cific period of time (van Dunne et al., 2006).
The other FOXO transcription factor, FOXO3a, has been implicated in a variety of biological 
processes, including metabolism, fertility, stress response and ageing. In this study, we found no 
associations between FOXO3a haplotypes, human fertility and fecundity. In mouse models, the 
lack of FOXO3a resulted in an age-dependent decline of fertility in homozygous knockout mice, 
whereas heterozygous mice were indistinguishable from the wild-types (Hosaka et al., 2004). 
This suggests that mutations or severe disruptions of human FOXO3a might lead to phenotypes 
similar to those observed in mice. Similar to the results with fertility and fecundity, we found no 
association with metabolic profile and FOXO3a haplotypes. Despite that, carriers of haplotype 
2 ’GAGC’ in FOXO3a block-A, had increased risks of stroke, and increased mortality, which 
was partly attributable to increased cardiovascular mortality. The mechanisms through which 
FOXO3a influences the occurrence of stroke are unknown, but the involvement of FOXO3a in 
the mediation of oxidative stress responses (Lehtinen et al., 2006) might be a possibility. 
Several studies have implicated FOXO1a and FOXO3a in the development of tumors (Galili 
et al., 1993; Hillion et al., 1997). In addition, FOXO proteins have been shown to induce cell-
cycle arrest, DNA repair and apoptosis, thereby making them attractive candidates for tumor 
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suppression. The results of this study did not reveal any significant differences in the estimates 
of cancer mortality risk for the different FOXO1a and FOXO3a haplotypes. For FOXO1a, we 
expected opposite results, as predisposition to diabetes and protection against cancer have been 
associated with FOXO gain of function (Hu et al., 2004; Yang et al., 2005). 
The regulation of an organism’s lifespan is complex and depends not only on multiple genetic, 
epigenetic and environmental factors, but also on the interaction between them. In this study, 
we used a candidate gene approach, which relies on predicting the identity of the correct gene 
or genes, on the basis of biological hypothesis, or the location of the candidate within a previ-
ously determined region of linkage. This approach, however, will identify only a fraction of the 
genetic factors that contribute to the complex phenotype. A complementary approach would be 
a whole genome association study that surveys most of the genome for causal genetic variants. 
Such an approach could reveal valuable additional information on the genetic bases of human 
lifespan regulation.
The first strength of this study is the haplotype-tagging SNP approach, which most probably 
captured the common genetic variations present in both the genes. The FOXO1a haplotype 3 
‘TCA’ consists of intronic SNPs. This suggests that these SNPs might be in LD with a nearby 
functional polymorphism that drives the observed associations. Since the LD in the FOXO1a 
gene extends beyond 5’ UTR then the functional SNP hypothesized probably is located in the 
regulatory region. Therefore, in addition to replication, further studies are needed to pinpoint 
the location of the functional variant and to prove its influence on the FOXO1a function. Other 
strengths of the study were the possibility of estimating several intermediate phenotypes in one 
cohort, and the prospective analyses. The high prevalence of age-associated diseases and mor-
tality in this cohort excludes the possibility that this cohort consists of healthy survivors only. 
A limitation of the study concerns the reproductive data, which were acquired from registries; 
therefore all conception times and fecundity rates were calculated. In addition, taking into ac-
count the number of tests performed, adjustment for multiple testing would eliminate all the 
significant p-values observed.
In conclusion, the present study shows that human homologues of genes identified as influ-
encing the life spans of model organisms, have the same impact in humans. In this study, we 
observed biologically plausible influences of FOXO1a and FOXO3a haplotypes on age-related 
trajectories and mortality.
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Supplementary materials
Supplementary Table 1. Risks of diabetes and cardiovascular disease (CVD) dependent on FOXO1a haplo-
types in cohort ’97 (n=563)
FOXO1a
Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 4
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Diabetes  (n=92) 1 (Ref ) 0.68 (0.44-1.03) 1.29 (0.86-1.92) 1.01 (0.60-1.70)
CVD total (n=365) 1 (Ref ) 0.85 (0.63-1.16) 1.08 (0.78-1.50) 0.90 (0.60-1.36)
Myocardial infarction (n=137) 1 (Ref ) 0.88 (0.63-1.23) 1.41 (1.00-2.00)* 1.08 (0.69-1.70)
Myocardial ischemia (n=286) 1 (Ref ) 0.90 (0.68-1.20) 1.09 (0.80-1.48) 1.12 (0.75-1.66)
Intermittent claudication (n=36) 1 (Ref ) 1.03 (0.65-1.63) 0.94 (0.52-1.71) 0.91 (0.36-2.28)
Arterial surgery (n=37) 1 (Ref ) 0.95 (0.60-1.52) 0.59 (0.28-1.22) 1.61 (0.75-3.46)
Stroke (n=57) 1 (Ref ) 0.93 (0.60-1.44) 0.94 (0.58-1.51) 0.99 (0.52-1.88)
The most common haplotype 1 was used as a reference group (Ref ); *p-value < 0.05
Supplementary Table 2. Fertility and fecundity dependent on FOXO1a haplotypes in females of the combined 
cohort (n=701)
FOXO1a
Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 4
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Fertility (n=701) 1 (Ref ) 1.00 (0.66-1.51) 1.06 (0.70-1.62) 0.87 (0.51-1.49)
Fecundity (n=610)1
≤3 months 1 (Ref ) 1.29 (0.89-1.87) 1.03 (0.70-1.51) 1.38 (0.80-2.39)
≤6 months 1 (Ref ) 0.94 (0.66-1.32) 1.01 (0.71-1.45) 1.35 (0.83-2.20)
≤12 months 1 (Ref ) 1.18 (0.84-1.66) 1.07 (0.75-1.51) 1.28 (0.80-2.06)
1 Conception interval, calculated as the time interval between the date of marriage and the birth date of the firstborn child. 
The most common haplotype 1 was used as a reference group (Ref )
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Supplem
entary Table 3. M
etabolic profile and BM
I dependent on FO
XO
3a haplotypes in cohort ’97 (n=563)
FO
XO
3a
Block-A
Block-B
H
aplotype1
H
aplotype 2
H
aplotype 3
H
aplotype 4
H
aplotype 5
H
aplotype 1
H
aplotype 2
H
aplotype 3
M
ean (95%
 CI)
D
if. (95%
 CI)*
D
if. (95%
 CI)*
D
if. (95%
 CI)*
D
if. (95%
 CI)*
M
ean (95%
 CI)
D
if. (95%
 CI)*
D
if. (95%
 CI)*
H
bA
1c (m
m
ol/l)
5.81 (5.62-5.99)
+0.01 (-0.13-0.16)
0.00 (-0.23-0.23)
-0.05 (-0.25-0.15)
+0.17 (-0.09-0.44)
5.88 (5.73-6.02)
-0.09 (-0.26-0.07)-0.09 (-0.33-0.14)
Triglycerides (m
m
ol/l)
1.68 (1.52-1.84)
-0.02 (-0.14-0.10)
+0.02 (-0.12-0.16)
-0.06 (-0.20-0.08)
-0.07 (-0.24-0.10)
1.67 (1.56-1.78)
+0.02 (-0.12-0.16)-0.03 (-0.19-0.12)
CRP (m
g/l)
7.88 (4.13-11.6)
-0.72 (-3.68-2.23)
-1.52 (-4.36-1.32)
+2.58 (-2.17-7.33)
+0.16 (-4.31-4.63)
7.44 (5.41-9.46)
-1.39 (-3.59-0.81)+4.42 (-2.24-11.1)
H
D
L (m
m
ol/l)
1.36 (1.29-1.44)
+0.01 (-0.05-0.06)
+0.02 (-0.06-0.09)
0.00 (-0.08-0.07)
+0.04 (-0.05-0.12)
1.37 (1.32-1.42)
+0.01 (-0.06-0.09)+0.01 (-0.07-0.09)
LD
L (m
m
ol/l)
3.90 (3.72-4.09)
-0.11 (-0.24-0.03)
+0.02 (-0.15-0.20)
-0.11 (-0.31-0.08)
-0.12 (-0.33-0.09)
3.80 (3.68-3.92)
+0.04 (-0.14-0.21)-0.02 (-0.24-0.20)
H
bA
1c - hem
oglobin A
1c; CRP - C-reactive protein; H
D
L - high-density lipoprotein cholesterol; LD
L - low
-density lipoprotein cholesterol; BM
I - body m
ass index
*D
ifferences (D
if) com
pared to the m
ost com
m
on haplotype 1 
Supplem
entary Table 4. Fertility and fecundity dependent on FO
XO
3a haplotypes in fem
ales of the com
bined cohort (n=701)
FO
XO
3a
Block-A
Block-B
H
aplotype 1
H
aplotype 2
H
aplotype 3
H
aplotype 4
H
aplotype 5
H
aplotype 1
H
aplotype 2
H
aplotype 3
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
O
R (95 %
 CI)
Fertility (n=701)
1 (Ref)
1.25 (0.83-1.90)
0.88 (0.57-1.36)
1.18 (0.72-1.94)
1.09 (0.64-1.84)
1 (Ref)
0.89 (0.57-1.37)
1.00 (0.59-1.70)
Fecundity (n=610) 1
≤3 m
onths
1 (Ref)
0.95 (0.66-1.38)
0.77 (0.49-1.20)
1.06 (0.66-1.70)
1.13 (0.67-1.93)
1 (Ref)
0.82 (0.54-1.27)
1.03 (0.63-1.69)
≤6 m
onths
1 (Ref)
0.96 (0.69-1.32)
0.88 (0.58-1.33)
1.33 (0.86-2.06)
1.13 (0.70-1.82)
1 (Ref)
0.95 (0.63-1.42)
1.30 (0.82-2.05)
≤12 m
onths
1 (Ref)
1.06 (0.76-1.46)
0.99 (0.65-1.50)
1.19 (0.77-1.84)
1.27 (0.79-2.04)
1 (Ref)
1.03 (0.69-1.54)
1.11 (0.70-1.75)
1 Conception interval, calculated as the tim
e interval betw
een the date of m
arriage and the birth date of the firstborn child. The m
ost com
m
on haplotype 1 w
as used as a reference group (Ref)
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Abstract
In the nematode Caenorhabditis elegans, nuclear hormone receptor DAF-12 regulates the deci-
sion to go into a resistant dauer diapause, in which the worm exhibits a decreased rate of aging. 
Using sequence similarity searches, we previously identified the liver X receptor alpha (LXRA) 
as one of the human nuclear hormone receptors the protein sequence of which is most similar 
to C. elegans DAF-12. Here, we studied whether variation in the gene encoding LXRA associates 
with human life span. In the Leiden 85-plus Study, a population-based prospective follow-up 
study, we genotyped four polymorphisms spanning the gene coding for LXRA (NR1H3) and 
tagged four common haplotypes. Among 563 participants, haplotype 2 associated with reduced 
mortality during the 7-year follow-up (hazard ratio 0.78; p=0.015), predominantly caused by re-
duced mortality from infectious disease (hazard ratio 0.31; p=0.023). Haplotype 2 also associated 
with higher levels of plasma apolipoprotein E, a target gene of the LXRA ( p=0.018), and higher 
levels of triglycerides ( p=0.041). Genetic variation in the gene coding for the LXRA (NR1H3) 
associates with human lifespan. 
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Introduction
Human lifespan is under genetic control (Schoenmaker et al., 2006; vB et al., 2006), but only 
few specific genes modulating lifespan have been identified. In the nematode worm Caenorhab-
ditis elegans, DAF-12 is a nuclear hormone receptor (NHR) that in response to environmental 
cues regulates the entry into dauer diapause (Antebi et al., 1998). Under adverse environmental 
conditions, unliganded DAF-12 coordinately turns down essential traits—such as metabolism, 
feeding, and reproduction— making the worm more stress resistant and extending larval sur-
vival up to 5-fold (Klass and Hirsh, 1976), which suggests that during the diapause the worm 
ages at a lower rate. Genetic mutations in daf-12 can be either dauer defective or dauer constitu-
tive (Antebi et al., 2000) and, in parallel, can decrease or increase adult life span of C. elegans 
(Fisher and Lithgow, 2006). Using sequence similarity searches, we previously identified the liver 
X receptor alpha (LXRA) as one of the human NHRs the protein sequence of which is most 
similar to C. elegans DAF-12 (Mooijaart et al., 2005). However, nothing is known about the as-
sociation of genetic variants in the gene coding for the LXRA (NR1H3) with human lifespan. 
In humans, the LXRA is expressed in the liver, kidney, macrophages, astrocytes, and other 
tissues (Peet et al., 1998). Oxysterols are breakdown products of cholesterol and serve as ligands 
for the LXRA ( Janowski et al., 1999). Binding of ligands leads to the transcription of target 
genes that coordinately regulate various processes that together result in increased catabolism 
and excretion of cholesterol from the body (Lu et al., 2001; Repa et al., 2000). In humans, 
cholesterol is a major determinant of mortality in old age, especially from infectious disease 
(Weverling-Rijnsburger et al., 1997).The LXRA is also involved in innate immunity, as activa-
tion of human macrophages that produce cytokines is dependent on LXRA ( Joseph et al., 2003). 
In humans, cytokine production is a highly heritable characteristic (de Craen et al., 2005) and 
associates with diseases and mortality up to the highest age category (van den Biggelaar et al., 
2004a). These observations make the LXRA a candidate to affect human life span. 
To test the hypothesis that the LXRA is involved in modulating human lifespan, we made 
use of genetic variation in the gene coding for the LXRA (NR1H3). Out of the data that recently 
came available from the HapMap Project, we selected four evenly spaced haplotype-tagging sin-
gle nucleotide polymorphisms (SNPs) spanning the NR1H3 gene. In the Leiden 85-plus Study, 
a prospective population-based follow-up study of 563 elderly persons aged 85 years or older 
and onwards, we studied the association of the common haplotypes with survival during a mean 
follow-up period of almost 5 years. To further explore a potential role of the LXRA in biological 
mechanisms associated with modulation of human lifespan, we associated the genetic variation 
to mortality-related phenotypic markers.
Participants and methods
Participants
The Leiden 85-Plus Study is a prospective population-based study, in which inhabitants of 
Leiden, The Netherlands, aged 85 years, were invited to take part. There were no selection 
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criteria related to health or demographic characteristics. The study population consists of 599 
individuals (all members of the 1912–1914 birth cohort) who were enrolled in the month of their 
85th birthday between 1997 and 1999 (der Wiel et al., 2002). DNA was available for 563 people. 
The Medical Ethical Committee of the Leiden University Medical Center approved the study, 
and written informed consent was obtained from all participants.  
Causes of death 
All participants in the Leiden 85-plus Study were followed for mortality until August 1, 2005. 
Primary causes of death were obtained from death certificates registered at the Dutch Central 
Bureau of Statistics and categorized according to the 10th International Classification of Dis-
eases (ICD). Specific causes of death were categorized into cardiovascular disease (ICD codes 
I00–I99), infectious disease (ICD codes A00–B99 or J11–J18), cancer (ICD codes C00–D48), or 
other causes (all other ICD codes).  
Plasma measurements 
At baseline, participants were visited twice at their place of residence within 1 month after 
their 85th birthday. All blood samples were collected early in the morning, but fasting was not 
required. 
Plasma levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, 
and C-reactive protein (CRP) were analyzed on fully automated computerized analyzers (Hitachi 
747 and 911; Hitachi, Ltd, Tokyo, Japan). The level of low-density lipoprotein (LDL) cholesterol 
was estimated by the Friedewald equation (LDL cholesterol [mmol/L] ¼ total cholesterol – 
HDL cholesterol – [triglycerides/2.2]), whereby participants with a triglyceride concentration 
higher than 443 mg/dL (5 mmol/L) were excluded (n=5). 
Apolipoprotein E (ApoE) levels were determined in 2005 in one batch of plasma samples 
that were collected at age 85 years at study baseline and stored frozen. Plasma ApoE levels 
were determined using a human ApoE-specific sandwich enzyme-linked immunosorbent assay 
(ELISA) essentially as described (van Vlijmen et al., 1994). The detailed procedure is described 
in (Mooijaart et al., 2006).   
Cytokine production capacity of the innate immune system 
The cytokine production capacity of the innate immune system was assessed by stimulating 
ex vivo whole-blood samples with lipopolysaccharide (LPS) as described elsewhere (van der Lin-
den et al., 1998). In short, all venous blood samples were drawn in the morning before 11 AM 
to exclude circadian variation, diluted 2-fold with RPMI-1640, and stimulated with Escherichia 
coli–derived LPS (10 ng/mL; Difco Laboratories, Detroit, MI). After 4 hours and after 24 hours 
of incubation at 378 C0 and 5 % CO2, supernatants were collected and stored at -808 C
0 to mea-
sure tumor necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1b), IL-6, IL-10, IL-12, IL-1 
receptor antagonist (IL-1Ra), and interferon-gamma (IFN-c), respectively. Standard ELISA 
techniques were performed according to the manufacturer’s guidelines (Central Laboratory of 
the Blood Transfusion Service, Amsterdam, The Netherlands). Because of a possible distortion 
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by frailty (van den Biggelaar et al., 2004b), we restricted these analyses to those participants who 
survived for at least 2 years (n=463). 
SNP selection 
Four SNPs in the NR1H3 gene were selected using the HapMap database (http://www.hapmap.
org; version June 2005). Only validated SNPs were selected, and calculations on linkage disequi-
librium (LD) and frequencies were performed using data from the European Centre d’Etude 
du Polymorphisme Humain (CEPH) population. As boundaries, the first SNP upstream of the 
ATG start site (LXRA5 untranslated region [UTR], rs11039149) and the first SNP downstream 
of the stop codon (LXRA3UTR, rs1449627) were selected. The expected D’ between these two 
SNPs was 1, indicating that the entire region is in strong LD. We additionally selected one SNP 
in exon 3 (LXRAex3, rs227923) and one in intron 6 (LXRAint6, rs712011), resulting in a set of 
four evenly spaced SNPs, separated by 5 kb. 
Genotyping 
The polymorphisms were genotyped using either an Assay-by-Design or an Assay-on-De-
mand (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands), consisting of PCR 
primers and TaqMan Major Groove Binding (MGB) probes. For LXRA5UTR an Assay-by-
Design was used with forward primer GAGCATCTGCAGGGTTCTCA, reverse primer GCCA-
GTGAAGTGCTGTAATGGAA, one probe CCCCTGTAGCCCACC labeled with VIC, and one 
probe CCCTGTGGCCCACC labeled with FAM. For the LXRAex3 SNP an Assay-on-Demand 
was used with identification number C_15967384_10. For LXRAint6 an Assay-on-Demand was 
used with identification number C_1301060_20. For LXRA3UTR, an Assay-by-Design was 
used with forward primer CCTCACGTGCATGTGTAGCAT, reverse primer AGGTCTTTCAG-
GTTGTGCCTTTT, one probe CCTTGGTTTTTCC labeled with VIC, and one probe CCTTG-
GGTTTTCC labeled with FAM. Amplification reactions were performed at standard conditions 
except for the following modifications. A qPCR core kit was used (Eurogentec, Maastricht, The 
Netherlands) with half of the amount of primers and probes. Real-time PCR was performed on 
an ABI 7900 HT (Applied Biosystems), and genotypes were called using the Sequence Detection 
System 2.1 (Applied Biosystems). A random 10 % of all genotypes were performed in duplicate, 
and genotyping errors were < 2 % for all assays. 
Statistical analysis 
The program Haploview (Barrett et al., 2005) was used to estimate allele frequencies, test the 
consistency of genotype frequencies at each SNP locus with Hardy–Weinberg equilibrium, and 
estimate and plot pairwise LD between the SNPs examined. LD was estimated for all two-way 
comparisons of individual SNPs using two common measures: the r2 (the square of the stan-
dardized correlation coefficient) and the Lewontin D’ (D’=D/Dmax if D > 0 or D’=D/Dmin 
if D < 0). Haplotypes and haplotype frequencies were estimated using the SNPHAP software 
(http://www-gene.cimr.cam.ac.uk/clayton/software). The posterior probabilities of pairs of haplotypes 
per subject as estimated by SNPHAP, were used as weights in the following analyses.
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Continuous variables were normally distributed, except for plasma ApoE levels, triglycerides, 
CRP levels, and cytokines, which therefore were ln-transformed. All analyses were sex adjusted, 
using homozygosity for the most common haplotype as the referent group. Associations be-
tween haplotypes and metabolic profile were analyzed using linear regression. Mortality risks 
and 95 % confidence intervals (CI) were calculated with the Cox proportional hazard model. 
These analyses included all the estimated haplotypes in the model weighted for probability, ex-
cept the reference haplotype. Clustered robust standard errors were calculated using individuals 
as clustering variable. These models assume an additive effect of the haplotypes. Haplotypes 
with low frequencies (< 5 %) fully participated in these analyses, but results on these haplotypes 
are not reported as their accuracy is low due to small numbers. The analyses were performed 
using STATA statistical software, version 9.0 (STATA Corp., College Station, TX).
Results 
The baseline characteristics of the study populations are listed in Table 1. All participants 
were aged 85 years, and 67 % were female. 
The position of the selected SNPs relative to the gene structure is shown in Figure 1a. The 
SNPs were in strong LD (D’ > 0.97) and constituted one haplotype block (Figure 1b) with seven 
haplotypes, of which the predicted frequencies are listed in Table 2. For the present analyses 
Table 1. Baseline characteristics of the study population
Characteristic Value
Total number 563
Female (n, %) 375 (67 %)
Age (mean, SD)* 85.0 (-)
Lipid and lipoprotein plasma level
Total cholesterol, mean mmol/L (SD) 5.71 (1.13)
LDL cholesterol, mean mmol/L (SD) 3.68 (0.97)
HDL cholesterol, mean mmol/L (SD) 1.31 (0.40)
Triglycerides, median mmol/L (IQR) 1.34 (1.01–1.95)
CRP, median mg/L (IQR) 4.00 (1.00–8.00)
LPS-stimulated cytokines
IL-1b, median ng/mL (IQR) 3.50 (2.10–6.50)
IL-1RA, median ng/mL (IQR) 30.8 (28.3–46.0)
IL-6, median ng/mL (IQR) 60.7 (43.2–82.9)
IL-10, median pg/mL (IQR) 762 (487–1089)
IL-12, median ng/mL (IQR) 6.70 (4.30–10.20)
IFN-c, median ng/mL (IQR) 139 (43.0–448)
TNF-a, median ng/mL (IQR) 10.3 (7.40–13.3)
*All participants were enrolled within the month of their 85th birthday; SD=standard deviation; LDL=low-density lipoprotein; 
HDL=high-density lipoprotein; IQR=interquartile range; CRP=C-reactive protein; LPS=lipopolysaccharide; IL=interleukin; 
IFN=interferon; TNF=tumor necrosis factor; RA=receptor antagonist
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we report the results of the four most common haplotypes (frequency > 5 %) that cumulatively 
account for > 97% of the haplotypes.
During a mean follow-up time of 4.9 years, 320 participants (57 %) had died. We compared 
the mortality risk associated with the various haplotypes, using the most common haplotype 1 
as the reference category (Figure 2). The mortality risk was lower for haplotype 2 compared to 
haplotype 1 (hazard ratio [HR] = 0.78; 95 % CI, 0.64–0.95; p=0.015), whereas other haplotypes 
were not significantly associated with a higher or lower mortality risk. When assessing specific 
causes of death, the lower mortality risk that was associated with haplotype 2 was mainly caused 
by a lower mortality risk from infectious disease (HR=0.31, 95 % CI, 0.12–0.85; p=0.023) and 
from mortality in the category ‘‘other causes’’ (HR= 0.71, 95 % CI, 0.50–1.00; p=0.052).   
Table 2. Haplotype structures and frequencies
SNP allele
Haplotype LXRa5UTR LXRaex3 LXRaint6 LXRa3UTR Frequency
1 A C T T 0.367
2 G C T T 0.273
3 A T C G 0.176
4 A C C G 0.164
5 A C T G 0.016
6 A T C T 0.004
7 A C C T 0.003
Minor alleles are depicted in bold. Minor allele frequencies of the four polymorphisms were: LXRa5UTR, 0.27 (G); LXRaex3, 
0.18 (T); LXRaint6, 0.35 (C); LXRa3UTR, 0.36 (G). All genotype distributions were in Hardy–Weinberg equilibrium, SNP=single 
nucleotide polymorphism; LXR=liver X receptor; UTR=untranslated region; ex = exon; int=intron
Figure 1. Haplotype structure of the NR1H3 
gene in the Leiden 85-plus Study population. (A) 
Relative position of the selected single nucleotide 
polymorphisms (SNPs) in the NR1H3 gene. Ver-
tical bars: exons 1–9. Arrows: positions of SNPs. 
(B) Visual representation of linkage disequilibri-
um within the gene. Based on standard confidence 
interval criteria, all four SNPs constitute one hap-
lotype block. Top triangles (pointing upwards, all 
black) indicate strong linkage disequilibrium of all 
four SNPs. Pairwise linkage disequilibrium is in-
dicated by the numbers in the top triangles. Pair-
wise R2 values are indicated by the numbers in the 
bottom triangles (pointing downwards), in which 
light gray triangles indicate low R2, and dark gray 
triangles indicate high R2.
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The relationship between the four common haplotypes and variables in lipid metabolism is 
shown in Table 3. Haplotype 2 associated with significantly higher plasma ApoE levels (+0.48 
mg/dL, p=0.018) and triglyceride levels (+0.098 mmol/dL, p=0.041) compared to haplotype 1. 
Haplotype 4 also associated with higher plasma ApoE levels compared to haplotype 1, although 
the association was borderline statistically significant (+0.45 mg/dL, p=0.057), possibly due to 
the lower haplotype frequency. 
To explore the association of NR1H3 haplotypes with innate immune function, we assessed 
cytokine production capacity by ex vivo whole-blood LPS-stimulated cytokine levels (Table 4). 
We found no association of any haplotype with cytokine production capacity. Finally, to investi-
gate the possibility that the LXRA regulates inflammation through alternative mechanisms, we 
associated the haplotypes with circulating CRP level, a plasma marker of systemic inflammation. 
We found no association for any haplotype with circulating levels of CRP (Table 4). 
Discussion 
In C. elegans, the NHR DAF-12 has been shown to be one of the key components that modu-
late lifespan in response to environmental cues. Based on protein sequence comparisons, we 
recently identified the LXRA as one of the human NHRs most similar to C. elegans DAF-12 
(Mooijaart et al., 2005). Here we report that genetic variation in the gene coding for the LXRA 
(NR1H3) associates with human life span. 
We found that a common haplotype of the NR1H3 gene associated with lifespan extension, 
predominantly attributable to decreased death from infectious disease. The LXRA is involved in 
various processes that contribute to infectious disease. The LXRA regulates specific processes 
that increase resistance to pathogens. For instance, LXRA regulates the expression of APa, a 
scavenging receptor that inhibits macrophage apoptosis and promotes the killing of the bacteria 
( Joseph et al., 2004). Although LXR agonists reduce inflammatory gene expression in models
Figure 2. Dots represent hazard ratios calculated using a Cox proportional model adjusting for gender; 
bars represent 95 % confidence intervals. Mean follow-up time was 4.9 years, in which time a total 
number of 320 participants (57 %) had died. 
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Table 3. A
ssociation of N
R1H
3 haplotypes w
ith param
eters of lipid m
etabolism
H
aplotype 1
H
aplotype 2
H
aplotype 3
H
aplotype 4
Plasm
a Com
ponent
M
ean
(95 %
 CI)
D
ifference
(95 %
 CI) 1
p-value
1
D
ifference
(95 %
 CI) 1
p-value
1
D
ifference
(95 %
 CI) 1
p-value
1
A
polipoprotein
A
poE (m
g/dL) 2
4.95 (4.52–5.42)
0.48 (0.08-0.91)
0.018
0.30 (-0.13-0.79)
0.188
0.45 (-0.01-0.96)
0.057
Lipids
Total cholesterol, m
m
ol/L
5.93 (5.74–6.13)
0.06 (-0.10-0.21)
0.473
-0.021 (-0.18-0.14)
0.802
-0.10 (-0.29-0.09)
0.294
LD
L cholesterol, m
m
ol/L
3.84 (3.67–4.02)
0.02 (-0.12- 0.15)
0.806
-0.072 (-0.21-0.07)
0.311
-0.10 (-0.27-0.06)
0.226
H
D
L cholesterol, m
m
ol/L
1.39 (1.32–1.46)
-0.01 (-0.07-0.20)
0.813
-0.004 (-0.07-0.06)
0.890
-0.01 (-0.08-0.06)
0.813
Triglycerides, m
m
ol/L
2
1.38 (1.28–1.49)
0.10 (0.00-0.20)
0.041
0.07 (-0.04-0.19)
0.195
0.02 (-0.08-0.14)
0.662
1 Com
pared to H
aplotype 1; 2 G
eom
etric m
ean; Freq= frequency; A
poE=apolipoprotein E; LD
L=low
-density lipoprotein; H
D
L=high-density lipoprotein. D
ata represent sex-adjusted 
m
eans and 95%
 confidence intervals (CI). A
ll participants w
ere aged 85 years
Table 4. A
ssociation of N
R1H
3 haplotypes w
ith w
hole-blood lipopolysaccharide (LPS)-stim
ulated cytokine levels at baseline
H
aplotype 1
H
aplotype 2
H
aplotype 3
H
aplotype 4
M
ean
(95 %
 CI)
D
ifference
(95 %
 CI) 1
p-value
1
D
ifference
(95 %
 CI) 1
p-value
1
D
ifference
(95 %
 CI) 1
p-value
1
Innate im
m
unity
2
IL-1b, ng/m
L
3.30 (2.80-3.80)
0.10 (-0.30-0.60)
0.680
-0.20 (-0.60-0.30)
0.440
0.40 (-0.10-1.00)
0.141
IL1-RA
, ng/m
L
35.4 (32.4-38.6)
-1.20 (-3.70-1.40)
0.340
0.10 (-2.80-3.20)
0.972
-0.20 (-3.30-3.30)
0.859
IL-6, ng/m
L
57.4 (51.8-63.4)
-0.90 (-5.20-3.70)
0.682
-1.40 (-6.20-3.90)
0.592
0.60 (-4.30-6.10)
0.794
IL-10, pg/m
L
709 (623-807)
5.00 (-64.0-82.0)
0.888
-6.00 (-85.0-83.0)
0.892
-19.0 (-101.0-75.0)
0.680
IL-12, ng/m
L
6.00 (5.20-6.90)
0.20 (-0.40-1.00)
0.494
-0.60 (-1.30-0.01)
0.054
0.50 (-0.30-1.30)
0.249
IFN
-c, ng/m
L
151 (108-209)
10.0 (-27.0-59.0)
0.617
-35.0 (-66.0-8.0)
0.100
15.0 (-32.0-82.0)
0.575
TN
F-a, ng/m
L
9.80 (9.00-10.7)
0.40 (-1.10-0.30)
0.240
-0.80 (-1.60-0.10)
0.035
0.30 (-0.50-1.30)
0.432
Chronic inflam
m
ation
2
CRP, m
g/L
2.00 (1.50-2.70)
0.20 (-0.30-0.80)
0.440
0.40 (-0.20-1.10)
0.224
0.20 (-0.40-0.90)
0.599
1 Com
pared to H
aplotype 1; 2 G
eom
etrical m
eans; Freq=frequency; IL=interleukin; RA
=receptor antagonist; IFN
=interferon; TN
F=tum
or necrosis factor; CRP=C-reactive protein. D
ata 
represent sex-adjusted m
eans and 95%
 confidence intervals (CI). A
ll participants w
ere aged 85 years
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of dermatitis and atherosclerosis ( Joseph et al., 2003), LXRA-/- knockout mice are more suscep-
tible to infection with Listeria monocytogenes ( Joseph et al., 2004). 
In the search for an intermediate phenotype, we associated genetic variation in the NR1H3 
gene with mortality-related markers in lipid metabolism and immunity. We selected these mark-
ers because these phenotypes are known to associate with mortality and a functional relation-
ship with the LXRA protein was plausible. Cholesterol metabolism is related to various causes 
of death (Weverling-Rijnsburger et al., 1997), and the LXRA is involved in various components 
of lipid metabolism, such as reverse cholesterol transport, cholesterol excretion, and fatty acid 
synthesis (Lu et al., 2001). We observed an association of haplotype 2 of the NR1H3 gene 
with increased plasma ApoE and triglyceride levels. ApoE is a component of triglyceride-rich 
lipoproteins, such as very low- density lipoprotein (VLDL), which may explain why haplotype 
2 associates with plasma levels of both ApoE and triglycerides. Furthermore, LXRA agonists 
have been suggested for therapeutic use against cardiovascular disease, but a serious side effect 
of the use of LXR agonists as therapeutic agents is the concomitant increase in liver and serum 
triglycerides (Grefhorst et al., 2002). These effects are caused by a strong induction of lipogenic 
genes in the liver and an increased VLDL production (Grefhorst et al., 2002). In line with these 
animal data, we found that haplotype 2 also associated with higher ApoE levels. Thus, the as-
sociations with increased levels of triglycerides and ApoE presented here suggest that haplotype 
2 associates with increased LXRA activity in the liver. It is interesting that triglyceride-rich lipo-
proteins (of which ApoE is a component) act as agents of the innate immune system (Barcia and 
Harris, 2005), for example, by binding and neutralizing bacterial components. ApoE redirects 
lipopolysaccharides (bacterial components) in the liver from Kupffer cells to hepatocytes and 
protects against endotoxemia in rats (Rensen et al., 1997). Recently, it was discovered that ApoE 
is also involved in lipid antigen presentation (van den et al., 2005) and that high plasma ApoE 
levels associate with increased systemic inflammation (Mooijaart et al., 2006). 
LPS-stimulated cytokine production levels are highly heritable (de Craen et al., 2005), and 
cytokine production profiles associate with patterns of old age mortality (van den Biggelaar et 
al., 2004a). However, genetic variation in the genes coding for the cytokines has so far been 
insufficient to explain the heritable component (Haukim et al., 2002). In the present study, varia-
tion in the NR1H3 gene did not associate with ex vivo LPS-stimulated whole-blood cytokine 
levels or with circulating CRP levels. Others have demonstrated an association of the LXRA 
with inflammation in macrophage and monocyte cell cultures ( Joseph et al., 2003; Landis et al., 
2002). However, inflammatory cytokines and other serum mediators were not different between 
LXRA and LXRB knockout mice and wild types ( Joseph et al., 2004). We interpret that NR1H3 
may not be a major determinant of cytokine production capacity in blood upon stimulation 
by LPS. This interpretation does not, however, exclude the possibility that in other cell types 
NR1H3 haplotypes may influence the local production of cytokines. 
We did not observe a beneficial effect of haplotype 2 on death from cardiovascular causes. 
In mouse models, LXR agonists reduce the formation of atherosclerotic lesions ( Joseph et al., 
2002) whereas macrophage-specific LXRA knockout aggravates atherosclerosis development 
(Tangirala et al., 2002). To date, the function of the LXRA in lipid and cholesterol metabolism 
has been studied in mouse models and in human cultured cell lines, mostly macrophages. How-
ever, caution must be taken in extrapolating these results based on cultured cells and mouse 
models of atherosclerosis to humans (Repa and Mangelsdorf, 2002). Whereas macrophage LXR 
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has been shown to be antiatherogenic (Levin et al., 2005; Tangirala et al., 2002), this beneficial 
effect on cardiovascular disease may be balanced by proatherogenic effect of liver LXR activa-
tion. 
Genetic variation in both C. elegans daf-12 and the human NR1H3 gene associates with dif-
ferences in life span, suggesting that the two genes may, at least to some extent, be functionally 
conserved. Other evolutionarily conserved pathways have previously been implicated in life-
span regulation. For example, it was first discovered that the C. elegans daf-2 mutant was long-
lived (Kenyon et al., 1993). Later it was discovered that the daf-2 gene shows homology to the 
mammalian genes encoding the insulin receptor (IR) and insulin-like growth factor 1 receptor 
(IGF-1R) (Kimura et al., 1997), which are conserved throughout evolution. Extended life span 
was then also demonstrated in IR mutants in Drosophila melanogaster (Tatar et al., 2001) and in IR 
and IGF-1R mutants in mice (Bluher et al., 2003; Holzenberger et al., 2003). Recently we showed 
that reduced insulin signaling in humans also associates with longevity (van Heemst et al., 2005). 
These observations suggest that the approach of studying evolutionarily conserved pathways is 
fruitful in identifying genes that regulate human life span. 
Very recently, several articles report on the biological function of daf-12 in C. elegans. Two 
hormones were identified that function as DAF-12 ligands (Motola et al., 2006), and the bio-
synthetic pathway of production of these ligands was described in more detail (Rottiers et al., 
2006). Furthermore, cholestenoic acid was found to rescue the worm from dauer diapause in 
a DAF-12–dependent manner (Held et al., 2006). These studies provide important new hints 
to investigate the functional conservation of life-span regulation throughout evolution and the 
biological function of the human LXRs or other NHRs. 
A limitation of our study is that it does not include analyses of the gene encoding the LXRB 
(NR1H2). The LXRA and LXRB are highly similar proteins, as their amino acid sequences are 
very alike and the proteins have similar functions in lipid metabolism and inflammation. It could 
therefore be hypothesized that a loss of function of one of the genes will be compensated for 
by the function of the other receptor and will therefore not have dramatic effects. The LXRA 
and LXRB are encoded by different genes and have different expression patterns. Whereas the 
LXRA is expressed only in a limited number of tissues, the LXRB is expressed ubiquitously. 
Indeed, in activated macrophages the inhibiting effect of LXR ligands on cytokine expression is 
completely abrogated in double knockout macrophages (nr1h3-/- nr1h2-/-). However, there was 
also a partial reduction of this effect in nr1h3-/- macrophages ( Joseph et al., 2003). Furthermore, 
whereas LXRA-/- knockout increases susceptibility to bacterial infection, additional knockout 
of LXRB does not increase this susceptibility ( Jonsson et al., 2003). These observations sug-
gest that genetic variation in LXRA may have functional significance independent of LXRB. A 
second limitation is that it is unclear which genetic variant within the haplotype is responsible 
for the observed functional variation. The SNP that tags haplotype 2 is located in the 5` UTR 
of the gene. It is, however, unknown whether this SNP itself has functional significance—for 
instance, by affecting promoter function or interaction domains. Alternatively, the 5` UTR SNP 
may be in LD with an SNP elsewhere in the genome, for instance in the coding region of the 
gene, which leads to an alteration with functional significance. 
The strong point of our study is that we selected genetic variants tagging all common hap-
lotypes of the NR1H3 gene and associated them with a range of variables in inflammation and 
lipid metabolism. Furthermore, the prospective nature of the mortality analyses and the rela-
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tively large number of deaths yield a powerful tool to study mortality risk. 
As this is the first report on the effect of common genetic variants in the human NR1H3 gene 
on human life span, the results of our observational study need further replication. Furthermore, 
more research is warranted to confirm which specific genetic variation on the haplotypes actu-
ally changes the function of the gene or protein.
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Abstract
Vitamin D has been recently implicated in brain function. Our objective was to test whether 
genetic variance in the vitamin D receptor (VDR) gene is associated with cognitive functioning 
and depressive symptoms in old age. The study was carried out in the prospective population-
based Leiden 85-plus Study. All 563 participants of the study were genotyped for Cdx-2, FokI, 
BsmI, ApaI and TaqI polymorphisms in the VDR gene. Our data revealed an overall worse 
performance on tests measuring cognitive functioning for carriers of BsmI ( p=0.013) and TaqI 
( p=0.004) polymorphisms, and of haplotype 2 (BAt) ( p=0.004). In contrast, carriers of ApaI 
variant-allele and of haplotype 1 (baT) had better cognitive functioning together with less de-
pressive symptoms. These associations could not be explained by differences in calcium levels, 
and by selective survival, since no associations between the VDR gene variants and calcium 
levels and mortality were observed. In conclusion, our results show that genetic variance in the 
VDR gene influence the susceptibility to age-related changes in cognitive functioning and in 
depressive symptoms. 
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Introduction
Ample data provide evidence that vitamin D is involved in brain function. The reported 
biological processes influenced by vitamin D in the brain include neuroprotection, immuno-
modulation and detoxification (Brown et al., 2003; Garcion et al., 2002). The neuroprotective 
effects of vitamin D appear to be exerted via the regulation of calcium homeostasis (Brewer et 
al., 2001; Brewer et al., 2006; de Viragh et al., 1989), and synthesis of neurotrophins, such as 
nerve growth factor and neurotrophin 3 (Naveilhan et al., 1996; Neveu et al., 1994a; Neveu et 
al., 1994b; Saporito et al., 1994; Wang et al., 2000). These biological effects suggest that vitamin 
D could influence cognitive functioning and the prevalence of depressive symptoms.
The functions of vitamin D are mediated by vitamin D receptor (VDR), which belongs to 
the nuclear hormone receptor (NHR) super-family, and which is ubiquitously expressed in the 
organism (Kamei et al., 1995; Langub et al., 2001). Defects in the vitamin D signaling system 
have been associated with multiple sclerosis, and various behavioral- and mood disorders in 
animals and humans (Cantorna et al., 1996; Garcion et al., 2002; Lansdowne and Provost, 1998; 
Munger et al., 2004). It has been shown that animals exposed to prenatal vitamin D deficiency 
have alterations in brain morphology (Eyles et al., 2003), locomotion (Burne et al., 2004; Kesby 
et al., 2006), and learning and memory (Becker et al., 2005). In addition, mice lacking a func-
tional VDR gene appear to suffer from anxiety-like behavior (Kalueff et al., 2004; Kalueff et 
al., 2006). In humans, vitamin D deficiency has been associated with the presence of an active 
mood disorder and with worse cognitive functioning (Przybelski and Binkley, 2007; Wilkins et 
al., 2006). In contrast, little is known about whether and how disturbed function of the VDR 
gene influences these endpoints. The VDR gene contains several polymorphisms of which five; 
Cdx-2, FokI, BsmI, ApaI and TaqI, have been most often investigated, and associated with a 
number of phenotypes, such as bone mineral density, and risks for fractures and cancer (Uitter-
linden et al., 2004b). In addition, haplotype alleles have been identified that influence the risk of 
osteoporotic fractures and the expression of the VDR gene (Fang et al., 2005; Grundberg et al., 
2007). The risk haplotypes that have recently emerged, baT and BAt, are composed of the BsmI, 
ApaI and TaqI polymorphisms, located in the 3‘ untranslated region (UTR). 
The aim of this study was to assess the influence of these five polymorphisms in the VDR 
gene and the risk haplotypes on cognitive functioning and depressive symptoms in old age. 
Furthermore, the association with calcium levels, and the incidence of fractures and mortality 
were assessed for the VDR polymorphisms and the haplotypes. The study was carried out in the 
Leiden 85-plus Study, a population-based prospective study of the oldest old. 
Participants and methods
Participants
The Leiden 85-plus Study is a prospective population based study in which all 85-year-old 
inhabitants of the city Leiden, in The Netherlands, were invited to take part. There were no 
selection criteria related to health or demographic characteristics. The population under study 
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consists of 599 subjects, all Caucasians and members of the 1912-1914 birth cohort, enrolled in 
the month of their 85th birthday between 1997 and 1999 (Bootsma-van der Wiel et al., 2002). For 
the present study, DNA was available for 563 participants. All participants of the Leiden 85-plus 
Study were followed for mortality until August 1, 2005. Primary causes of death were obtained 
from the Dutch Central Bureau of Statistics and categorized according to the 10th International 
Classification of Diseases (ICD-10). The Medical Ethical Committee of the Leiden University 
Medical Centre approved the study and informed consent was obtained from all participants or 
in case of severe cognitive impairment, from their guardian. 
Calcium levels at baseline
Calcium and albumin concentrations were determined in serum using fully automated ana-
lyzers (Hitachi 747 and 911; Hitachi, Ltd, Tokyo, Japan). Total calcium levels were adjusted for 
albumin using the following formula: corrected calcium = uncorrected calcium - [(40 – albumin) 
× 0.02] (Palmer et al., 1988). 
Cognitive function and depressive symptoms 
Overall cognitive function was measured with the Mini-Mental State Examination (MMSE) 
(Folstein et al., 1975). From the specific domains of cognitive functioning, attention was as-
sessed with the Stroop Test (Klein et al., 1997), processing speed with the Letter Digit Coding 
Test (LDT) (Houx et al., 2002) and memory with the 12-Word Learning Test, which assesses 
immediate recall (WLTI) and delayed recall (WLTD)(Brand and Jolles, 1985). The prevalence 
of depressive symptoms was assessed with the 15-item Geriatric Depression Scale (GDS-15) 
(De Craen et al., 2003). The tests assessing specific domains of cognitive functioning could not 
be administered to 92 participants because of severe cognitive impairment (MMSE score < 19 
points). All participants were visited annually for re-measurement of cognitive functioning and 
depressive symptoms during a mean follow-up period of 4.2 years. During the study, parallel 
versions of the tests were used and details of testing are described elsewhere (Houx et al., 2002). 
In addition to the specific tests, a composite cognitive score was calculated by converting the 
scores of the individual tests (Stroop Test, LDT, WLTI and WLTD) into a z-score ((individual 
level – mean level)/SD), and computing the average. A higher composite cognitive score reflects 
better performance on the tests measuring cognitive functioning. 
The incidence of fractures
The incidence of fractures was assessed yearly during the five-year follow-up period. The 
number of fractures was obtained by self-reporting using a standardized yes/no format. When 
the participant was severely cognitively impaired, a guardian was asked for the information. In 
addition, the general practitioner, or the nursing home physician in case of institutionalization, 
was interviewed concerning fracture related contacts with the participant. The composite of 
self-reported and physician reported fractures were used. Fractures included hip, wrist and other 
fractures.
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Possible confounders
Socio-demographic characteristics, such as sex and level of education were considered as 
possible confounders. Education was divided into two levels: a lower education level, includ-
ing individuals without schooling or with only primary school education (less than 6 years of 
schooling), and a higher education level (6 years or more of schooling).
Genotyping
The Cdx-2 G/A (rs11568820) and BsmI C/T (rs1544410) single nucleotide polymorphisms 
(SNPs) were genotyped using an Assay-by-Design (Applied Biosystems, Foster City, CA, USA), 
consisting of PCR primers and TaqMan MGB probes, on an ABI 7900 HT real-time PCR (Ap-
plied Biosystems, Foster City, CA, USA). Amplification reactions were made at standard condi-
tions except for the following modifications. A qPCR core kit was used (Eurogentec, Liege, Bel-
gium) and one-third of the amount of assay mix. FokI G/A (rs10735810), ApaI A/C (rs7975232) 
and TaqI A/G (rs731236) polymorphisms were genotyped using MassArray platform according 
to the protocols of the manufacturer (Sequenom Inc., San Diego, CA, USA).
Statistical analysis
The program Haploview (Barrett et al., 2005) was used to estimate allele frequencies, test for 
Hardy-Weinberg equilibrium and to estimate pair-wise linkage disequilibrium (LD) between 
the SNPs. Haplotypes and haplotype frequencies were calculated using the program SNPHAP 
(http://www-gene.cimr.cam.ac.uk/clayton/software). In order to take into account the uncertainty in 
haplotype probabilities, the multiple imputation approach was used (Rubin, 1987), and with 
SNPHAP ten datasets were generated by randomly assigning a haplotype to each subject accord-
ing to its haplotype probabilities. All statistical analyses were performed with the ten datasets. 
The haplotype specific estimates were calculated by averaging the ten dataset-specific estimates, 
and the standard errors were estimated using the estimated variance within and across the data-
sets. The associations between baseline calcium levels and VDR polymorphisms and haplotypes 
were tested using sex adjusted linear regression. Associations between cognitive functioning, 
depressive symptoms and VDR polymorphisms and haplotypes were analyzed using a sex and 
education adjusted linear mixed model, estimating the overall mean difference in cognitive 
functioning or depressive symptoms during follow-up. Cox proportional hazard model, measur-
ing time-to event was used to estimate the risk of incident fractures, and mortality during the 
follow-up period, in relation to the polymorphisms or haplotypes. The reference group con-
tained zero-copies of a risk allele or haplotype. All analyses were performed with SPSS, version 
12.0 (SPSS Inc., Chicago, IL, USA) statistical software.
Results
Demographic characteristics and baseline measures of cognitive functioning and depres-
sive symptoms of the 563 participants of the Leiden 85-plus Study are presented in Table 1. All 
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study participants were genotyped for Cdx-2, FokI, BsmI, ApaI and TaqI polymorphisms in the 
VDR gene. The genotype frequencies of the SNPs (Table 1) were in agreement with Hardy-
Weinberg equilibrium and similar to those reported in other Caucasian populations (Uitterlin-
den et al., 2004a). The BsmI, ApaI and TaqI polymorphisms were in strong linkage disequilibrium 
(LD) (D’> 0.99) (Figure 1), and defined five haplotypes, of which the first three had frequencies 
> 5 %. These haplotypes have previously been described as baT, BAt and bAT, respectively. The 
haplotype frequencies were similar to those reported in other Caucasian populations (Fang et 
al., 2005; Grundberg et al., 2007).
Global cognitive functioning, attention, processing speed, memory and the prevalence of 
depressive symptoms were assessed at baseline, age 85 years, and re-examined annually during 
a mean follow-up period of 4.2 years. During follow-up, a significant decline in cognitive func-
tioning, and an increase in depressive symptoms were observed in all participants (all p<0.001) 
(Vinkers et al., 2005). These changes were not attributable to the Cdx-2 or FokI polymorphisms, 
since during follow-up no differences in cognitive functioning and depressive symptoms were 
observed for carriers of these polymorphisms (data not shown). On the other hand, carriers 
of the BsmI and TaqI polymorphisms performed worse on all tests measuring cognitive func-
tioning (Table 2). This worse performance was reflected by a lower composite cognitive score 
(BsmI ptrend=0.013; TaqI ptrend=0.004), but not by a lower MMSE, which measures global cognitive 
functioning (BsmI ptrend=0.999; TaqI ptrend=0.899). From specific domains of cognitive functioning, 
attention, immediate- and delayed memory were affected most, whereas for the prevalence
Table 1. Characteristics of study participants 
Number 563
Age1 85 (-)
Female (%) 375 (67 %)
Low level of education (%) 362 (65 %)
Calcium (mmol/l)1 2.23 (2.16-2.29)
MMSE (points)1 26 (22-28)
MMSE >18 points (%) 471 (84 %)
Specific domains of cognitive functioning1
Stroop Test (seconds) 74 (60-97)
LDT (digits) 16 (12-21)
WLTI (pictures) 25 (20-28)
WLTD (pictures) 9 (7-11)
GDS-15 (points)1 2 (1-3)
Polymorphisms2 
Cdx-2 (G/A) 0.19
FokI (G/A) 0.34
BsmI (C/T) 0.43
ApaI (A/C) 0.46
TaqI (A/G) 0.42
1 Data are presented as medians with interquartile ranges; 2 Data are presented as minor allele frequencies; MMSE - Mini-Men-
tal State Examination;  LDT - Letter Digit Coding Test; WLTI - Word Learning Test Immediate Recall; WLTD - Word Learning Test 
Delayed Recall; GDS-15 - 15-item Geriatric Depression Scale
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Figure 1. The VDR gene structure and haplo-
types. The VDR gene spans a genomic region 
of 100 kb and contains 14 exons (indicated with 
boxes). The approximate positions of the five 
polymorphisms analyzed in this study are in-
dicated with arrows. The BsmI, ApaI and TaqI 
polymorphisms are in strong linkage disequilib-
rium (LD) and define five haplotypes. The first 
three haplotypes, haplotype 1, haplotype 2 and 
haplotype 3 have previously been described as 
baT, BAt and bAT, respectively.
Table 2. Cognitive functioning and depressive symptoms during follow-up dependent on the VDR polymor-
phisms
VDR genotypes
wt/wt wt/var var/var
Mean (SE) Difference (SE) Difference (SE) ptrend
BsmI (C/T)
Composite cognitive score -0.08 (0.06) -0.12 (0.08) -0.25 (0.10)* 0.013*
MMSE (points) 22.6 (0.48) 0.47 (0.61) -0.15 (0.78) 0.999
Stroop Test (seconds) 84.3 (2.31) 2.00 (2.95) 10.4 (3.78)* 0.010*
LDT (digits) 16.2 (0.51) -1.04 (0.65) -0.34 (0.83) 0.471
WLTI (pictures) 21.3 (0.48) -1.07 (0.61) -2.18 (0.77)* 0.004*
WLTD (pictures) 7.33 (0.23) -0.30 (0.29) -0.78 (0.39)* 0.037*
GDS-15 (points) 2.93 (0.21) -0.05 (0.26) 0.55 (0.34) 0.158
ApaI (A/C)
Composite cognitive score -0.22 (0.07) 0.00 (0.08) 0.16 (0.10) 0.135
MMSE (points) 23.1 (0.51) -0.32 (0.63) -0.56 (0.76) 0.456
Stroop Test (seconds) 89.9 (2.45) -2.65 (3.05) -6.80 (3.68) 0.068
LDT (digits) 16.4 (0.53) -1.40 (0.66)* -0.06 (0.80) 0.737
WLTI (pictures) 19.8 (0.51) 0.49 (0.63) 1.61 (0.76)* 0.041*
WLTD (pictures) 6.83 (0.24) 0.23 (0.30) 0.44 (0.36) 0.222
GDS-15 (points) 3.42 (0.21) -0.56 (0.26)* -0.72 (0.32)* 0.019*
TaqI (A/G)
Composite cognitive score -0.07 (0.06) -0.13 (0.08) -2.94 (0.10)* 0.004*
MMSE (points) 22.7 (0.48) 0.55 (0.60) -0.30 (0.78) 0.899
Stroop Test (seconds) 84.0 (2.29) 2.12 (2.92) 11.0 (3.80)* 0.008*
LDT (digits) 16.3 (0.50) -0.96 (0.64) -0.63 (0.84) 0.310
WLTI (pictures) 21.4 (0.47) -1.15 (0.60) -2.51 (0.78)* 0.001*
WLTD (pictures) 7.40 (0.23) -0.37 (0.29) -0.99 (0.37)* 0.009*
GDS-15 (points) 2.93 (0.20) -0.06 (0.26) 0.60 (0.33) 0.135
* p < 0.05; SE – standard error; MMSE - Mini-Mental State Examination;  LDT - Letter Digit Coding Test; WLTI - Word Learning Test 
Immediate Recall; WLTD - Word Learning Test Delayed Recall; GDS-15 - 15-item Geriatric Depression Scale 
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of depressive symptoms no differences were observed (Table 2). In contrast, carriers of the 
ApaI variant-allele tended to have less depressive symptoms than non-carriers during follow-up 
( ptrend=0.019) (Table 2). These differences were observed for both heterozygous (-0.56 points, 95 
% CI:-1.07 to -0.04, p=0.036) and homozygous (-0.72 points, 95 % CI: -1.35 to -0.09, p=0.026) 
ApaI variant-allele carriers. In addition, these participants performed better, although not statis-
tically significant, on tests measuring processing speed, attention and memory (Table 2). 
The haplotype analyses revealed similar results as those with the individual polymorphisms. 
Carriers of at least one copy of haplotype 1 (baT), which contains the ApaI polymorphism, 
had less depressive symptoms ( ptrend=0.026), and performed better, although statistically not sig-
nificantly, on tests measuring attention, immediate memory and delayed memory compared to
non-carriers (Table 3). The opposite was observed for carriers of haplotype 2 (BAt), which com-
bines the variant alleles of BsmI and TaqI polymorphisms (Table 3). For all these associations, 
an allele dosage dependent effect was observed, which was more pronounced for haplotype 
2 (BAt) carriers, who had mainly impairments in attention ( ptrend=0.008), immediate memory 
( ptrend=0.001) and delayed memory ( ptrend=0.009) (Figure 2).
Table 3. Cognitive functioning and depressive symptoms during follow-up dependent on the VDR haplotypes
VDR haplotypes
0-copies
Mean (SE)
1-copy
Difference (SE)
2-copies
Difference (SE) p-trend
Haplotype 1 (baT)  
Composite score -0.09 (0.07) -0.01 (0.08) 0.13 (0.10) 0.215
MMSE (points) 22.5 (0.55) -0.32 (0.62) -0.60 (0.76) 0.424
Stroop Test (seconds) 84.3 (2.72) -1.72 (3.01) -5.78 (3.67) 0.124
LDT (digits) 15.3 (0.59) -1.44 (0.66)* -0.23 (0.80) 0.576
WLTI (pictures) 22.6 (0.56) 0.52 (0.62) 1.47 (0.76) 0.056
WLTD (pictures) 7.95 (0.27) 0.26 (0.29) 0.39 (0.36) 0.254
GDS-15 (points) 2.60 (0.24) -0.48 (0.26) -0.69 (0.33)* 0.026*
Haplotype 2 (BAt) 
Composite score 0.05 (0.07) -0.13 (0.08) -0.29 (0.10)* 0.004*
MMSE (points) 22.0 (0.53) 0.57 (0.60) -0.29 (0.77) 0.912
Stroop Test (seconds) 79.3 (2.70) 2.12 (2.92) 10.7 (3.77)* 0.008*
LDT (digits) 15.2 (0.59) -1.01 (0.64) 0.63 (0.83) 0.298
WLTI (pictures) 24.1 (0.55) -1.15 (0.60) -2.50 (0.77)* 0.001*
WLTD (pictures) 8.51 (0.26) -0.37 (0.28) -0.98 (0.37)* 0.009*
GDS-15 (points) 2.14 (0.24) -0.03 (0.26) 0.56 (0.33) 0.147
Haplotype 3 (bAT) 
Composite score -0.10 (0.05) 0.12 (0.09) 0.56 (0.28)* 0.032*
MMSE (points) 22.0 (0.40) 0.76 (0.68) 2.77 (2.25) 0.124
Stroop Test (seconds) 83.3 (2.05) -3.17 (3.30) -13.3 (10.5) 0.153
LDT (digits) 14.2 (0.44) 1.25 (0.72) 3.74 (2.29) 0.024*
WLTI (pictures) 22.9 (0.42) 0.76 (0.68) 3.84 (2.20) 0.074
WLTD (pictures) 8.05 (0.20) 0.32 (0.32) 2.13 (1.04)* 0.067
GDS-15 (points) 2.14 (0.18) 0.39 (0.30) 0.48 (0.94) 0.171
* p < 0.05; SE – standard error; MMSE - Mini-Mental State Examination;  LDT - Letter Digit Coding Test; WLTI - Word Learning Test 
Immediate Recall; WLTD - Word Learning Test Delayed Recall; GDS-15 - 15-item Geriatric Depression Scale
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In order to explore whether differences in calcium levels or selective survival have influenced 
the associations observed with cognitive functioning, we analyzed the relation between these 
phenotypes and VDR gene variants. In cross-sectional analyses at age 85 years, serum calcium 
levels were not associated with the VDR polymorphisms (data not shown), except the Cdx-2 
polymorphism. Homozygous (-0.05 mmol/l, 95 % CI: -0.10 to -0.00, p=0.032) but not heterozy-
gous (0.001 mmol/l, 95 % CI: -0.02 to 0.02, p=0.955) Cdx-2 variant allele carriers had lower 
serum calcium levels compared to non-carriers. No associations between the VDR haplotypes 
and calcium levels were observed. Likewise, the mortality risks did not differ between the dif-
ferent VDR polymorphism and haplotype carriers during mean 4.2-year follow-up period (data 
not shown). 
Since in other studies the same polymorphisms and haplotypes as analyzed in this study have 
been associated with the risk of fractures, we assessed the influence of VDR polymorphisms 
and haplotypes on the incidence of fractures during follow-up. There were no differences in the 
incidence of fractures between the different polymorphism carriers (data not shown). However, 
the additional haplotype analyses revealed a trend for increased incidence of fractures for haplo-
type 1 (baT) carriers (1-copy HR: 1.46, 95 % CI: 0.86 to 2.49; 2-copies HR: 1.52, 95 % CI: 0.81 
to 2.83).
Discussion
The main finding of this study is that genetic variance in the VDR gene contributes to 
differences in cognitive functioning and depressive symptoms in old age. An overall better 
performance on tests measuring attention, processing speed and memory, together with a lower 
prevalence of depressive symptoms were observed for carriers of ApaI variant-allele and of hap-
lotype 1 (baT), which contains the ApaI variant-allele. In contrast, carriers of the BsmI and TaqI 
polymorphisms had impairments in attention and memory. Similar associations were observed 
Figure 2. Differences in cognitive functioning between participants carrying 0-, 1- or 2-copies of the 
haplotype 2 (BAt). The p-value represents the overall mean difference in cognitive functioning during 
follow-up. * p < 0.05
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with haplotype 2 (BAt), which combines the variant alleles of BsmI and TaqI. 
The research on the role of vitamin D in the human brain has so far focused mainly on the 
influence of vitamin D on mood disorders. Vitamin D deficiency is considered as a possible con-
tributor to seasonal affective disorder (SAD), since SAD has been associated with winter months 
and sunlight deprivation (Rosenthal et al., 1984; Schlager et al., 1993; Spoont et al., 1991). In ad-
dition, there are studies showing associations between low vitamin D levels and mood disorders, 
accompanied with worse cognitive functioning (Lansdowne and Provost, 1998; Przybelski and 
Binkley, 2007; Wilkins et al., 2006). In accordance with the latter studies, we observed in this 
study that genetic variance in the VDR gene influences both cognitive functioning and depres-
sive symptoms. From the specific domains of cognitive functioning, attention and memory were 
affected most. These two cognitive domains are most vulnerable and tend to decline constantly 
across adult lifespan, in contrast to cognitive abilities such as autobiographical memory and 
emotional processing, which stay unchanged throughout life (Hedden and Gabrieli, 2004). Our 
data suggest that carriers of the BsmI and TaqI polymorphisms are more susceptible for the age-
related deterioration of cognitive functioning, whereas the ApaI polymorphism contributes to 
a protective effect.  
In the assessment of overall influence of the VDR gene polymorphisms on cognitive func-
tioning, we observed differences with composite cognitive score but not with MMSE. The com-
posite cognitive score used in this study was calculated from four individual tests that have been 
designed to measure changes in specific domains of cognitive functioning. Therefore, the com-
posite cognitive score might be more sensitive in detecting cognitive impairments than MMSE, 
which has been designed to assess global cognitive functioning, and contains only few items 
from the specific cognitive tests. It also might be that due to the ‘ceiling’ effect of the MMSE, 
mild impairments in cognitive functioning are not detectable (Houx et al., 2002). 
There are several mechanisms through which vitamin D can affect mental performance. The 
downregulation of the expression of L-type voltage-sensitive calcium-channels (L-VSCC) by vi-
tamin D in hippocampal neurons, has been shown to reduce the influx and excitotoxic effects of 
calcium to neurons (Brewer et al., 2001). The detrimental role of excessive calcium for memory 
formation and overall cognitive functioning is widely acknowledged (Sattler and Tymianski, 
2000; Thibault et al., 2001; Veng et al., 2003).  However, the differences in cognitive function-
ing between the VDR polymorphism and haplotype carriers were unlikely caused by increased 
or decreased calcium levels, since none of these polymorphisms and haplotypes were associated 
with calcium levels. However, it is unknown how well the peripheral calcium levels reflect those 
in the brain. The vitamin D endocrine system plays an essential role in overall calcium homeo-
stasis and therefore we expected to see differences also in peripheral calcium levels within the 
polymorphism and haplotype carriers. Possibly, other brain specific functions of vitamin D are 
responsible for the observed effects. It has been shown that in the brain, vitamin D increases 
the production of neurotrophins, which support the survival of existing neurons and encourage 
the growth and differentiation of new neurons and synapses (Naveilhan et al., 1996; Neveu et al., 
1994a; Neveu et al., 1994b; Saporito et al., 1994; Wang et al., 2000). These effects provide protec-
tion to, and diminish cognitive impairment underlying neurodegenerative disorders. 
In previous studies, several polymorphisms and haplotypes in the VDR gene have been as-
sociated with bone mineral density and risk of fractures (Fang et al., 2005; Uitterlinden et al., 
2004b). The risk haplotypes that have been identified include haplotype 1 (baT) and haplotype 
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2 (BAt), which were reported to contribute to increased and decreased risk of fractures, respec-
tively (Fang et al., 2005; Uitterlinden et al., 2004b). In this study, we analyzed the same risk 
haplotypes, and observed a trend for increased risk of fractures for haplotype 1 (baT) carriers, 
which is in accordance with the other studies. However, for the same haplotype carriers we also 
observed better performance on test measuring cognitive functioning. An explanation for the 
apparent contradiction could be that people with better cognitive functioning are more active 
and therefore may face a higher risk for an incident fall and fracture. The lack of associations 
between the VDR polymorphisms and haplotypes and mortality suggest that selective survival 
has not influenced the associations observed with cognitive functioning. We speculate that the 
better cognitive functioning in the haplotype 1 (baT) carriers is due to a higher expression of the 
haplotype, since increased vitamin D levels have previously been associated with better cognitive 
functioning. The evidence for the functionality of haplotype 1 (baT), however, is contradictory. 
In one study it was reported that the haplotype 1 (baT) results in lower VDR gene expression 
and increased mRNA decay (Fang et al., 2005), whereas in another study it was shown that the 
haplotype 1 (baT) is overexpressed in human trabecular bone samples (Grundberg et al., 2007). 
It might also be that the associations observed in this study are resulted by other polymorphisms 
that are in LD with those analyzed in this study. Recently, several new polymorphisms in the 
VDR gene have been identified together with a complete description of the LD and haplo-block 
structure (Fang et al., 2005). 
The strengths of the present study include the population-based sample of the oldest old with 
a high incidence of depression and cognitive decline, and the annual repeated assessment of 
depressive symptoms and the functioning of various cognitive domains. The limitations of the 
study include the lack of vitamin D levels, and information on environmental factors, such as 
(dietary) calcium and vitamin D intake, which could have influenced the associations. Another 
limitation is the ascertainment of incident fractures through self-reporting by a questionnaire. 
This might have led to ascertainment errors, but random errors would only underestimate as-
sociations. To our knowledge, this is the first and only report of a relationship between genetic 
variance in the VDR gene and cognitive functioning and depressive symptoms, and therefore 
until further replication, the possibility of a chance finding cannot be excluded. 
In conclusion, our results show that genetic variance in the VDR gene influences cognitive 
functioning and the prevalence of depressive symptoms in old age. 
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Abstract
The Sir2 gene has been shown to regulate the lifespan of several model organisms. In mam-
mals, the evolutionarily conserved homologue SIRT1 regulates neuroprotection, metabolism 
and cell survival in response to stress. Based on these data, we hypothesized that SIRT1 might 
influence the prevalence of age-related diseases and modify the lifespan of humans. In order to 
test this, we genotyped five single nucleotide polymorphisms (SNPs) in 1245 participants of the 
population-based Leiden 85-plus Study. SIRT1 haplotypes were assessed and tested for associa-
tion with the risks of mortality, metabolic profile, age-related diseases and cognitive functioning. 
These analyses revealed a trend for lower cardiovascular mortality for haplotype 2 and rs3758391 
SNP carriers. In further analyses, this trend was not supported by intermediate phenotypes, 
albeit the rs3758391 T-allele carriers had better cognitive functioning. In conclusion, our re-
sults indicate a role for SIRT1 in cognitive functioning, but the role in lifespan remains to be 
elucidated.
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Introduction
Increased expression of Sir2 (Silent Information Regulator 2) either due to an extra copy of 
the gene or to caloric restriction, prolongs lifespan in various model organisms (Kaeberlein et 
al., 1999; Tissenbaum and Guarente, 2001; Wood et al., 2004). In mammals, there are seven Sir2 
homologues, of which SIRT1 (Sirtuin 1) is the most similar to Sir2 (Frye,  1999; Frye,  2000). 
In response to environmental signals, SIRT1 regulates metabolism and cell survival in various 
types of mammalian cells (Bordone and Guarente, 2005; Cohen et al., 2004; Yang et al., 2006). 
To date, it is unknown whether SIRT1 influences the prevalence of age-related diseases and 
modifies the lifespan of humans.
SIRT1 is a NAD+-dependent (nicotinamide adenine dinucleotide) protein deacetylase (Imai 
et al., 2000) and it regulates metabolism and cell survival through influencing gene silencing, 
and the activity of various transcription factors and co-regulators (Bordone and Guarente, 2005; 
Vaquero et al., 2004). It has been shown that activation of SIRT1 increases glucose tolerance and 
enhances insulin response to glucose in pancreatic β-cells (Bordone et al., 2006; Motta et al., 
2004; Moynihan et al., 2005). Increased SIRT1 activity also promotes hepatic gluconeogenesis 
and inhibits glycolysis via PGC1-α during fasting (Rodgers et al., 2005). Furthermore, SIRT1 has 
an effect on fat metabolism, via inhibition of PPARγ (Picard et al., 2004). These findings suggest 
that increased SIRT1 activity results in a favorable metabolic profile, with decreased prevalence 
of diabetes and cardiovascular diseases. In addition, the role of SIRT1 in providing resistance to 
damage- or stress-induced apoptosis, may help to preserve organ function over time, although 
by doing so it may promote cancer (Hekimi and Guarente, 2003; Lim,  2006). Recent evidence 
also suggests a role for SIRT1 in neuroprotection and neurodegenerative disorders (Araki et al., 
2004; Parker et al., 2005; Qin et al., 2006). Altogether, SIRT1 could influence lifespan through 
several ways. The involvement of SIRT1 in human lifespan has been previously studied in a case-
control study of elderly and young (Flachsbart et al., 2006). No differences in SIRT1 allele and 
haplotype frequencies were observed between these groups. This, however, does not exclude the 
possibility that SIRT1 gene has an influence on human physiology and lifespan. 
The aim of this study was to analyze the association between genetic variation in the SIRT1 
gene, and all-cause and cause-specific mortalities. In addition, metabolic profile, prevalence of 
age-related diseases, and cognitive functioning were tested in the participants of the prospective 
population-based Leiden 85-plus Study. 
Participants and methods
Participants
The Leiden 85-plus Study is a prospective population-based study, in which all 85-year-old 
or older inhabitants of the city Leiden, The Netherlands, were invited to take part. The study 
design and data collection have been described elsewhere (der Wiel et al., 2002; Weverling-Rijns-
burger et al., 1997). The study population consists of two cohorts, cohort ’87 and ’97, and all the 
study participants are of Caucasian origin. Cohort ’87 includes 977 participants aged 85 or older, 
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enrolled between 1987 and 1989 (Weverling-Rijnsburger et al., 1997). Cohort ’97 consists of 599 
subjects, all members of the 1912-1914 birth cohorts, who were enrolled in the month of their 
85th birthday between 1997 and 1999 (der Wiel et al., 2002). DNA was available for 682 partici-
pants from cohort ’87 and for 563 participants from cohort ’97. All participants were followed 
for mortality until August 1, 2005, with a mean follow-up period of 4.4 years. Primary causes of 
death were obtained from the Dutch Central Bureau of Statistics and categorized according to 
the 10th International Classification of Diseases (ICD-10). The Medical Ethical Committee of 
the Leiden University Medical Center approved the study and informed consent was obtained 
from all participants.
Metabolic profile in cohort ‘97
HbA1c (hemoglobin A1c), triglycerides, C-reactive protein (CRP) and high-density lipopro-
tein (HDL)-cholesterol concentrations were determined in serum using fully automated analyz-
ers (Hitachi 747 and 911; Hitachi Ltd, Tokyo, Japan). Low-density lipoprotein (LDL)-cholesterol 
was estimated with the Friedewald equation (Friedewald et al., 1972). 
Cardiovascular pathologies and diabetes in cohort ‘97
The prevalence and number of cardiovascular pathologies and diabetes were obtained from 
the participants’ general practitioner or nursing home physician. For cardiovascular pathologies, 
also electrocardiograms were recorded (Macfarlane and Latif, 1996). Cardiovascular pathologies 
were classified as myocardial infarction, myocardial ischemia, stroke, arterial surgery and inter-
mittent claudication (van Exel et al., 2002). Subjects were classified as having diabetes when they 
met at least one of the following criteria: 1) history of diabetes obtained from the general practi-
tioner or the subject’s treating physician; 2) use of sulfonylurea, biguanide, or insulin, based on 
information obtained from the subject’s pharmacist; or 3) non-fasting glucose of ≥11.1 mmol/l.
Cognitive function and depressive symptoms in cohort ‘97
Overall cognitive functioning was measured with Mini-Mental State Examination (MMSE) 
(Folstein et al., 1975). From specific domains of cognitive functioning attention was assessed 
with Stroop Test (Klein et al., 1997), processing speed with  Letter Digit Coding Test (LDT) 
(Houx et al., 2002) and memory with 12-Word Learning Test, which assesses immediate- (WLTI) 
and delayed recall (WLTD) (Brand and Jolles, 1985). The prevalence of depressive symptoms 
was assessed with 15-item Geriatric Depression Scale (GDS-15) (de Craen et al., 2003). The tests 
assessing specific domains of cognitive functioning could not be administered to 92 participants 
because of severe cognitive impairment (MMSE score < 19 points). All participants were vis-
ited annually for re-measurement of cognitive functioning and depressive symptoms during a 
mean follow-up period of 4.2 years. In addition to the specific tests, a composite cognitive score 
was calculated by converting the scores of the individual tests (Stroop Test, LDT, WLTI and 
WLTD) into a z-score ((individual level – mean level)/SD), and computing the average.
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SNP selection and genotyping
The single nucleotide polymorphisms (SNPs) were selected from the public database of Na-
tional Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov) to cover the 
SIRT1 gene region (GeneID: 23411) in equally spaced intervals. The minor allele frequencies 
(MAF) of the polymorphisms had to be > 5 %. The selected SNPs were rs3758391 (promoter), 
rs3740051 (promoter), rs2236319 (intron), rs2273773 (exon) and rs3818291 (intron). All these 
SNPs were genotyped using the MassArray platform, according to the protocols of the manu-
facturer (Sequenom Inc., San Diego, CA, USA). 
Statistical analysis
The program Haploview (Barrett et al., 2005) was used to estimate the SNPs’ allele fre-
quencies, test the genotypes for Hardy-Weinberg equilibrium, and estimate pair-wise linkage 
disequilibrium (LD) between the polymorphisms. Haplotypes and haplotype frequencies were 
calculated using SNPHAP software (http://www-gene.cimr.cam.ac.uk/clayton/software). The posterior 
probabilities of pairs of haplotypes per subject, as estimated by the SNPHAP, were used as 
weights in all analyses. The haplotype analyses approach used in this study assumes an additive 
effect of the haplotypes, and details of this approach have been described elsewhere (Wallen-
stein et al., 1998). CRP, triglyceride and HbA1c levels were not normally distributed and were 
ln-transformed. All-cause and cause-specific mortality risks with 95 % confidence intervals (CI) 
were calculated with Cox proportional hazard model, using left censoring to correct for the 
delayed entry into the risk set according to age. Associations between haplotypes and metabolic 
profile were analyzed using general linear model. Differences in the prevalence of cardiovascular 
pathologies and diabetes between the haplotypes were tested using binary logistic regression. 
The associations between cognitive functioning, depressive symptoms and haplotypes were 
tested with linear mixed model. All analyses were sex adjusted, except the analyses of cogni-
tive functioning and depressive symptom, which were additionally adjusted for education. The 
analyses were performed with STATA version 9.0 (StataCorp LP, Texas, USA) and SAS version 
8.2 (SAS Institute Inc., Cary, NC, USA) statistical software.
Table 1. Characteristics of the study subjects 
Leiden 85-plus Study
Cohort ’87 Cohort ’97
Number 682 563
Age (median, IQR) 89 (88-92) 85 (-)
Female (n, %) 491 (72 %) 375 (67 %)
Polymorphisms*
rs3758391 (C/T) 0.33 0.36
rs3740051 (A/G) 0.07 0.07
rs2236319 (A/G) 0.07 0.07
rs2273773 (T/C) 0.07 0.08
rs3818291 (G/A) 0.13 0.13
IQR – interquartile range; *minor allele frequency
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Results
All 1245 participants of the Leiden 85-plus Study were genotyped for the five SIRT1 poly-
morphisms (Table 1). The genotype frequencies of the SNPs were in Hardy-Weinberg equilib-
rium, and the allele frequencies were similar between the two elderly cohorts (Table 1). The 
polymorphisms were in strong linkage disequilibrium (D’ 0.97-1.00), and gave rise to five differ-
ent haplotypes of which four were common (frequencies > 5 %) and cumulatively accounted for 
99.9 % of the haplotypes (Figure 1).
All-cause and cause-specific mortality risks were assessed after a mean follow-up period of 4.4 
years. During that time 1001 (80 %) of the 1245 participants had died. From these 406 (41%) had 
died due to cardiovascular disease, 162 (16%) due to cancer, and 431 (43%) due to other causes. 
The cause of death was unknown for two participants. The mortality risk analyses revealed a 
trend for lower cardiovascular mortality (HR 0.82, 95 % CI: 0.66 to 1.01, p=0.062) for haplotype 
2 carriers, compared to the reference haplotype (Figure 2). A similar trend was observed in the 
two Leiden 85-plus Study cohorts separately (data not shown). For the other haplotypes, no dif-
ferences in all-cause or cause-specific mortality risks were observed (Figure 2). 
In order to study further the role of SIRT1, we analyzed the associations between SIRT1 hap-
lotypes and metabolic profile, prevalence of cardiovascular diseases and diabetes. The data on 
these endpoints were available for 563 participants of the cohort ’97. At baseline, no associations 
between the SIRT1 haplotypes and various metabolic profile parameters were observed, except 
for LDL-cholesterol and haplotype 3. These haplotype carriers had 0.18 mmol/l lower (95 % 
CI: -0.34 to -0.02, p=0.030) LDL levels compared to the reference haplotype. In contrast, none 
of the SIRT1 haplotypes were associated with the prevalence of cardiovascular pathologies or 
diabetes. For haplotype 2 carriers, non-significant trends for lower prevalence of arterial surgery 
(OR 0.82, 95 % CI: 0.41-1.65, p=0.574) and intermittent claudication (OR 0.76, 95 % CI: 0.36-
1.60, p=0.471) were observed (Table 2).
Figure 1. Structure and haplotypes of the 
SIRT1 gene. The SIRT1 gene is located in 
chromosome 10 and the coding region spans 
33 715 bp. It contains nine exons, which are 
represented by gray boxes in the figure. The 
approximate positions of the SNPs are indi-
cated with arrows. All SNPs were in strong 
LD and resulted in five haplotypes, of which 
four had frequencies > 5 %. 
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Table 2. SIRT1 haplotypes, prevalence of cardiovascular diseases and diabetes at baseline in the Leiden 85-plus 
Study cohort ’97 (n=563)
Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 4
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
CVD total  (n=365)* 1 (ref ) 1.17 (0.83-1.64) 1.11 (0.77-1.60) 0.84 (0.53-1.33)
Myocardial infarction (n=137) 1 (ref ) 0.99 (0.69-1.44) 0.90 (0.60-1.36) 0.98 (0.58-1.67)
Myocardial ischemia (n=286) 1 (ref ) 1.02 (0.74-1.40) 1.08 (0.77-1.51) 0.91 (0.58-1.44)
Stroke (n=57) 1 (ref ) 1.07 (0.61-1.88) 1.14 (0.67-1.95) 0.90 (0.37-2.23)
Arterial surgery (n=37) 1 (ref ) 0.82 (0.41-1.65) 0.98 (0.48-1.97) 0.75 (0.27-2.08)
Intermittent claudication (n=36) 1 (ref ) 0.76 (0.36-1.60) 0.92 (0.43-2.00) 0.78 (0.29-2.09)
Diabetes (n=92) 1 (ref ) 1.37 (0.89-2.11) 1.46 (0.93-2.28) 0.79 (0.40-1.55)
CVD – cardiovascular disease; OR - odds ratio; CI – confidence interval; * Participants with one or more cardiovascular pathol-
ogy 
In the cohort ’97, cognitive functioning and the prevalence of depressive symptoms were as-
sessed at baseline, age 85 years, and re-examined annually during a mean follow-up period of 4.2 
years. Compared to the reference haplotype, there were no differences in cognitive functioning 
or in prevalence of depressive symptoms between the SIRT1 haplotypes (data not shown).
In addition to haplotype analyses, univariate analyses with the individual polymorphisms 
were performed. From the five polymorphisms, associations with only one (rs3758391), which 
also resides in the haplotype 2, were observed. Heterozygous (HR 0.77, 95 % CI: 0.62 to 0.96, 
p=0.018) but not homozygous (HR 1.01, 95 % CI: 0.73 to 1.39, p=0.965) carriers of rs3758391 
T-allele, had lower cardiovascular mortality risks. These differences were not attributable to 
changes in metabolic profile or in prevalence of age-related diseases (data not shown). In con-
trast, homozygous but not heterozygous carriers of the rs3758391 T-allele performed better on 
all tests measuring cognitive functioning (Table 3). These differences were most pronounced for 
immediate memory (2.26 points, 95 % CI: 0.62 to 3.89, p=0.007 ) and for delayed memory (1.06 
points, 95 % CI: 0.29 to 1.84, p=0.007 ) (Table 3). 
Figure 2. SIRT1 haplotypes, all-
cause and cause-specific mortality 
risks. Mortality risks were calculated 
in the combined cohort of the Le-
iden 85-plus Study (n=1245). All-
cause and cause-specific mortality 
risks are presented as hazard ratios 
(HR) with 95 % confidence intervals 
(CI). The most common haplotype 1 
was used as a reference group. 
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Discussion
In this study, we tested the role of SIRT1 in age-related diseases, cognitive functioning and 
mortality in humans. The analyses of SIRT1 haplotypes revealed a trend for decreased cardio-
vascular mortality for haplotype 2 carriers, and for the rs3758391 SNP carriers, which resides in 
the haplotype 2. None of these, however, were associated with metabolic profile or cardiovascu-
lar pathologies. In contrast, carriers of the rs3758391 polymorphism performed better on tests 
measuring cognitive functioning. 
A specific role of SIRT1 in cell survival and in development of cancer has been proposed (Al-
cendor et al., 2004; Giannakou and Partridge, 2004; Luo et al., 2001). In this study, we found no 
associations between SIRT1 haplotypes and cancer mortality, but we observed a trend for lower 
cardiovascular mortality for haplotype 2 carriers. This trend was observed in the combined, but 
also in the separate cohorts. Altogether, these observations are in accordance with the results 
from cell culture studies, where a protective effect of SIRT1 on cardiac myocytes has been dem-
onstrated (Alcendor et al., 2004; Pillai et al., 2005). In addition, SIRT1 appears to be important 
for the development of heart, since Sirt1 knock-out mice presented cardiac abnormalities (Cheng 
et al., 2003; McBurney et al., 2003). Based on these data, the lower cardiovascular mortality 
in the haplotype 2 carriers in our study population is in line with the expected functions of 
SIRT1. This implies that these SIRT1 haplotype carriers might suffer less from cardiovascular 
diseases. In order to test that, we analyzed the prevalence of various cardiovascular pathologies 
dependent on SIRT1 haplotypes. However, no associations were found, and also the parameters 
of metabolic profile, which underlie atherosclerosis, did not differ. For the latter, a beneficial 
profile was expected for the SIRT1 haplotype 2 carriers. The lack of a consistent risk profile sug-
gests that the association between the lower cardiovascular mortality and the SIRT1 haplotype 
2 could have arisen either due to other mechanisms or due to chance. It might also be that the 
beneficial effects of SIRT1 only appear in acute disease states, thereby decreasing the severity 
of outcomes from crisis events. This mode of action is consistent with the effects of SIRT1 on 
apoptosis.
Table 3. SIRT1 rs3758391 SNP, cognitive functioning and depressive symptoms during mean follow-up period 
of 4.2 years in the Leiden 85-plus Study cohort ’97 (n=563). 
rs3758391
CC
Mean (SE)
CT
Difference  (SE)
TT
Difference  (SE) p-trend
Composite cognitive score -0.23 (0.06) 0.02 (0.08) 0.28 (0.11)* 0.031*
Global cognitive function (points) 22.7 (0.43) 0.24 (0.59) 0.63 (0.83) 0.443
Attention (seconds) 87.0 (2.12) 1.67 (2.90) -2.28 (4.10) 0.823
Processing speed (digits) 15.7 (0.46) -0.11 (0.63) 0.97 (0.88) 0.414
Immediate memory (pictures) 20.1 (0.43) -0.10 (0.59) 2.26 (0.83)* 0.035*
Delayed memory (pictures) 6.86 (0.20) 0.02 (0.28) 1.06 (0.39)* 0.029*
Depressive symptoms (points) 2.97 (0.18) 0.18 (0.25) -0.17 (0.36) 0.912
SE – standard error; * p-value < 0.05
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Besides mortality and various intermediate phenotypes, we tested the role of SIRT1 in cogni-
tive functioning and in prevalence of depressive symptoms. The involvement of SIRT1 in neu-
rophysiological functioning has been discovered recently. Several studies have linked the SIRT1 
protein and its biological activator, resveratrol, to axonal protection and survival of neurons 
(Araki et al., 2004; Parker et al., 2005; Qin et al., 2006). Axonal degeneration often precedes the 
death of neuronal cell bodies in neurodegenerative diseases such as Parkinson’s and Alzheimer’s 
disease (Raff et al., 2002). As a result, impairments in cognitive functioning occur. In this study, 
we found no associations between SIRT1 haplotypes and cognitive functioning and depressive 
symptoms. In contrast, a promoter polymorphism (rs3758391), which is the only variant allele in 
the haplotype 2, was associated with better cognitive functioning. From the specific domains of 
cognitive functioning, memory was the best preserved. These data, together with the evidence 
from recent literature, support a possible role of SIRT1 in the brain. 
Our results are partly in accordance with a recent case-control study, where also no asso-
ciations between SIRT1 polymorphisms/haplotypes and lifespan were found (Flachsbart et al., 
2006). In both studies, five polymorphisms from the SIRT1 gene were analyzed, although only 
two were the same between the studies. However, besides analyzing individual polymorphisms 
we calculated haplotypes and tested their association with various phenotypes. The SIRT1 gene 
is embedded in a region of strong LD (Supplementary Figure 1) and a haplotype-based approach 
enables to capture the majority of the genetic variation in the SIRT1 gene. Since no associa-
tions with intermediate phenotypes were observed, we reason that the association between the 
rs3758391 SNP and cognitive functioning has arisen due to polymorphisms in LD with those 
analyzed in this study. These SNPs could reside in neighboring genes (DNAJC12 in 5’ and 
HERC4 in 3’) or in the regulatory regions of the SIRT1 gene. We speculate that functional 
variability in the SIRT1 gene itself is constrained because it plays diverse but essential roles in 
human physiology. 
In mammals, the Sir2 gene has several homologues (Michishita et al., 2005) and perhaps one 
or more of the other SIRT family members (SIRT1-7) have bigger influences on lifespan. From 
this point of view, SIRT3 gene which encodes a mitochondrial protein, has been implicated 
to play a role in human longevity (Bellizzi et al., 2005; Rose et al., 2003). In addition, recent 
evidence suggests a similar role for SIRT6, since Sirt6-deficient mice displayed genomic instabil-
ity and premature aging-like phenotype (Mostoslavsky et al., 2006). Therefore, the analyses of 
other SIRT family members might shed more light into the regulation of human lifespan.
The strengths of the study include the possibility to estimate several phenotypes in one co-
hort, and the prospective analyses with high number of deaths during follow-up. A limitation of 
the study is the lack of data on the activity or levels of SIRT1, which would reflect the function-
ality of the polymorphisms analyzed. In addition, considering the number of tests performed, 
adjustment for multiple testing would eliminate all the statistically significant associations ob-
served. Consequently, the results of this study are not exhaustive.
In conclusion, the results of this study provide evidence for a role of SIRT1 in cognitive 
functioning, but due to the lack of associations with intermediate phenotypes, the influence of 
genetic variation in the SIRT1 gene on lifespan remains to be elucidated. 
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Supplementary materials
Supplementary Figure 1. Overview of the physical and genetic structure of the SIRT1 gene region as 
generated by Haploview from the Caucasian HapMap data (release nr. 21a). The polymorphisms geno-
typed by the HapMap are shown in the top panel. The SNPs marked with boxes were analyzed in this 
study. The lower panel gives an overview of the linkage disequilibrium structure of the locus (D’) 
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Abstract
Depression and cognitive decline have been associated with changes in circulating cortisol 
concentrations. Cortisol exerts its functions through mineralocorticoid (MR) and glucocorticoid 
(GR) receptors. However, data on the influence of variations in the MR and GR genes on depres-
sive symptoms and cognitive functioning in older adults are scarce. Therefore, we explored the 
impact of MR-215G/C, MR-I180V, GR-ER22/23EK, GR-N363S and GR-BclI polymorphisms 
on these endpoints in the population-based Leiden 85-plus Study. This prospective study in-
cludes 563 participants aged 85 years and older, with a mean follow-up of 4.2 years. In this study, 
high morning cortisol levels (per 1 SD cortisol) associated with impairments in global cognitive 
functioning ( p=0.002) at baseline (age 85). These impairments were mainly attributable to lower 
attention ( p=0.057) and slower processing speed ( p=0.014). Similar effects were also observed 
during follow-up (age 85-90), where participants with higher cortisol levels (per 1 SD corti-
sol) had impaired global cognitive functioning ( p=0.003), as wells as impairments in attention 
( p=0.034) and processing speed ( p=0.013). Changes in depressive symptoms were observed for 
the MR-I180V single nucleotide polymorphism (SNP), where during follow-up the prevalence of 
depressive symptoms was higher in the 180V-allele carriers ( p=0.049) compared to non-carriers. 
Dependent on these polymorphisms, no differences in overall and in specific domains of cog-
nitive functioning were observed. In conclusion, the MR-I180V SNP has a specific effect on 
depressive symptoms, independent from cognitive functioning and other polymorphisms in the 
MR and GR genes. In contrast, these genetic variants in the MR and GR genes do not influence 
cognitive functioning in old age. 
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Introduction
In response to a real or imagined threat the organism reacts by eliciting a stress-response 
in order to cope with the stressor. In humans, cortisol is the primary active stress hormone 
that mediates counter-responses to stress, aimed to re-establish homeostasis and coordinate 
behavioral adaptations (de Kloet et al, 1998, 2005; Munck et al, 1984). Cortisol exerts its effects 
through mineralocorticoid (MR) (NR3C2) and glucocorticoid (GR) (NR3C1) receptors, which 
are abundantly co-expressed in the neurons of limbic structures (Herman, 2003). MRs, which 
have ten times higher affinity for cortisol than GRs, determine the threshold or sensitivity of the 
stress system and thus the onset of the stress response (de Kloet et al, 2005). GRs, on the other 
hand, represent the slower mode that promotes the termination of the stress response (de Kloet 
et al, 2005). Balancing these two systems is essential for cell homeostasis, mental performance 
and health.
Various studies have shown that stress-responsiveness is highly variable among human sub-
jects, and an inadequate stress-response increases vulnerability for disease. Changes in the stress 
hormone system have been shown to play a role in the development of depression (Belanoff et 
al, 2001b; Holsboer, 2000, 2001). In addition, changes in the circulating cortisol concentrations 
have been associated with impairments in various cognitive domains, including attention, per-
ception and memory ( Jameison and Dinan, 2001; Lupien et al, 2005; Newcomer et al, 1999). In 
terms of memory, excess cortisol levels have been shown to impair mainly declarative and not 
non-declarative memory (Lupien et al, 2005).
As MRs and GRs mediate the cortisol signal, variations in these genes may introduce changes 
in cortisol signaling dynamics, and thereby lead to changes in mood and cognitive function. In 
the MR gene, the 215G/C and I180V single nucleotide polymorphisms (SNPs) have been shown 
to change cortisol signaling in vitro (Arai et al, 2003), whereas in the GR gene, the ER22/23EK, 
N363S and BclI SNPs have been shown to change HPA-axis reactivity after a dexamethasone 
suppression test or a psychosocial stressor (Huizenga et al, 1998; van Rossum et al, 2002, 2003). 
In addition, the ER22/23EK variant has been associated with major depression in two studies 
(van Rossum et al, 2006; van West et al, 2006). To date, there are no publications that examine 
the role of these MR and GR variants in cognitive functioning and as yet no study has assessed 
the effects of variants in the MR gene on mood. Furthermore, a combined effect of the genetic 
variants in the MR and GR genes may have a different effect on depressive symptoms and cogni-
tive functioning, owing to the interplay between these genes. 
In this study, we examined the influence of cortisol levels and variants in the MR and GR 
genes on overall cognitive functioning, attention, processing speed, immediate and delayed 
memory, and on depressive symptoms in old age. All analyses were performed in the prospec-
tive population-based Leiden 85-plus Study. Since in old age cognitive decline and depressive 
symptoms are more prevalent, the effects of a lifelong exposure to changes in cortisol signaling 
owing to polymorphisms should be more easily detectable on these endpoints.
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Participants and methods
Participants
The Leiden 85-plus Study is a population based prospective study of inhabitants of the city 
Leiden, The Netherlands. All 85 year old inhabitants were invited to participate. There were no 
selection criteria related to health or demographic characteristics. The study population con-
sists of 599 participants, all Caucasians and members of the 1912-1914 birth cohorts, who were 
enrolled in the month of their 85th birthday between 1997 and 1999 (Bootsma-van der Wiel et 
al, 2002). For the present study DNA was available for 563 participants. The Medical Ethical 
Committee of the Leiden University Medical Center approved the study and informed consent 
was obtained from all participants or their guardian. 
Cognitive function and depressive symptoms
Global cognitive functioning was assessed in all participants with the Mini-Mental State Ex-
amination (MMSE) (Folstein et al, 1975). Participants with a MMSE score 19 points or higher 
were subjected to additional tests to measure attention (Stroop Test) (Klein et al, 1997), process-
ing speed (Letter Digit Coding Test, LDT) (Houx et al, 2002), immediate recall memory (Word 
Learning Test Immediate Recall, WLTI), delayed recall memory (Word Learning Test Delayed 
Recall, WLTD) (Brand and Jolles, 1985) and depressive symptoms (15-item Geriatric Depres-
sion Scale, GDS-15) (De Craen et al, 2003). The tests assessing specific domains of cognitive 
functioning were not administered in subjects with a MMSE score of 18 points or lower, because 
diminished reliability and validity in subjects with severe cognitive impairment. All participants 
were visited annually for re-measurement of cognitive functioning during a mean follow-up 
period of 4.2 years. Parallel versions of the tests were used. Details of cognitive testing are de-
scribed elsewhere (Houx et al, 2002). 
Cortisol measurement at baseline
All blood samples were drawn in the morning before 11.00 AM. The median time between 
venipuncture and centrifugation in our laboratory was 50 min (interquartile range: 30–70 min). 
Non-fasting plasma cortisol levels were determined by a fluorescence polarization immunoassay 
using the Abbott TDx (Abbott Laboratories, Abbott Park, IL, USA) according to the manufac-
turer’s instructions. The within-assay coefficient of variation (CV) was below 5 % at different 
levels.
Possible confounders
Socio-demographic characteristics, such as sex and level of education were considered as 
possible confounders. Education was divided into two levels: a lower education level, includ-
ing individuals without schooling or with only primary school education (less than 6 years of 
schooling), and those with a higher education level (6 years or more of schooling). Health related 
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correlates were assessed at baseline (age 85), and included drug use, obtained from the pharma-
cist’s registers, and chronic diseases.  Data on the use of oral corticosteroids were available for 
all participants. Chronic diseases included cardiovascular disease, diabetes mellitus, chronic 
obstructive pulmonary disease, arthritis, malignancy, dementia and Parkinson’s disease. Data 
were obtained at baseline from a structured questionnaire and based on the diagnoses of the 
general practitioner.
Genotyping
The GR-ER22/23EK polymorphism consists of two single nucleotide polymorphisms 
(SNPs) in codons 22 (rs6189) and 23 (rs6190). The MR-I180V (rs5522), GR-ER22/23EK, GR-
N363S (rs6195) and GR-BclI (van Rossum et al, 2003) variants were genotyped using an Assay-
by-Design (Applied Biosystems, Foster City, CA), consisting of PCR primers and TaqMan MGB 
probes, on an ABI 7900 HT with real-time PCR (Applied Biosystems). MR-215G/C (rs2070951) 
was genotyped using the MassArray platform according to the protocols of the manufacturer 
(Sequenom, San Diego, CA).
Statistical analysis
Allele and genotype frequencies were calculated and analyzed for deviation from Hardy-
Weinberg equilibrium using the χ2-test. Cortisol levels were converted into z-scores ((individual 
level – mean level)/SD) in order to normalize the data and provide comparable estimates per 
1-SD increase in cortisol level. The cross-sectional (age 85) and longitudinal (age 85-90) asso-
ciations between baseline cortisol levels, cognitive functioning and depressive symptoms were 
analyzed using a linear regression and a linear mixed model, respectively. Differences in cortisol 
levels dependent on polymorphisms were assessed with a univariate general linear model. As-
sociations between genotypes, cognitive functioning and depressive symptoms were analyzed 
using the linear mixed model, estimating the overall mean difference in cognitive functioning 
or depressive symptoms during follow-up. In multivariate analyses, the other polymorphisms 
were added to the model as independent covariates. The analyses of cognitive functioning were 
adjusted for sex and level of education, and the analyses of depressive symptoms were adjusted 
for sex and presence of chronic diseases. All these analyses were also performed with additional 
adjustment for cortisol levels or chronic diseases. The analyses were performed with SPSS sta-
tistical software, version 12.0 (Chicago, IL, USA).
Results
Baseline characteristics of the participants are shown in Table 1. From the 563 participants, 
12 were excluded from the analyses owing to the use of corticosteroids. Global cognitive func-
tioning was assessed in all participants using MMSE. Some 460 (83 %) scored 19 points or 
more on MMSE, and these subjects performed additional tests, measuring attention, processing 
speed, immediate and delayed recall memory, and depressive symptoms. All 551 subjects were 
genotyped for the MR-215G/C, MR-I180V, GR-ER22/23EK, GR-N363S and GR-BclI poly-
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morphisms. The overall genotype distributions and resulting allelic frequencies of the variants 
were in agreement with the distribution predicted by the Hardy-Weinberg equilibrium, and in 
case of the GR gene similar to the frequencies observed in other studies. This is the first study 
reporting allele frequencies for the SNPs in the MR gene. Because of the low allele frequencies 
of the SNPs (Table 1), the heterozygous and homozygous minor allele carriers of all the poly-
morphisms were combined. However, for the MR-215G/C and GR-BclI variants, the analyses 
were also repeated using all genotypes, as these polymorphisms have higher allele frequencies.
Global cognitive functioning, attention, processing speed, memory and depressive symp-
toms were assessed at baseline and re-examined annually during a mean follow-up period of 4.2 
years. During follow-up, there was a significant increase in depressive symptoms and a decline 
in cognitive functioning in all participants (all p<0.001). The influence of plasma cortisol levels 
on depressive symptoms and cognitive functioning was assessed at baseline (age 85) and also 
during follow-up (age 85-90). The cross-sectional analysis at age 85 revealed that higher cortisol 
levels (per 1 SD cortisol) were associated with impairments in overall cognitive performance. 
This was observed in the whole study population ( p=0.008), as well as in the restricted sample 
(MMSE ≥ 19 points) ( p=0.002) (Table 2). These differences were attributable to lower attention 
( p=0.057) and slower processing speed ( p=0.014) (Table 2). Similar effects were also observed 
during follow-up (age 85-90), where participants with higher cortisol levels (per 1 SD cortisol) 
had impaired global cognitive functioning ( p=0.004), attention ( p=0.034) and processing speed 
( p=0.013) (Table 2). The overall difference in cognitive functioning and depressive symptoms
Table 1. Baseline characteristics of study participants
Number 551
Age1 85 (-)
Female (%) 365 (66 %)
Low level of education (%) 356 (65 %)
Chronic diseases 391/461
Cortisol (μmol/l)1 0.49 (0.15)
Mini-Mental State Examination (points)1 23.9 (6.27)
Mini-Mental State Examination  ≥ 19 points (%) 460 (83 %)
Specific domains of cognition1
Stroop Test (seconds) 82.4 (34.3)
Letter Digit Coding Test (digits) 17.1 (7.12)
Word Learning Test Immediate Recall (pictures) 23.9 (6.00)
Word Learning Test Delayed Recall (pictures) 8.65 (2.76)
15-item Geriatric Depression Scale (points)1 2.32 (2.44)
Polymorphisms (minor allele frequency)
MR - 215G/C 0.47
MR - I180V 0.14
GR - ER22/23EK 0.03
GR - N363S 0.05
GR - BclI C/G 0.34
1 Data presented as means with standard deviations (SD)
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Table 2. Cortisol, cognitive functioning and depressive symptoms at baseline (age 85), and during the annual 
follow-up (age 85-90) 
Age 85
difference per 1 SD cortisol
Age 85-90
difference per 1 SD cortisol
Estimate (SE) p-value Estimate (SE) p-value
All participants (n=551)
Mini-Mental State Examination (points) -0.67 (0.25) 0.008 -0.78 (0.27) 0.004
Restricted sample (n=460)1
Mini-Mental State Examination (points) -0.40 (0.13) 0.002 -0.37 (0.12) 0.003
Specific domains of cognitive function
Stroop Test (seconds) 3.15 (1.65) 0.057 2.86 (1.34) 0.034
Letter Digit Coding Test (digits) -0.79 (0.32) 0.014 -0.74 (0.30) 0.013
Word learning Test Immediate Recall (pictures) -0.39 (0.29) 0.187 -0.38 (0.28) 0.186
Word learning Test Delayed Recall (pictures) -0.21 (0.14) 0.129 -0.19 (0.13) 0.160
15-item Geriatric Depression Scale (points) 0.18 (0.12) 0.146 0.10 (0.13) 0.424
1 Restricted to participants who scored on MMSE ≥ 19 points 
Figure 1. Cognitive functioning and depressive symptoms during the mean 4.2 year follow-up period 
in participants with low (<0.47 μmol/l) and high (>0.47 μmol/l) cortisol levels. The p-values represent 
the overall mean difference in cognitive functioning and mood during the follow-up between the two 
groups
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during follow-up dependent on cortisol levels (two groups based on median cortisol level 0.47 
μmol/l) is shown in Figure 1.
The influence of MR and GR gene polymorphisms on plasma cortisol levels is shown in Table 
3. Plasma cortisol levels were associated with the 215G/C variant in the MR gene, where the 
C-allele carriers had lower cortisol levels than non-carriers ( p=0.008) (Table 3). In addition, for 
the GR-BclI C/G SNP, a trend for an increase in cortisol levels in G-allele carriers was observed 
( p=0.084) (Table 3). 
Cognitive functioning and the prevalence of depressive symptoms were also analyzed de-
pendent on the MR and GR gene polymorphisms. Differences in depressive symptoms were ob-
served for the MR-I180V SNP, where carriers of the 180V-allele had more depressive symptoms 
than non-carriers ( p=0.049) (Table 4, Figure 2). This difference increased after adjusting for 
cortisol levels (0.54 points, SE (0.27), and p=0.043). On the other hand, the analyses with cog-
nitive functioning dependent on the polymorphisms revealed no differences, either in overall 
(Table 4) or in specific domains of cognitive functioning (data not shown). The results remained 
unaltered after the analyses with a multivariate model, or adjustment for depressive symptoms 
and cortisol concentrations (data not shown). The analyses using all the MR-215G/C and GR-
BclI genotypes did not provide any extra information.
All the cognitive functioning analyses were repeated with additional adjustment for chronic 
diseases, as participants with higher cortisol levels had a higher prevalence of chronic diseases at 
baseline. This adjustment only marginally changed the results (data not shown).
Figure 2. Prevalence of depressive symp-
toms in non-carriers and carriers of the 
MR-I180V polymorphism during the mean 
4.2-year follow-up period. P-value represents 
the overall mean difference in the 15-item 
Geriatric Depression Scale (GDS-15) scores 
during follow-up between the two groups. (n) 
represents the number of participant 
Table 3. Cortisol levels (μmol/l) dependent on the MR and GR polymorphisms
Non-carriers Carriers
n mean (SE) n mean (SE) p-value
MR - 215G/C 135 0.52 (0.01) 376 0.48 (0.01) 0.008
MR - I180V 394 0.49 (0.01) 145 0.48 (0.01) 0.423
GR - ER22/23EK 504 0.49 (0.01) 33 0.49 (0.03) 0.895
GR - N363S 494 0.49 (0.01) 50 0.50 (0.02) 0.491
GR - BclI C/G 234 0.47 (0.01) 288 0.50 (0.01) 0.084
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Discussion
In this study, we assessed the impact of cortisol levels and of variations in the MR and 
GR genes on cognitive function and depressive symptoms. The results revealed associations 
between high cortisol levels and cognitive impairment, but not with depressive symptoms. In 
contrast, the prevalence of depressive symptoms was dependent on a variation in the MR gene, 
where carriers of the 180V-allele had more depressive symptoms compared to the non-carriers. 
This association remained unchanged after taking into account the influence of the other poly-
morphisms in the MR and GR genes. Variations either in the MR gene or in the GR gene were 
not associated with cognitive function. 
Similar to observations in other studies, we found an association between high cortisol levels 
and cognitive impairments. These differences were observed at baseline (age 85) and also during 
follow-up period (age 85-90). Impairments in global cognitive functioning, owing to high cor-
tisol, were observed in the whole study population, and also in the restricted sample (MMSE ≥ 
19 points). In the restricted sample, the estimates were without exception smaller however, they 
had increased significance. This implies that by excluding severely cognitively impaired partici-
pants, we lose some power but increase specificity, as these participants may have impaired cog-
nition caused by other factors than high cortisol. From the specific domains of cognitive func-
tioning, attention and speed of information processing were most affected, whereas for memory 
and mood only a modest influence was observed. Intriguingly, in literature high cortisol levels 
have been mainly associated with memory impairments and depression (Holsboer, 2000, 2001; 
Lupien et al, 2005). Most of these studies have been conducted with exogenous administration 
of glucocorticoids or with depressed patients, with higher cortisol concentrations than observed 
in this study. Therefore, it might be that cortisol levels higher than the average values in older 
Table 4. Cognitive functioning and depressive symptoms during the mean 4.2 year follow-up period depen-
dent on the MR and GR polymorphisms
Non-carriers Carriers
mean (SE) mean (SE) p-value
Mini-Mental State Examination (points)1
MR - 215G/C 25.2 (0.25) 25.6 (0.15) 0.179
MR - I180V 25.5 (0.15) 25.5 (0.23) 0.926
GR - ER22/23EK 25.5 (0.14) 25.8 (0.48) 0.458
GR - N363S 25.5 (0.13) 25.3 (0.43) 0.776
GR - BclI C/G 25.5 (0.19) 25.4 (0.17) 0.809
15-item Geriatric Depression Scale (points)1
MR - 215G/C 3.12 (0.24) 2.98 (0.15) 0.594
MR - I180V 2.90 (0.15) 3.42 (0.23) 0.049
GR - ER22/23EK 3.02 (0.13) 3.53 (0.48) 0.297
GR - N363S 3.04 (0.13) 2.55 (0.41) 0.248
GR - BclI C/G 3.26 (0.19) 2.89 (0.17) 0.133
1 Restricted to participants who scored on MMSE ≥ 19 points
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adults are necessary to affect memory function and depressive symptoms. However, the lack of 
associations could also be related to the single cortisol measurement, or to the tests used in this 
study. It has been shown, that not the acute basal cortisol levels, but rather the change in cortisol 
levels over time predicts cognitive impairments in aging (Belanoff et al, 2001a). In addition, it 
has been shown that in some cases, cortisol effects on cognitive performance are very difficult 
to detect with the use of standardized, less sensitive cognitive tests. Thus, it is plausible that the 
memory tests used in this study are not sensitive enough to detect cognitive impairments related 
to cortisol.
MRs have been implicated in the control of HPA-axis activity, as they determine the thresh-
old of stress system’s activation (de Kloet et al, 2005). To date, there is no information on 
how polymorphisms in the MR gene influence these functions. In this study, we found that 
plasma cortisol levels were lower in C-allele carries of the 215G/C SNP in the MR gene. As 
the 215G/C SNP precedes the start codon of the MR gene (Arai et al, 2003), it could interfere 
with the translational start site and thus, lead to a less efficient translation and change in MR-A 
and MR-B balance (Pascual-Le Tallec et al, 2004). However, the influence of the different MR 
isoforms on cortisol levels is not known. From the other MR polymorphisms, we found that the 
I180V amino acid change in the MR gene was associated with higher prevalence of depressive 
symptoms. It has been reasoned that this SNP changes MR’s transactivational properties (Arai 
et al, 2003), which might change stress responsiveness and lead to increased vulnerability to 
develop depressive symptoms. On the other hand, carriers of the MR-I180V polymorphism did 
not display any deficits in overall or in specific domains of cognitive functioning, which suggests 
that the polymorphism specifically influences depressive symptoms and not cognitive function-
ing. The mechanisms behind cortisol mediated effects on cognitive functioning and depressive 
symptoms are most probably different, and modulated by different neuronal pathways and/or 
contextual conditions (Lupien et al, 2005).
Previously, it has been shown that the GR gene polymorphisms alter HPA-axis responsive-
ness and thereby cortisol sensitivity. The ER22/23EK variation has been associated with resis-
tance to cortisol (van Rossum et al, 2002), whereas the N363S and BclI polymorphisms were 
shown to increase the sensitivity to cortisol (Huizenga et al, 1998; van Rossum et al, 2002, 2003). 
We reasoned, that the increased resistance to cortisol attained by the ER22/23EK variant would 
protect against the damaging effects of high cortisol levels on cognitive decline and depression, 
whereas increased cortisol sensitivity would have opposite effects. In this study, we found no 
influences of the analyzed polymorphisms on plasma cortisol levels, or on cognitive function-
ing. For depressive symptoms, only a trend for an influence by the ER22/23EK variant was ob-
served. In contrast, the 22/23EK-allele carriers tended to have more depressive symptoms than 
non-carriers, without any deficits in cognitive functioning. The lack of a significant difference 
in depressive symptoms between the ER22/23EK carriers and non-carriers in our study may 
result from the low number of participants carrying the variant allele. Despite that, the trend 
observed in our study, is in accordance with two recent studies, showing an enrichment of the 
22/23EK-allele in patients with major depression (van Rossum et al, 2006; van West et al, 2006). 
It could be that in our study the lack of a distinct influence of the GR gene SNPs on cognitive 
functioning and mood is a result of the non-stressful testing conditions. GRs are activated in 
response to stress and they promote the termination of the stress response and normalization of 
homeostasis (de Kloet et al, 2005). This suggests that the effects of the polymorphisms are only 
seen in response to stress or challenge, and that testing in basal conditions does not reveal any 
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differences in cognitive functioning and depressive symptoms.
The response to stress is modulated by the interplay between MRs and GRs, and a combined 
effect of genetic variants in these genes may have a different effect on depressive symptoms and 
cognitive functioning. In this study, we attempted to take into account the influence of genetic 
variability in both the MR and GR genes. However, the multivariate analysis did not add any 
extra information. The cortisol signaling cascade is complex and involves numerous chaperones, 
accessory proteins, co-regulators and interacting transcription factors that permit differentia-
tion between the MR- and GR-mediated actions (De Bosscher et al, 2003; Pascual-Le Tallec 
and Lombes, 2005). For instance, recently it was found that increase in recurrence of depressive 
episodes is associated with a variant in a gene (FKBP5) that regulates GR activity (Binder et 
al, 2004). Therefore, not only genes directly involved in stress-induced signaling pathways, but 
genes regulating their activity also appear to be involved in the development of these disorders, 
and their actions should be analyzed in more detail.
Strengths of the present study include the population-based sample of the oldest old with 
high incidence of depression and cognitive decline, and the annual repeated assessment of de-
pressive symptoms and various cognitive domains. A major limitation of the study is the one 
time cortisol measurement. Cortisol is secreted diurnally, and the single measurement of cortisol 
over an entire day of the circadian cortisol secretion, considerably weakens the value of this mea-
sure. Cortisol levels measured only once could be confounded by acute effects, and not reflect 
the basal concentration. It has been shown, that cortisol is relatively stable from day to day but 
it is not indisputably stable across the years. Therefore, the results on the predictability of base-
line cortisol levels on cognitive decline over the years should be interpreted with care. Another 
limitation of the study is the lack of data on HPA-axis reactivity, or on other parameters that 
reflect the stress system’s activity.
In conclusion, this is the first study looking into the influence of polymorphisms in the MR 
and GR genes on mood and cognitive functioning in older adults. We found an association be-
tween high baseline cortisol levels and impairments in cognitive functioning during follow-up. 
However, no differences in cognitive functioning were observed dependent on the polymor-
phisms in the MR and GR genes. On the other hand, the I180V variant in the MR gene influ-
enced the prevalence of depressive symptoms, independently from cognitive functioning.
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Abstract
Recently, the ER22/23EK, N363S and BclI polymorphisms in the glucocorticoid receptor 
(GR) gene have been linked to altered cortisol sensitivity and to cortisol-associated disorders. 
The aim of this study was to investigate the effect of these genetic variants in the GR gene on 
cardiovascular disease and mortality in elderly persons aged 85 years and over. In the popula-
tion-based Leiden 85-plus Study, 552 participants were genotyped for the ER22/23EK, N363S 
and BclI polymorphisms, and the effects of the polymorphisms on metabolic profile, body com-
position, and on the prevalence of cardiovascular pathologies at baseline, were assessed. All-
cause and cardiovascular disease mortality risks dependent on the SNPs were calculated after a 
4.2-year follow-up. The analyses of metabolic profile revealed that carriers of the ER22/23EK 
polymorphism have higher HbA1C levels ( p<0.001) and carriers of the N363S SNP have higher 
LDL cholesterol ( p<0.001) and triglyceride concentrations ( p=0.03), compared to the non-car-
riers. The only signficant association between genotype and body composition analyses was 
for height and the ER22/23EK polymorphism. Men carrying the ER22/23EK polymorphism 
were taller ( p=0.02) compared to non-carriers. No associations with cardiovascular patholo-
gies, allcause and cardiovascular mortality were observed for any of the polymorphisms. We 
conclude that, in spite the effect of the ER22/23EK and N363S SNPs on metabolism, these 
polymorphisms together with the BclI SNP, do not affect the risks of cardiovascular disease and 
survival at old age.
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Introduction
In response to various stimuli, including stress, cortisol coordinates metabolic, endocrine, 
immune, and nervous system responses (Chrousos,  1995; Chrousos,  1998; de Kloet et al., 
1998; McEwen,  1998; Munck et al., 1984). Cortisol exerts the majority of its functions through 
glucocorticoid receptors (GRs). Disturbances in cortisol signaling, resulting either from altered 
hormone availability or decreased/increased receptor-mediated signal transduction have been 
associated with a variety of phenotypes including cardiovascular disease, which is a major cause 
of death at old age.
It is known that sensitivity to cortisol varies considerably between individuals as demonstrat-
ed by the dexamethasone suppression test (Huizenga et al., 1998b). Therefore, the underlying 
susceptibility to cortisol-associated disorders may vary. A degree of inter-individual variation 
in responsiveness to cortisol is attributable to three polymorphisms in the GR gene (NR3C1). 
Recently an ER22/23EK variation in the GR gene was associated with a resistance to cortisol, 
and shown to result in a better metabolic and cardiovascular health profile, leading to increased 
survival rate (van Rossum et al., 2002; van Rossum et al., 2004a; van Rossum et al., 2004b). On 
the other hand, increased sensitivity to cortisol, related to the N363S (Huizenga et al., 1998a) 
and BclI (van Rossum et al., 2003) polymorphisms, has been shown to cause opposite effects. In 
middle-aged subjects, the N363S and BclI polymorphisms were associated with increased body 
mass index (BMI) and with several risk factors for atherosclerosis and coronary artery disease 
(Di Blasio et al., 2003; Lin et al., 2003; van Rossum et al., 2003). Together these results suggest 
that the GR gene plays an important role in modulating the susceptibility to cardiovascular dis-
ease. Futhermore, there are disparities in the published literature. For instance in some studies, 
associations between these three polymorphisms and metabolic parameters or body composition 
have been found (Di Blasio et al., 2003; Huizenga et al., 1998a; Lin et al., 1999; Lin et al., 2003; 
van Rossum et al., 2002; van Rossum et al., 2003; van Rossum et al., 2004b), whereas in other 
studies no association, or opposite effects have been observed (Dobson et al., 2001; Echwald et 
al., 2001; Panarelli et al., 1998; Rosmond et al., 2001; van Rossum et al., 2002; van Rossum et al., 
2004a). However, the recent results with cardiovascular disease (Lin et al., 2003) and survival 
(van Rossum et al., 2004a) have never been replicated in elderly subjects. Therefore, the effect of 
the GR gene on cardiovascular disease and survival at old age remains to be elucidated.
In this study, we assessed the impact of the ER22/23EK, N363S and BclI variants in the GR 
gene on metabolic profile, body composition, and on the prevalence of cardiovascular patholo-
gies. Also the risks of allcause and cardiovascular mortalities dependent on the polymorphisms 
were calculated. The study was carried out in the population-based Leiden 85-plus Study, using 
cross-sectional and prospective study designs. 
Participants and methods
Participants
The Leiden 85-plus Study is a prospective population based study, in which all 85 year old in-
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habitants of Leiden, The Netherlands were invited to take part. There were no selection criteria 
related to health or demographic characteristics. The study population consists of 599 subjects, 
all members of the 1912-1914 birth cohort, enrolled in the month of their 85th birthday between 
1997 and 1999 (Bootsma-van der Wiel et al., 2002). For the present study DNA was available for 
563 people. All participants of the Leiden 85-plus Study were followed for mortality until April 
1, 2004. Primary causes of death were obtained from the Dutch Central Bureau of Statistics and 
categorized according to the 10th International Classification of Diseases (ICD-10). The Medical 
Ethical Committee of the Leiden University Medical Centre approved the study and informed 
consent was obtained from all participants. We also genotyped 370 blood donors (median age 
32, inerquartile range (27-36)) from Leiden and surrounding areas for a cross-sectional analysis 
of genotype frequencies (Heijmans et al., 1999).
Metabolic profile and body composition at baseline
C-reactive protein, high-density lipoprotein (HDL)-cholesterol, triglycerides and HbA1c 
(hemoglobin A1c) concentrations were determined in serum using fully automated analyzers 
(Hitachi 747 and 911; Hitachi, Ltd, Tokyo, Japan). Low-density lipoprotein (LDL)-cholesterol 
was estimated with the Friedewald equation (Friedewald et al., 1972). Cortisol was determined 
by a fluorescence polarization immunoassay using the Abbott TDx (Abbott Laboratories, Ab-
bott Park, IL, USA) according to the manufacturer’s instructions. The within-assay coefficient 
of variation (CV) was below 5 % at different levels. Body weight (kg) and height (cm) were mea-
sured in all participants and body mass index (BMI, kg/m2) was calculated. The measurement 
of height is often unreliable in elderly, and therefore also armspan (cm) was measured, which 
approximates to height at maturity.
Cardiovascular pathologies at baseline
The prevalence and number of cardiovascular pathologies were obtained from the partici-
pant’s general practitioner or nursing home physician. In addition, electrocardiograms were re-
corded on a Siemens Siccard 440 and transmitted by telephone to the ECG Core Lab in Glasgow 
for automated Minnesota coding (Macfarlane and Latif, 1996). Cardiovascular pathologies were 
classified as: myocardial infarction, myocardial ischemia, intermittent claudication or stroke 
(van Exel et al., 2002).
Genotyping
The ER22/23EK variant consists of two single nucleotide polymorphisms (SNPs) in codons 
22 (A/G, rs6189) and 23 (G/A, rs6190). The ER22/23EK, N363S (A/G, rs6195) and BclI (C/G) 
(van Rossum et al., 2003) polymorphisms were genotyped using an Assay-by-Design (Applied 
Biosystems), consisting of PCR primers and TaqMan MGB probes on an ABI 7900 HT with 
real-time PCR (Applied Biosystems). Amplification reactions and parameters were based on 
manufacturer’s instructions.  
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Statistical analysis
Allele frequencies were calculated and analyzed for deviation from the Hardy-Weinberg equi-
librium using the χ2-test. Mean differences in the parameters of the metabolic profile and body 
composition dependent on the polymorphisms were assessed with the univariate general linear 
model. All continuous variables were normally distributed, except for the C-reactive protein 
and triglyceride levels, which were ln-transformed. Differences in the prevalence of cardiovas-
cular pathologies between genotypes were tested using the binary logistic regression model 
adjusted for sex. Mortality was first estimated using the Kaplan-Meier method, followed by the 
calculation of sex adjusted mortality risks and 95 % confidence intervals (CI) for allcause and 
Table 1. Baseline characteristics of the Leiden 85-plus Study
Number 552
Age 85
Female 366 (66 %)
Independently living 451 (82 %)
Metabolic profile 
Cortisol (mmol/l) 0.49 (0.15)
C-reactive protein (mg/l) 2.83 (4.26)
HDL cholesterol (mmol/l) 1.31 (0.40)
LDL cholesterol (mmol/l) 3.67 (0.97)
Triglycerides (mmol/l) 1.40 (1.58)
HbA1c (mmol/l) 5.79 (1.09)
Body composition 
BMI (kg/m2)
Men 26.3 (5.17)
Women 27.7 (4.74)
Weight (kg)
Men 74.5 (15.2)
Women 67.5 (12.7 )
Height (cm)
Men 168.1 (6.49)
Women 156.2 (6.24)
Armspan (cm)
Men 178.1 (7.31)
Women 162.5 (7.03)
Cardiovascular pathologies
Myocardial infarction 134 (24 %)
Myocardial ischemia 280 (51 %)
Intermittent claudication 34 (6 %)
Stroke 56 (10 %)
Metabolic profile and body composition values presented as means (SD), except for C-reactive protein where geometric mean 
(SD) is presented
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cardiovascular mortality with the Cox proportional hazard model. All analyses were performed 
with SPSS statistical software, version 12.0 (Chicago, Illinois, USA), with the exception of the 
mortality analyses, which were performed with STATA software, version 9.0 (Texas, USA). 
Results
DNA was available for 563 participants, of which 11 were excluded due to the use of corti-
costeroids. The baseline characteristics of the remaining 552 participants are presented in Table 
1. All study subjects were genotyped for the ER22/23EK, N363S and BclI polymorphisms with 
a genotyping error of lower than 5 %. Therefore the total number of analyzed participants was 
540 for ER22/23EK, 548 for N363S and 526 for the BclI polymorphisms. The minor allele 
frequencies were 0.03, 0.05 and 0.34 for the ER22/23EK, N363S and BclI polymorphisms re-
spectively. The overall genotype distributions and resulting allelic frequencies of the SNPs were 
in agreement with the distribution predicted by the Hardy-Weinberg equilibrium. In this study, 
the calculated allele and genotype frequencies did not differ between elderly and young subjects 
(n=370, median age 32 years)(data not shown). 
At baseline, several parameters of the metabolic profile dependent on the ER22/23EK, 
N363S and BclI variants were assessed. The analyses revealed that carriers of the ER22/23EK 
variant have higher HbA1c levels (6.54 (0.19) vs. 5.74 (0.05), p<0.001) compared to the non-car-
riers (Table 2). For the carriers of the N363S polymorphism, higher concentrations of LDL cho-
lesterol (4.18 (0.13) vs. 3.62 (0.04), p<0.001) and triglycerides (1.60 (1.06) vs. 1.39 (1.02), p=0.03) 
compared to the non-carriers were observed (Table 2). No associations between the metabolic 
profile and the BclI polymorphism were found. The analyses of body composition showed only 
differences in height for the ER22/23EK polymorphism, where men carrying the ER22/23EK 
variant were taller (171.9 (1.71) vs. 167.8 (0.50), p=0.02) compared to the non-carriers. The same 
trend was observed for women (Table 3).
The effect of the polymorphisms on the prevalence of cardiovascular pathologies was assessed 
at baseline. No associations with the prevalence of myocardial infarction, myocardial ischemia, 
intermittent claudication and stroke were found for the different polymorphisms (Table 4).
During the 4.2-year follow-up, 278 (50 %) of the participants had died, of which 115 (41 %) 
of deaths were due to cardiovascular disease. The Kaplan-Meier estimates of cumulative mor-
tality indicated that the carriers of BclI polymorphism have lower allcause mortality during the 
follow-up compared to the non-carriers (Figure 1). The all-cause mortality risk estimate for the 
BclI variant was 0.85 (0.67-1.08). The cardiovascular mortality analyses revealed no differences
in survival for any of the ER22/23EK, N363S and BclI polymorphism carriers (Figure 1). The 
results remained unaltered after repeating the analyses for men and women separately. 
All the above mentioned analyses were also repeated with independently living participants 
(n=451), in order to implement the selection criteria used in other studies (van Rossum et al., 
2003; van Rossum et al., 2004a). These analyses did not reveal additional associations, but con-
firmed those observed in the whole cohort. 
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Table 2. M
etabolic profile and body com
position dependent on the ER22/23EK (G
/A
), N
363S (A
/G
) and BclI (C/G
) polym
orphism
s
ER22/23EK
N
363S
BslI C/G
G
G
 (n=507)
m
ean (SE)
G
A
/A
A
 (n=33)
m
ean (SE)
p-value
A
A
 (n=497)
m
ean (SE)
AG
/G
G
 (n=51)
m
ean (SE)
p-value
CC (n=236)
m
ean (SE)
CG
/G
G
 (n=290)
m
ean (SE)
p-value
Cortisol (m
m
ol/l)
0.49 (0.01)
0.49 (0.03)
0.90
0.49 (0.01)
0.51 (0.02)
0.35
0.48 (0.01)
0.50 (0.01)
0.10
C-reactive protein (m
g/l)
2.80 (1.06)
3.35 (1.30)
0.51
2.86 (1.07)
2.80 (1.22)
0.91
2.69 (1.09)
3.06 (1.09)
0.29
H
D
L cholesterol (m
m
ol/l)
1.31 (0.02)
1.26 (0.07)
0.45
1.31 (0.02)
1.26 (0.05)
0.33
1.31 (0.03)
1.32 (0.02)
0.87
LD
L cholesterol (m
m
ol/l)
3.66 (0.04)
3.67 (0.17)
0.92
3.62 (0.04)
4.18 (0.13)
<0.001
3.72 (0.06)
3.63 (0.06)
0.29
Triglycerides (m
m
ol/l)
1.40 (1.02)
1.32 (1.08)
0.47
1.39 (1.02)
1.60 (1.06)
0.03
1.40 (1.03)
1.39 (1.03)
0.81
H
bA
1c (m
m
ol/l)
5.74 (0.05)
6.54 (0.19)
<0.001
5.81 (0.05)
5.72 (0.15)
0.60
5.78 (0.07)
5.80 (0.06)
0.84
Sex adjusted univariate general linear m
odel. For C-reactive protein and triglycerides geom
etric m
eans w
ith standard errors (SE) are presented
Table 3. Body com
position dependent on the ER22/23EK (G
/A
), N
363S (A
/G
) and BclI (C/G
) polym
orphism
s
ER22/23EK
N
363S
BslI C/G
G
G
 (n=507)
m
ean (SE)
G
A
/A
A
 (n=33)
m
ean (SE)
p-value
A
A
 (n=497)
m
ean (SE)
AG
/G
G
 (n=51)
m
ean (SE)
p-value
CC (n=236)
m
ean (SE)
CG
/G
G
 (n=290)
m
ean (SE)
p-value
BM
I (kg/m
2)
M
en
26.3 (0.42)
26.1 (1.40)
0.91
26.3 (0.41)
26.0 (1.39)
0.84
25.8 (0.59)
26.6 (0.54)
0.30
W
om
en
27.8 (0.26)
27.7 (1.15)
0.99
27.7 (0.27)
27.5 (0.80)
0.77
27.2 (0.39)
28.1 (0.35)
0.06
W
eight (kg)
M
en
74.3 (1.22)
77.9 (4.12)
0.40
74.7 (1.19)
72.8 (4.09)
0.65
73.4 (1.72)
75.2 (1.59)
0.43
W
om
en
67.4 (0.70)
69.6 (3.07)
0.48
67.5 (0.72)
67.2 (2.11)
0.90
66.4 (1.05)
68.2 (0.94)
0.19
H
eight (cm
)
M
en
167.8 (0.50)
171.9 (1.71)
0.02
168.3 (0.50)
167.2 (1.73)
0.56
168.4 (0.69)
167.8 (0.65)
0.48
W
om
en
156.0 (0.34)
158.6 (1.47)
0.09
156.2 (0.35)
156.6 (1.04)
0.73
156.3 (0.52)
156.1 (0.46)
0.73
A
rm
span (cm
)
M
en
177.8 (0.57)
180.6 (1.97)
0.18
178.3 (0.56)
176.5 (1.93)
0.36
178.7 (0.79)
177.6 (0.74)
0.31
W
om
en
162.4 (0.39)
164.3 (1.66)
0.26
162.5 (0.40)
162.6 (1.17)
0.91
162.5 (0.58)
162.4 (0.52)
0.85
U
nivariate general linear m
odel. D
ata presented as m
eans w
ith standard errors (SE)
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Discussion
The aim of this study was to examine whether in old age polymorphisms in the GR gene 
(NR3C1) influence the prevalence of cardiovascular pathologies and survival due to differences 
in metabolic profile and body composition. The analyses revealed differences in metabolic pro-
file for the ER22/23EK and N363S SNPs, and in body composition for the ER22/23EK variant
but no associations with the prevalence of cardiovascular pathologies and lifespan.
Increased sensitivity to cortisol, accompanied with sub-optimal metabolic profile and in-
creased risk for cardiovascular disease has been associated with the N363S and BclI polymor-
phisms (Di Blasio et al., 2003; Lin et al., 2003; van Rossum et al., 2003). In this study, we found 
no associations with the BclI polymorphism, but carriers of the N363S SNP had higher LDL-
cholesterol and triglyceride levels, and a non-significantly higher prevalence for cardiovascular 
Figure 1. Kaplan-Meier curves of cumulative all-cause and cardiovascular mortality, dependent on the 
ER22/23EK, N363S and BclI genotypes in the 552 participants from age 85 years onwards.
Table 4. Risk of cardiovascular pathologies at baseline dependent on the ER22/23EK (G/A), N363S (A/G) and 
BclI (C/G) polymorphisms
ER22/23EK N363S BclI
GG
n=507
GA/AA
n=33
AA
n=497
AG/GG
n=51
CC
n=236
CG /GG
n=290
Myocardial infarction (n=134) 1 1.35 (0.62-2.93) 1 1.25 (0.65-2.40) 1 0.91 (0.61-1.37)
Myocardial ischemia (n=280) 1 1.82 (0.87-3.78) 1 1.41 (0.78-2.52) 1 0.80 (0.57-1.13)
Intermittent claudication (n=34) 1 0.87 (0.20-3.86) 1 1.03 (0.30-3.52) 1 1.00 (0.49-2.04)
Stroke (n=56) 1 1.56 (0.58-4.24) 1 1.79 (0.79-4.05) 1 1.22 (0.69-2.16)
Sex adjusted binary logistic regression. Data presented as odds ratios (OR) with 95 % confidence intervals (CI)
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diseases. The latter results are in accordance with another study in middle aged subjects (Lin et 
al., 2003), where N363S variant was associated with elevated cholesterol and triglyceride concen-
trations, and also with coronary artery disease. The lack of a relation between the N363S poly-
morphism and cardiovascular pathologies in our study population could be due to the fact that 
in the elderly high levels of LDL-cholesterol and triglycerides are not risk factors for cardiovas-
cular disease anymore (Weverling-Rijnsburger et al., 1997; Weverling-Rijnsburger et al., 2003).
For the ER22/23EK variant, associations opposite of those expected were observed. It has 
been previously reported that elderly carriers of the ER22/23EK polymorphism have lower 
total cholesterol and LDL-cholesterol levels, lower fasting insulin concentrations, better insulin 
sensitivity and lower C-reactive protein levels, leading to a beneficial metabolic profile (van Ros-
sum et al., 2002; van Rossum et al., 2004a). In this study, carriers of the ER22/23EK variant 
had higher levels of HbA1c compared to non-carriers, and a trend for higher C-reactive protein 
and LDL-cholesterol concentrations, which indicate a worse metabolic profile. Furthermore, 
no beneficial effects of the ER22/23EK polymorphism on the prevalence of cardiovascular 
pathologies, all-cause and cardiovascular mortality were found. These result are at odds with 
results from the previously published studies (van Rossum et al., 2002; van Rossum et al., 2004a). 
It could be, that the discrepancy between these studies has arisen due to the age difference of 
the subjects. In our study, participants aged 85-90 years were analyzed compared to subjects 
aged 67-77 years in the other studies (van Rossum et al., 2002; van Rossum et al., 2004a). The 
analyzed polymorphisms might have an effect before a certain age, and therefore the Leiden 
85-plus cohort could consists of survivors. To test this, allele and genotype frequencies between 
the elderly and young participants in this study, and also between a young study group from the 
published literature (van Rossum et al., 2004b) were compared, revealing no differences. Thus, 
in contrast to an earlier report of an age-dependent enrichment for the ER22/23EK variation 
(van Rossum et al., 2002), no such enrichment was observed in our study.
Another possible source for differences could come from the participant’s inclusion criteria. 
In order to apply similar inclusion criteria used in the other studies, only independently living 
participants were analyzed. However, this did not change our results, as well as stratification 
for gender. A more likely explanation could be that some of the observations have arisen by 
chance, leading to false negative or false positive associations. Recently it has been suggested 
that the role of genetic variations in common traits should be built up based on the evidence of 
many studies. Significant between-study diversity is frequent, and the results of the first study 
often correlate only modestly with subsequent research on the same association (Ioannidis et 
al., 2001).
The results of this study raise doubts whether the analyzed polymorphisms, shown to result 
in either resistance or increased sensitivity to cortisol (Huizenga et al., 1998a; van Rossum et al., 
2002; van Rossum et al., 2003), are really functional. For the ER22/23EK variant, it has been 
reported that it does not alter the in vitro capacity to activate transcription (de Lange et al., 1997) 
and no altered response to cortisol was observed (Koper et al., 1997). However, a more recent 
study shows, that the transcriptional activity of the ER22/23EK carriers is decreased, due to 
higher expression of less transcriptionally active GR-A protein in the ER22/23EK carriers. It 
was proposed that this leads to the decrease in the sensitivity to cortisol (Russcher et al., 2005). 
For the other two polymorphisms, N363S and BclI, the functionality has not been established in 
vitro. On the other hand, the polymorphisms could be functional and result in altered hormone 
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sensitivity, which is counterbalanced by adaptive changes that attempt to normalize cortisol 
signaling. These adaptive changes may vary between individuals.
The strengths of this study are the ability to estimate several phenotypes in one cohort, and 
the prospective analysis with a high number of deaths, including the high number of cardio-
vascular deaths, during the follow-up. A weakness of the study is the lack of data on HPA-axis 
reactivity or on other parameters reflecting the stress system activity. However, in this aspect, 
we rely on the information presented in the published literature. 
In conclusion, the results of this study show that in old age the ER22/23EK and N363S poly-
morphisms but not the BclI SNP in the GR gene have an influence on metabolic profile. How-
ever, the noticed differences in metabolic profile do not affect the prevalence of cardiovascular 
pathologies and the risks for all-cause and cardiovascular disease mortality at old age.
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Abstract
Mutations in the WRN gene lead to the Werner syndrome (WS), which resembles prema-
ture ageing. Here, we hypothesize that genetic variations in the WRN gene may also influence 
ageing-trajectories in the population at large. To test this hypothesis, we assessed the impact of 
the i1-C/T, L1074F and C1367R polymorphisms in the WRN gene on the occurrence of car-
diovascular pathologies, on cognitive performance and on the risks of all-cause, cardiovascular 
and cancer mortalities in the population-based Leiden 85-plus Study. This prospective follow-
up study includes 1245 participants aged 85 years and older, with a total follow-up of 5164 
person-years. At baseline the risks of myocardial infarction, myocardial ischemia, intermittent 
claudication, arterial surgery and stroke dependent on the i1-C/T, L1074F and C1367R polymor-
phisms, did not vary between the different genotypes. In addition, no differences in cognitive 
functioning were observed, except for attention, where carriers of the 1367R allele performed 
worse compared to the 1367C homozygotes (94.2 (4.35) versus 84.8 (1.84), p=0.04). Mortality 
risks, calculated separately for all SNPs, were similar between the different genotype carriers 
of the i1-C/T, L1074F and C1367R polymorphisms, showing no evidence of altered survival. In 
conclusion, the i1-C/T, L1074F and C1367R polymorphisms in the WRN gene do not influence 
the ageing-trajectories and survival in the population at large.
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Introduction
Werner syndrome (WS) is a segmental progeroid disorder with an autosomal recessive pat-
tern of inheritance. Patients with WS exhibit a number of symptoms that resemble premature 
ageing. Characteristic clinical features of the syndrome include diabetes, osteoporosis, vascular 
diseases and high incidence of malignant neoplasms. Death usually occurs before the age of 50 
years due to cancer or atherosclerosis (Martin,  1978; Salk, 1982). WS is caused by loss-of func-
tion mutations in the WRN gene. Since mutations in the WRN gene lead to accelerated ageing, 
it has been reasoned that polymorphisms in the WRN gene may also associate with age-related 
pathologies and thus influence ageing in the population at large. 
The WRN gene encodes a nuclear protein with both helicase and exonuclease activities (Liu 
et al., 1999; Morozov et al., 1997; Mushegian et al., 1997). Evidence from several studies suggests 
that this protein is involved in the response to DNA damage during replication, recombination 
and transcription processes (Balajee et al., 1999; Webb et al., 1996). WRN is active in unwinding 
alternate DNA structures, such as DNA-RNA hybrids, triplexes and tetraplexes that may other-
wise cause genomic instability (for review (Bachrati and Hickson, 2003; Opresko et al., 2003)). 
Genomic instability along with accumulation of damage and cellular senescence is commonly 
seen in WS cells (for review (Brosh, Jr. and Bohr, 2002; Macario and Conway, 2002)). Senescent 
cells go through alterations in gene expression patterns, which in turn have been shown to un-
derpin several pathologies in tissues such as skin and vasculature (Minamino et al., 2004; Shel-
ton et al., 1999). These processes are likely to lead to the disease pathologies seen in WS patients, 
and also during ageing in the population at large (Bird et al., 2003; Hasty et al., 2003). Since WS 
resembles accelerated ageing, it has been suggested that the WRN gene may also modulate the 
course of ageing in the population at large and play a role in the sensitivity or resistance to the 
development of age-related disorders. Only few studies have addressed this question, with con-
tradictory results. Studies in Japanese have shown that a C1367R variation in the WRN gene is 
associated with myocardial infarction (Morita et al., 1999; Ye et al., 1997), whereas in Caucasians 
no associations with cardiovascular disease  have been found (Bohr et al., 2004; Castro et al., 
1999). An i1-C/T polymorphism, on the other hand, has been related with cognitive function-
ing (Bendixen et al., 2004), and for a L1074F SNP an age-dependent enrichment of the 1074L 
allele in Finnish and Mexican populations has been observed (Castro et al., 2000). The latter 
result suggests a beneficial effect on survival. These associations have been found in separate 
studies and to date there are no data on the influence of the C1367R polymorphism on cogni-
tive function and survival, and no information of the i1-C/T and L1074F polymorphisms on 
cardiovascular disease risks in elderly. 
The aim of this study was to assess the impact of the i1-C/T, L1074F and C1367R polymor-
phisms in the WRN gene on the occurrence of cardiovascular pathologies, on cognitive per-
formance and on the risks of all-cause and cause-specific mortalities in the population at large. 
Since these polymorphisms are potentially functional (Bohr et al., 2004; Kamath-Loeb et al., 
2004b), univariate analyses were performed. The study was carried out in elderly aged 85 years 
and older, using cross-sectional and prospective study designs. The use of elderly participants 
provides the best opportunities for determining the impact of genetic variations on ageing tra-
jectories, since at that age the effects of truly functional variations should be most pronounced.
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Participants and methods
Participants
The Leiden 85-plus Study is a prospective population-based study, in which inhabitants of 
Leiden, The Netherlands, aged 85 years or over, were invited to take part. There were no selec-
tion criteria related to health or demographic characteristics. The study population consists of 
two cohorts, cohort ‘87 and ‘97. Cohort ‘87 includes 977 participants aged 85 years and older, 
enrolled between 1987 and 1989 (Weverling-Rijnsburger et al., 1997). Cohort ‘97 consists of 599 
subjects, all members of the 1912-1914 birth cohort, who were enrolled in the month of their 85th 
birthday between 1997 and 1999 (der Wiel et al., 2002). DNA was available for 682 participants 
from cohort ‘87 and for 563 people from cohort ‘97. All participants of the Leiden 85-plus Study 
were followed for mortality until April 1, 2004. Primary causes of death were obtained from the 
Dutch Central Bureau of Statistics and categorized according to the 10th International Classifi-
cation of Diseases (ICD-10). The Medical Ethical Committee of the Leiden University Medical 
Center approved the study and informed consent was obtained from all participants. In addi-
tion, 247 young blood donors (aged 19-40 years) from Leiden were included for a cross-sectional 
comparison of genotype frequencies. To avoid population stratification due to geographic differ-
ences between the elderly and young, we restricted the young control population to those with 
either two Leiden-born parents or one Leiden-born parent and the other born within a 12-km 
distance from Leiden. Information regarding the birthplace of their grandparents was obtained 
from a written questionnaire (Heijmans et al., 1999). 
Cardiovascular pathologies at baseline in cohort ‘97
The prevalence and number of cardiovascular pathologies were obtained from the partici-
pants’ general practitioner or nursing home physician. In addition, electrocardiograms were 
recorded on a Siemens Siccard 440 and transmitted by telephone to the ECG Core Lab in Glas-
gow for automated Minnesota coding (Macfarlane and Latif, 1996). Cardiovascular pathologies 
were classified as: myocardial infarction, myocardial ischemia, intermittent claudication, arterial 
surgery and stroke (van Exel et al., 2002).
Cognitive function tests in cohort ‘97
Overall, cognitive function was measured with the Mini-Mental State Examination (MMSE). 
Individuals who scored equal to or above 19 points also performed tests measuring attention 
(Stroop Test) (Klein et al., 1997), processing speed (Letter Digit Coding Test) (Houx et al., 2002), 
immediate recall memory (Word Learning Test Immediate Recall) and delayed recall memory 
(Word Learning Test Delayed Recall) (Brand and Jolles, 1985). All participants were visited an-
nually for re-measurement of cognitive functioning during a mean follow-up of 4.2 years. Paral-
lel versions of the tests were used. Details of cognitive testing are described elsewhere (Houx et 
al., 2002). 
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Genotyping
The i1-C/T (rs2725335) and C1367R (rs1346044) variations were genotyped using an Assay-
by-Design (Applied Biosystems), consisting of PCR primers and TaqMan MGB probes. Ampli-
fication reactions were made at standard conditions except for the following modifications. A 
qPCR core kit was used (Eurogentec) and a half of the amount of primers and probes. Real time 
PCR was performed on ABI 7900 HT (Applied Biosystems). The L1074F (rs2725362) polymor-
phism was genotyped by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-
TOF) mass spectrometry (MS), using the Sequenom MassARRAYtm (Sequenom Inc.) method-
ology. Amplification reactions and parameters were based on the manufacturer’s instructions 
Statistical analysis
Allele frequencies were calculated and analyzed for deviation from the Hardy-Weinberg equi-
librium using the χ2-test. Differences in the prevalence of cardiovascular pathologies between 
genotypes were tested using the binary logistic regression model adjusted for sex. Associations be-
tween genotypes and cognitive functioning were analyzed using a linear mixed model, estimating 
the overall mean difference in cognition during the follow-up, adjusted for sex and level of educa-
tion. Mortality was first estimated using the Kaplan-Meier method, followed by the calculation of 
sex adjusted mortality risks and 95 % confidence intervals (CI) for all-cause, cardiovascular and 
cancer mortality with the Cox proportional hazard model, using left censoring to correct for the 
delayed entry into the risk set according to age. For each polymorphism, hazard ratios (HR) were 
calculated using common allele homozygotes as the referent group. All analyses were performed 
with SPSS statistical software, Version 12.0 (Chicago, IL, USA), with the exception of the mortal-
ity analyses, which were performed with STATA software, Version 9.0 (StataCorp LP, TX, USA). 
Results
All 1245 participants of the Leiden 85-plus Study and 247 young blood donors were geno-
typed for the i1-C/T, L1074F and C1367R polymorphisms. The location of the SNPs in the 
WRN gene and protein are indicated in Figure 1. The genotype and resulting allelic frequencies 
of the SNPs were in agreement with the Hardy-Weinberg equilibrium, except for the C1367R 
polymorphism in the cohort ‘97 (Table 1). In that case, a deficit of heterozygotes and an excess 
of both homozygote allele carriers were observed. The overall genotype distributions and result-
ing allelic frequencies of the SNPs were similar to these found in Caucasians (Bendixen et al., 
2004; Castro et al., 1999; Castro et al., 2000). In this study, the calculated allele and genotype 
frequencies did not differ between the elderly and young subjects, showing no enrichment for 
any of the alleles (Table 1). 
The prevalence of cardiovascular pathologies dependent on the i1-C/T, L1074F and C1367R 
polymorphisms, and the influence of these SNPs on cognitive functioning were assessed only 
in cohort ‘97. At baseline the risks of myocardial infarction, myocardial ischemia, intermittent 
claudication, arterial surgery and stroke dependent on the i1-C/T, L1074F and C1367R polymor-
phisms did not vary between the different genotypes (Table 2).
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Figure 1. The WRN gene and protein structure with a graphic representation of the i1-C/T, L1074F 
and C1367R SNP localization. The positions of the SNPs in the WRN gene and protein are indicated 
with arrows. The WRN gene is located in chromosome 8 and it spans a genomic region of 140 kb, 
containing 35 exons. The WRN protein is 1432 amino acids long and has 5 functional domains: exo-
nuclease domain, helicase domain, RecQ helicase domain (RQC), helicase and RNaseD-C-terminal 
(HRDC) domain and C-terminal nuclear localization signal (NLS). The WRN protein has in addition 
acidic residues with unknown function.
Cognitive functioning was measured at baseline and annually during a mean follow-up of 
4.2 years. Global cognition, as measured with MMSE, was similar between the different geno-
type carriers of the i1-C/T, L1074F and C1367R polymorphisms (Table 3). From the specific 
domains of cognitive functioning, only differences in attention were observed for the C1367R 
polymorphism. Homozygous carriers of the 1367R allele had worse attention compared to the 
1367C homozygotes (94.2 (4.35) versus 84.8 (1.84), p=0.04). The same trend was observed for 
the heterozygous 1367R allele carriers. The results remained unaltered after the adjustment for 
depressive feelings. No associations with processing speed, immediate and delayed memory 
were observed with the different genotypes (Table 3). 
The influence of the i1-C/T, L1074F and C1367R polymorphisms on mortality risks was 
assessed separately for cohort ‘87 and cohort ‘97, and also in the combined cohort of 1245 par-
ticipants (Supplementary Table 1). Since in some instances the mortality risk estimates found in 
cohort ‘87 were not replicated in cohort ‘97, the results for the combined cohort are presented. 
The higher number of participants in the combined cohort provides better statistical power 
and enables to calculate estimates that are more accurate. During the total follow-up of 5164 
person-years, 957 (77 %) participants had died, of which 365 (38 %) from cardiovascular disease 
and 143 (15 %) due to cancer. The Kaplan-Meier estimates of cumulative mortality according 
to the genotypes of the different SNPs are presented in the Figure 2. According to the Kaplan-
Meier mortality curves, it seems that carriers of the i1-CT genotype, and heterozygous and 
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homozygous carriers of the 1367R allele have lower cancer mortality. Although not statistically 
significant, the mortality risk estimates of 0.56 (0.26-1.20) for i1-CT, 0.84 (0.59-1.20) for C1367R 
and 0.57 (0.27-1.17) for R1367R genotypes, show lower cancer mortality. The same trend was 
observed in cohort ‘87 and ‘97 (Supplementary Table 1). The other all-cause and cause-specific 
mortality risks, calculated separately for all polymorphisms, were similar between the different 
genotype carriers of the i1-C/T, L1074F and C1367R polymorphisms, showing no evidence of 
altered survival. 
Discussion
The results of this study show that the i1-C/T, L1074F and C1367R polymorphisms in the 
WRN gene do not influence the occurrence of cardiovascular pathologies, cognitive perfor-
mance and the risks of all-cause and cause-specific mortalities in a cohort of elderly aged 85 
years and older.
Table 1. Characteristics of the study subjects
Young control Cohort ‘87 Cohort ‘97
Number 247 682 563
Age 19-40 84-100 85
Female 137 (56 %) 491 (72 %) 375 (67 %)
i1-C/T
CC 223 (92 %) 586 (91 %) 489 (91 %)
CT 18 (8 %) 56 (9 %) 47 (9 %)
TT - - -
Total 241 642 536
MAF 0.04 0.04 0.04
HWE 0.83 0.51 0.57
L1074F
LL 66 (27 %) 202 (32 %) 175 (32 %)
LF 126 (51 %) 316 (51 %) 260 (47 %)
FF 55 (22 %) 105 (17 %) 117 (21 %)
Total 247 623 552
MAF 0.48 0.42 0.45
HWE 0.94 0.61 0.54
C1367R
CC 139 (58 %) 329 (49 %) 316 (57 %)
CR 81 (34 %) 285 (42 %) 192 (34 %)
RR 21 (8 %) 58 (9 %) 50 (9 %)
Total 241 672 558
MAF 0.26 0.30 0.26
HWE 0.20 0.95 0.04
MAF-minor allele frequency, HWE- Hardy-Weinberg equilibrium
WRN, Age-related Disease and Mortality
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Figure 2. Kaplan-Meier curves of cumulative all-cause, cardiovascular and cancer mortality, depen-
dent on i1-C/T, L1074F and C1367R genotypes in the combined cohort of 1245 individuals from age 
85 years onwards
From the three polymorphisms polymorphisms analyzed in this study, the C1367R SNP 
was found to be out of Hardy-Weinberg equilibrium in cohort ‘97. Since all DNAs from cohort 
‘87, ‘97 and from blood bank donors were genotyped simultaneously then a specific genotyping 
failure in cohort ‘97 is unlikely. Furthermore, 10 % of the samples were genotyped twice and for 
the C1367R SNP in cohort ‘97 the genotyping error was less than 1 %. Therefore, the marginal 
deviation from Hardy-Weinberg equilibrium could have been arisen by chance. 
In this study, most major outcomes of atherosclerosis, including myocardial infarction, myo-
cardial ischemia, intermittent claudication, arterial surgery and stroke, were assessed. None of 
the analyzed polymorphisms in the WRN gene associated with these pathologies. Furthermore, 
dependent on the polymorphism, either higher or lower risk estimates for the different car-
diovascular pathologies were observed. In contrast, a consistent risk profile over these various 
outcomes of atherosclerosis was expected. Therefore, we concluded that the i1-C/T, L1074F and 
C1367R polymorphisms do not contribute to the risk of developing cardiovascular pathologies. 
For the C1367R SNP, these results are in line with recent studies in Caucasians (Bohr et al., 
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2004; Castro et al., 2000), but at odds with findings in Japanese, where the carriers of the 1367R 
allele had lower risks for myocardial infarction (Morita et al., 1999; Ye et al., 1997). As already 
suggested by others (Bohr et al., 2004), the disparity in results might come from population dif-
ferences, which is also supported by the fact that in the Japanese the minor allele frequency of 
the C1367R polymorphism is more than three times lower than in Caucasians. In the Japanese, 
the C1367R variation may also be in linkage disequilibrium with another, so far unidentified 
polymorphism that is not present in Caucasians. 
Cognitive functioning dependent on the WRN gene i1-C/T and C1367R polymorphisms has 
been assessed previously only in one study (Bendixen et al., 2004). In that study, the T allele of 
the i1-C/T SNP was associated with better cognitive functioning in the elderly, and no associa-
tions with the C1367R SNP were found (Bendixen et al., 2004). The beneficial effect of the i1-T 
allele was only seen on the cognitive composite score and not on MMSE. In our study, carriers 
of the i1-T allele seemed to perform better on all the analyzed cognitive domains, however the 
differences did not reach statistical significance. A significant association on the other hand, was 
observed between the C1367R polymorphism and attention. Carriers of the 1367R allele had 
worse attention compared to the 1367C homozygotes. The other domains of cognition seemed 
to be unaffected. The positive association between the C1367R SNP and attention could be a 
chance finding. In this study we did not correct for multiple testing, however if such correction 
had been applied then the borderline significance would have disappeared. In order to exclude 
that the findings of this and the other study (Bendixen et al., 2004) between cognition and 
WRN gene polymorphisms are due to chance, corroboration in independent samples is needed. 
In WS patients, cognitive decline and dementia have not been described. It has been reasoned 
that the central nervous system may be less prone for damage due to the absence of mitotic activ-
ity during adult life. However subtle defects might emerge over time, if the WRN is important 
for neural stem cell function during adult life (Gage,  2002). 
The influence of the WRN gene on mortality before the age of 85 years was examined in a 
cross-sectional design by comparing allele frequencies of the SNPs in elderly aged 85 years and 
older with those in young subjects. No differences were found in the allele frequencies between 
the elderly and young. With regard to the L1074F polymorphism, this finding is in contrast 
with a study showing an age-dependent enrichment of the 1074L allele in Finnish and Mexican 
populations (Castro et al., 2000). The latter indicates a beneficial effect on survival. To evaluate 
further the impact of the polymorphisms on lifespan, mortality risks after the age of 85 years, 
dependent on the SNPs, were assessed. The mortality risk estimates calculated for all-cause 
and cardiovascular mortality did not differ between the different genotype carriers of the poly-
morphisms. However, the observed trend for lower cancer mortality risks for the minor allele 
carriers of the i1-C/T and C1367R polymorphism needs to be studied in more detail, in order to 
make more profound conclusions. Taking together, the cross-sectional and prospective analyses 
provided no evidence for differential survival for any of these polymorphisms. 
In WS patients, the observed pathologies and decrease in lifespan are attributable to the loss 
of a functional WRN protein. Polymorphisms in the WRN gene may also affect the functional-
ity of the protein. The i1-C/T SNP is located in the first intron of the WRN gene. An intronic 
SNP may influence the splicing process or the stability of the mRNA, and thereby the amount of 
functional protein synthesized. However, for the i1-C/T polymorphism the effect has still to be 
established. The L1074F polymorphism is in exon 26, and in the vicinity of the RecQ C-terminal 
(RQC) domain. The C1367R SNP is located in exon 34, near to the nuclear localization signal 
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(Matsumoto et al., 1998). It has been shown that these polymorphisms result in subtle changes 
in the helicase/exonuclease activities of the WRN protein (Bohr et al., 2004; Kamath-Loeb et 
al., 2004a). The localization to the nucleus of the protein carrying the C1367R polymorphism 
appeared to be unaffected (Bohr et al., 2004). It can be reasoned that the differential functional 
effects caused by the polymorphisms in the WRN gene, are not sufficient for causing patholo-
gies or influence the lifespan. However, another possibility is that the polymorphisms alter the 
functionality of the WRN protein, but due to compensatory mechanisms, no effects at pheno-
typic level are observed. 
The first strength of this study is the elderly cohort, which is suitable for testing the effect of 
variations in the WRN gene on age-associated disease and mortality patterns in the population 
at large. The other strength is the possibility to estimate several phenotypes in one cohort, and 
the prospective analysis with a high number of events (deaths) during the follow-up. The latter 
results in a good power for the detection of effects on lifespan. The weakness of the study might 
be related to the selection of analyzed polymorphisms. The SNPs were selected based on their 
published associations, however there might be other, so far undetected functional polymor-
phisms in the WRN gene leading to changes in the pace of ageing. An approach to overcome 
this is to analyze, either separately and/or in a combination of haplotypes, a larger set of evenly 
distributed SNPs in the WRN gene, and determine their influence on the prevalence of age-
associated diseases and lifespan.
In conclusion, the present study shows that the i1-C/T, L1074F and C1367R variations in 
the WRN gene do not influence the sensitivity or resistance to the development of age-related 
disorders and the course of ageing. 
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Abstract
Ample evidence from model organisms has indicated that subtle variation in genes can dra-
matically influence lifespan. The key genes and molecular pathways that have been identified so 
far encode for metabolism, maintenance- and repair mechanisms that minimize age related ac-
cumulation of permanent damage. Here, we describe the evolutionary conserved genes that are 
involved in lifespan regulation in model organisms and have been studied for association with 
lifespan in humans. The accumulated data reveal that when moving up the evolutionary lad-
der, together with an increase of genome complexity, the impact of candidate genes on lifespan 
becomes smaller. The presence of genetic networks makes it more likely to expect impact of 
variation in several interacting genes to affect lifespan in humans. Extrapolation of findings 
from experimental models to man is further complicated as phenotypes are critically dependent 
on the setting in which genes are expressed while laboratory conditions and modern environ-
ments are markedly dissimilar. Finally, currently used methodologies may have only little power 
and validity to reveal genetic variation in the population. In conclusion, although the study of 
model organisms has revealed potential candidate genetic mechanisms determining ageing and 
lifespan, to what extent they explain variation in human populations is still uncertain.
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Introduction
Over the last century, mean life expectancy in Western societies has increased dramatically 
(Oeppen and Vaupel, 2002). In Japan for instance, mean life expectancy has increased from fifty 
to eighty years in no more than six decades. It is unlikely that changes in the population genome 
over this time-period can explain for the observed increase in lifespan which is more likely to 
be attributable to the improvement of environmental conditions and medical care. The increase 
in mean life expectancy of the total population, however, has left the marked inter-individual 
variance in lifespan unaltered. Socio-economic factors can in part explain this phenomenon, 
but ample evidence suggests that genetic factors are also at play. Studies of twins and long-lived 
families have estimated that 20 to 30 per cent of the variation in human lifespan is determined 
by genetic factors, which impact becomes more important for survival at older ages (Herskind 
et al., 1996; Hjelmborg J. et al., 2006; Mitchell et al., 2001). Furthermore, siblings of centenar-
ians have a significantly higher chance of becoming a centenarian themselves when compared to 
other members of their birth cohort (Perls et al., 2002). The survival benefits of family-members 
of these long-lived subjects are lifelong and persist up to the highest age-categories (Hjelmborg 
J. et al., 2006; Perls et al., 2002). Offspring of long-lived sibling pairs have a lower mortality risk 
already at middle age, whereas their spouses, with whom they have shared in part a common 
environment, do not show this survival benefit (Schoenmaker et al., 2006). 
As for lifespan, ageing is under moderate genetic control influencing the rate at which sto-
chastically induced damaged molecules accumulate. Such damage is caused by various endog-
enous and exogenous biological- and biochemical stresses. As a result, over the life course there 
is a constant rise in vulnerability of the body, leading to a continuously increasing risk of disease 
and death. Longevity and the maintenance of health in old age can be ensured via two princi-
pally different strategies that minimize the risk of permanent damage to occur i.e. by a decrease 
of environmental hazards or an increase of the durability of the body. Pathways that influence 
metabolism, maintenance and repair mechanisms, and prevent the accumulation of permanent 
damage thus represent key molecular candidates for the preservation of health and longevity.
Experiments in model organisms have demonstrated that a series of induced mutations in 
various genes that make up an integrated molecular pathway can dramatically increase lifespan. 
The most prominent example includes the Caenorhabditis elegans daf-2 and clk double mutants that 
live nearly five times longer than wild-type worms (Lakowski and Hekimi, 1996). Most of the 
genes of model organisms are evolutionarily conserved and present in humans. Here, we will 
briefly review the genes and mechanisms that have been shown to regulate lifespan in model 
organisms, but limiting ourselves to those genes, which have human homologues, and have 
been studied for association with human health and/or longevity (Table 1). In addition, it is 
addressed whether we can expect to find single genes or molecular pathways that substantially 
affect lifespan in humans; whether the information obtained from model organisms can be 
translated to variation in lifespan in humans; and whether present genetic surveys are able to 
pick up this genetic variation.
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The evidence
Insulin/IGF-1 signaling (IIS)
The first evidence for genetic regulation of lifespan came from studies with C. elegans. It was 
discovered that worms with mutations in the dauer formation (Daf) genes, such as daf-2 and 
age-1, were able to bypass dauer formation, and become long-lived adults (Larsen,  2001). The 
molecular characterization of the daf-2 and age-1 genes revealed that these show homology to the 
mammalian genes encoding Insulin Receptor (IR) and Insulin-like Growth Factor 1 Receptor 
(IGF-1R) (Kimura et al., 1997), which are evolutionary conserved. Next, it was shown that, simi-
lar to C. elegans, reduced insulin signaling extends lifespan in Drosophila melanogaster. The increase 
in lifespan was observed for flies with mutated insulin-like receptor (InR) or its substrate (chico), 
and for flies with ablated insulin-producing cells (Giannakou and Partridge, 2007). In the latter 
case, the adult flies also exhibited increased storage of lipids and carbohydrates, reduced fecun-
dity, and increased stress- and starvation resistance. 
In vertebrates, the insulin signaling system is more complex and contains separate receptors 
for insulin (IR) and IGF-1 (Navarro et al., 1999). Data from mice indicate that both these recep-
tors, IR and IGF-1R, are involved in lifespan regulation. The IGF-1 branch, which acts through 
growth-hormone-releasing hormone (GHRH), growth hormone (GH) and IGF-1, influences 
body composition and is involved in the regulation of gonadal function (Bartke,  2005). The 
long-lived Ames and Snell dwarf mice, which are deficient in growth hormone, thyroid hor-
moneand prolactin are infertile (Brown-Borg et al., 1996). A similar phenotype is observed for 
GH receptor knockout mice (Bartke,  2005). Furthermore, mice mutated for the IGF-1 receptor 
hint at a direct role for reduced IGF-1 signaling in mammalian longevity: Igf1r+/- females, but 
not males, exhibit a long-lived phenotype (Holzenberger et al., 2003). In contrast, complete dis-
ruption of the IR gene leads to insulin resistance, diabetes and shortened lifespan (Okamoto and 
Accili, 2003). Likewise, tissue specific IR knockout mouse models develop obesity, insulin resis-
tance and impaired glucose regulation, with the exception of the fat-specific IR knockout mice 
(FIRKO) (Okamoto and Accili, 2003). These mice have reduced fat mass, are protected against 
age-related obesity, and live longer than their littermates. Taken together, the evidence in mouse 
models shows that reduced insulin/IGF-1 signaling can extend lifespan also in mammals.
In humans, there is some evidence that long-lived subjects, such as centenarians, have de-
creased plasma IGF-I levels and preserved insulin action, thus indicating that insulin respon-
siveness influences human longevity (Paolisso et al., 1997). For instance, a polymorphisms in 
the  IGF-IR locus, that has been associated with lower plasma IGF-1 levels was shown to be 
enriched among Italian centenarians (Bonafe et al., 2003). This finding was not replicated in a 
prospective follow-up study of elderly Dutch subjects, but in the same study it was found that a 
polymorphism in the GH1 gene, which controls IGF-1 activity, associates with longevity  (van 
Heemst et al., 2005a). In addition, a combined effect of variation at the GH1, IGF-1 and IRS1 
loci was observed, demonstrating an additive effect of multiple variants associated with reduced 
IIS signaling on human longevity.
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Klotho
The Klotho gene, which was identified in mouse models (Kuro-o M et al., 1997), encodes a 
mammalian specific hormone that negatively regulates the activity of IR and IGF-1R through re-
pressing their autophosphorylation (Kurosu et al., 2005). In mice, genetic variation in the Klotho 
gene results in an early onset of various age-related disorders, including ectopic calcification, 
skin- and muscle atrophy, osteoporosis, atherosclerosis, and pulmonary emphysema (Kuro-o M 
et al., 1997). On the other hand, over-expression of Klotho in mice leads to inhibition of insulin 
and IGF1 signaling and increased lifespan (Kurosu et al., 2005). In humans, a haplotype allele 
called KL-VS, which contains six sequence variants that are in complete linkage disequilibrium, 
has been associated with KLOTHO expression and shown to be underrepresented in elderly 
individuals (Arking et al., 2002). Additional studies have demonstrated that the survival advan-
tage is only present in heterozygous KL-VS allele carriers, whereas in homozygous allele carriers 
a disadvantage for HDL-cholesterol levels, systolic blood pressure, stroke, and longevity was 
observed (Arking et al., 2005).
Forkhead transcription factors
In C. elegans, the IIS pathway negatively regulates the activity of DAF-16, which is its main 
downstream target. The long-lived phenotype of the IIS mutants depends on the presence of an 
Table 1. Selected example of genes identified to influence lifespan in model organisms (in alphabetical order)
Symbol Gene name/description Function Organism* Reference
age-1 phosphatidylinositol kinase insulin signaling C. elegans (Morris et al., 1996)
Cat catalase antioxidant activity D. melanogaster (Orr and Sohal, 1994)
Chico insulin receptor substrate insulin signaling D. melanogaster (Clancy et al., 2001)
daf-2 insulin receptor-like gene insulin signaling C. elegans (Kimura et al., 1997)
daf-12 nuclear hormone receptor
regulation of metabolic and 
developmental pathways C. elegans (Larsen et al., 1995)
daf-16 forkhead transcription factor
regulation of metabolic and 
developmental pathways C. elegans (Ogg et al., 1997)
Gh growth hormone
insulin signaling, tissue 
proliferation M. musculus (Bartke,  2005)
Klotho beta-glucuronidase inhibits IIS signaling M. musculus (Kuro-o M et al., 1997)
Mei-41 phosphatidylinositol kinase DNA repair D. melanogaster
(Symphorien and 
Woodruff, 2003)
Pcmt
protein carboxyl methyl-
transferase protein repair D. melanogaster (Chavous et al., 2001)
p53 tumor protein p53 tumor suppression M. musculus (Tyner et al., 2002)
Sir2
NAD(+)-dependent deacety-
lase
regulation of metabolism, 
stress resistance S. cerevisiae (Kaeberlein et al., 1999)
Sod1 superoxide dismutase antioxidant activity D. melanogaster (Parkes et al., 1998)
Sod2 superoxide dismutase antioxidant activity D. melanogaster (Sohal et al., 1995)
*Organism, in which the gene was first shown to influence lifespan
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active DAF-16 protein (Mukhopadhyay and Tissenbaum, 2007). In mammals, the DAF-16 ho-
mologues are forkhead transcription factors (FOXOs): FOXO1a, FOXO3a, FOXO4 and FOXO6 
(Furuyama et al., 2000). Similar to DAF-16 in C. elegans, in mammals the FOXO proteins relay 
the effects of insulin on lifespan, influence fertility, and play a role in complex diseases such as 
diabetes (Carter and Brunet, 2007). In humans, only few studies have analyzed the role of FOXO 
proteins in the development of age-related diseases, fertility and lifespan. In most studies, no 
associations between genetic variance in the FOXO1a and FOXO3a genes and lifespan have been 
detected (Bonafe et al., 2003; Kojima et al., 2004). These findings, contrast with recent studies 
where genetic variance in the FOXO1a gene was linked to increased glucose levels (Karim et al., 
2006; Kuningas et al., 2007a) increased risk of diabetes and decreased lifespan (Kuningas et al., 
2007a). Support for these findings has come also from the Framingham Heart Study (personal 
communications). For genetic variance in the FOXO3a gene, associations were observed with 
increased risks of stroke and mortality, but not with fertility (Kuningas et al., 2007a).
DAF-12 
In C. elegans, DAF-12 is a member of the evolutionarily conserved Nuclear Hormone Recep-
tor (NHR) super-family (Mangelsdorf et al., 1995) and it has been implicated in dauer diapause, 
developmental timing, metabolism, fertility, and longevity. Current data have positioned DAF-
12 downstream of the insulin- and germline signaling, as the long-lived phenotype of germline 
ablated mutants and of some IIS mutants depends on DAF-12 activity, but the exact position is 
still unknown (Rottiers and Antebi, 2006). In humans, the NHRs most similar to DAF-12 are 
the Liver X Receptors (alpha and beta), which have cholesterol breakdown products (oxysterols) 
as ligands. Upon activation, LXRs regulate various processes that result in cholesterol excretion 
from the body (Zelcer and Tontonoz, 2006). Recently, a common haplotype of the LXRA gene 
was associated with increased survival, predominantly due to lower mortality from cardiovas-
cular causes and infection (Mooijaart et al., 2007a). A possible mechanism through which LXR 
could lead to the observed beneficial effects includes involvement of its target gene Apolipo-
protein E (APOE). ApoE is an anti-atherosclerotic protein involved in the efflux of cholesterol 
from macrophages. Genetic variation in APOE has consistently been associated with cognitive 
decline and cardiovascular disease mortality. Moreover, we have recently shown that indepen-
dent of genetic variation in APOE, high plasma apoE levels associate with increased risk of 
stroke (van Vliet et al., 2007), increased risk of cardiovascular mortality (Mooijaart et al., 2006) 
and decreased cognitive functioning (Mooijaart et al., 2007b). These data support previous ob-
servations that lipoprotein metabolism is critical for exceptional longevity. It has been shown 
that families of Ashkenazi Jewish centenarians have larger particles of HDL and LDL, which 
are associated with a decreased incidence of metabolic syndrome, cardiovascular disease and 
hypertension (Barzilai et al., 2003). Also in the Dutch Caucasian population, offspring of long-
lived sibling pairs have larger LDL particles than their age-matched partners, again suggesting 
that larger LDL particles confer a survival benefit (Heijmans et al., 2006). 
Sirtuins
The Sirtuins represent an evolutionarily conserved family of Silent Information Regulator 2 
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(Sir2) NAD-dependent protein deacetylases that interact with and influence the activity of vari-
ous transcription factors and co-regulators (Bordone and Guarente, 2005). Increased expression 
of the Sir2 gene, either due to an extra copy of the gene or to caloric restriction, prolongs lifespan 
in various model organisms (Haigis and Guarente, 2006). In mammals, there are seven Sir2 ho-
mologues (SIRT1-7), of which SIRT1 is the most closely related to Sir2 (Frye,  2000). In mouse 
models, SIRT1 and SIRT3 have been studied the most. SIRT1 has been associated with glucose 
and fat metabolism, stress resistance and cell survival (Haigis and Guarente, 2006), whereas 
SIRT3 regulates the activity of acetyl-CoA synthetase (AceCS), and thereby the entry of carbons 
from acetate into central metabolism (Haigis and Guarente, 2006). In humans, polymorphisms 
within SIRT1 and SIRT3 genes have been analyzed for association with age-related diseases and 
longevity. In case of SIRT1, no associations have been found (Flachsbart et al., 2006; Kunin-
gas et al., 2007b), whereasof SIRT3, a G477T polymorphism and a variable number of tandem 
repeats (VNTR) have been associated with increased lifespan (Bellizzi et al., 2005; Rose et al., 
2003). These results demonstrate that at least one member of the SIRT family is involved in hu-
man lifespan regulation.
Antioxidative enz ymes
Antioxidative enzymes, such as catalase and superoxide dismutase (SOD), prevent damage 
from reactive oxygen species (ROS), but the evidence from model organisms on the beneficial 
effects of antioxidative enzymes on lifespan has been controversial. Studies with D. melanogaster 
have demonstrated that overexpression of CuZn-SOD (SOD1), Mn-SOD (SOD2), and catalase 
lead to lifespan extension (Orr and Sohal, 2003; Sohal et al., 1995). Additional experiments, 
however, showed that this effect depends on genetic background of the used lines (Orr and 
Sohal, 2003). Likewise, the extended lifespan of C. elegans by administration of synthetic SOD/
catalase mimetics was shown to depend on laboratory conditions (Keaney and Gems, 2003; 
Melov et al., 2000).
In mammals, one catalase and three SOD genes have been characterized; SOD1, SOD2 and 
SOD3, of which Catalase and SOD2 seem to influence lifespan. In mice, disruption of the SOD2 
gene is lethal due to neurodegeneration and to damage to the heart (Li et al., 1995; Melov et al., 
1998). In contrast, overexpression of SOD2 leads to increased lifespan (Hu et al., 2007), as does 
overexpression of Catalase targeted to mitochondria (Schriner et al., 2005). Mice heterozygous 
for the mitochondrial form of SOD2 showed high levels of DNA oxidation in multiple organs. 
In spite of their abnormally oxidized DNA, these animals showed no decline in lifespan and 
no acceleration in the hallmarks of aging, such as cataracts, immune dysfunction, and protein 
modifications (Van Remmen et al., 2003). These data suggest that mice can live reasonably long 
and healthy lives despite unusually high levels of oxidative damage.
The evidence for the role of antioxidative enzymes in the preservation of human health is 
not well established. It has been shown that RNA interference (RNAi) of SOD1 induces senes-
cence in human fibroblasts (Blander et al., 2003), which suggests that SOD1 may play a role in 
the regulation of cellular lifespan. However, genetic variants in the SOD1 gene have never been 
studied for that relationship. In contrast, genetic variants in the SOD2 gene have been studied 
and associated with a number of phenotypes including increased risk for prostate- and breast 
cancer, immunosenescence profile, and DNA damage (Liu et al., 2004; Taufer et al., 2005), but 
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not with mortality (De Benedictis et al., 1998; van Heemst et al., 2005a). Likewise, no associa-
tions between genetic variants in the Catalase gene and mortality have been found (Christiansen 
et al., 2004).
Macromolecule repair mechanisms
Defects in mechanisms that repair damage to cellular components, such as DNA, proteins 
and membranes have been shown to reduce lifespan in various model organisms. Even though 
these mechanisms are evolutionarily conserved (Eisen and Hanawalt, 1999), systematic com-
parative genomic analyses across species have not been conducted. In addition, within species, 
there are many studies demonstrating detrimental effects of impaired repair systems on lifespan, 
but only few demonstrating beneficial effects of increased repair capacity on lifespan. The only 
evidence for the latter has come from experiments with D. melanogaster, where the absence of mei-
41 excision repair reduces lifespan, whereas flies with one- or two extra copies of the gene have 
significantly increased lifespan (Symphorien and Woodruff, 2003). Likewise, overexpression of 
protein carboxyl methyltransferase (PCMT ), which is a protein repair enzyme, has been corre-
lated with enhanced longevity in a temperature-dependent manner (Chavous et al., 2001). Both 
of these genes, mei-41 and Pcmt have homologues in mammals, which are ataxia telangiectasia 
and Rad3 related (ATR) and PCMT, respectively. In mice, the disruption of the ATR gene leads 
to chromosomal fragmentation and early embryonic lethality (Brown and Baltimore, 2000), and 
in humans to a rare Seckel syndrome (Casper et al., 2004). The Pcmt1-null mice, on the other 
hand, display a fatal seizure disorder and retarded growth (Kim et al., 1999), and die at a mean 
age of 42 days (Lowenson et al., 2001).  
Compared to the other repair mechanisms, DNA repair has been studied the most in relation 
to ageing and lifespan. The DNA repair deficient mouse models that have been generated, dis-
play a common phenotype of segmental premature ageing (progeria), or cancer predisposition, 
or both, and have a reduced lifespan (Hasty et al., 2003). Similarly, in humans, all mutations 
identified in DNA repair genes severely compromise health. For instance, mutations in the com-
ponents of transcription coupled repair (TCR) have been associated with the premature ageing 
syndromes of Cokayne syndrome (CS) and Trichthiodystrophy (TTD) (Cleaver,  2005; Hoeij-
makers,  2001). Likewise, mutations in the RecQ-like DNA helicase genes, WRN, BLM and 
RecQ4 lead to the premature ageing syndromes of Werner-, Blooms-, and Rothmund–Thomson-
Syndrome, respectively (Navarro et al., 2006). In contrast to the strong phenotypes associated 
with mutations in RecQ helicases, common polymorphisms in these genes do not seem to influ-
ence the aging-trajectories and survival in the general population (Bohr et al., 2004; Castro et 
al., 2000; Kuningas et al., 2006). The RecQ helicases are highly conserved throughout evolution, 
but in higher eukaryotes, the different homologues seem to have distinct functions because 
failure of one given RecQ gene cannot be complemented by another RecQ gene. These observa-
tions underpin the importance of DNA repair in all organisms. The key question that has yet to 
be answered is whether subtle variants in the DNA repair genes contribute to different lifespans 
and whether above average repair makes for a lifespan extension.
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Cellular responses to damage
In response to unrepaired damage, cells trigger either apoptosis or cell cycle arrest. The most 
well known protein implicated in the maintenance of genomic stability is p53. Recently, p53 ho-
mologues were identified in C. elegans and D. melanogaster. In contrast to mammalian p53, which 
elicits apoptosis or cell-cycle arrest (Attardi,  2005), the p53 in C. elegans and D. melanogaster affects 
only apoptosis (Brodsky et al., 2004; Derry et al., 2001; Schumacher et al., 2001). Nevertheless, 
in all of these organisms, reduced p53 activity leads to lifespan extension (Bauer and Helfand, 
2006). In mammals, this extension comes at the cost of increased cancer risk (Campisi,  2003). 
In humans, it has been shown that Pro/Pro carriers of the TP53 codon 72 polymorphism have a 
significantly lower apoptotic potential than Arg/Arg carriers, both in p53-inducible human cell 
lines (Dumont et al., 2003; Pim and Banks, 2004; Sullivan et al., 2004) and in normal diploid 
fibroblasts (Bonafe et al., 2004). Later on it was shown that despite an increased mortality from 
cancer, carriers of the same polymorphism have a significantly increased survival at old age in 
line with the experimental models (van Heemst et al., 2005b). Altogether, these observations 
support the hypothesis that reduced p53-mediated induction of apoptosis can have beneficial 
effects on lifespan if tumor formation can be avoided. This might hold true also for other genes 
that mediate cellular responses to damage.
Discussion 
Experiments in model organisms have demonstrated that changes in genes can dramatically 
increase their lifespan. In some cases, mean and maximum lifespan is extended up to fivefold. 
The equivalent life extending effect in humans would result in an average lifespan of 400 years 
and maximum lifespan of over 600 years. Many of the pathways regulating lifespan in model 
organisms are conserved throughout evolution. Why then, have we not yet identified genetic de-
terminants that could increase human lifespan by more than a few years? Are we looking at the 
right genes? Is it fair to expect such dramatic effects? Do we have the tools to observe genetic 
determinants of human lifespan?
Increased complexity 
In vertebrate organisms novel genes and signaling components have appeared during evolu-
tion, contributing to increased complexity of the genomes (Long,  2001). Among several mo-
lecular mechanisms, gene duplication  plays a major role in genome evolution (Britten,  2006; 
Long,  2001). Often, a mammalian genome contains several homologues of a single invertebrate 
gene with similar or distinct functions and expression patterns. This can hinder the assessment 
of the role of a specific candidate gene, since genetic variance in duplicated genes is likely to 
have less dramatic effects than in the original single gene in invertebrate organisms (Conant and 
Wagner, 2004; Gu et al., 2003). Furthermore, since vertebrates have acquired pathways that are 
more diverse, the homologous genes in phylogenetically distant animals could be involved in 
different pathways. 
The genomes of vertebrate organisms also contain genes, which have no homologues in 
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invertebrates. The appearance of novel genes, or “add-ons”, probably contributed to the arise 
of elaborate systems that regulate the activity of the conserved or “shared” genes (Levine and 
Tjian, 2003). The GH control over IGF-1 and the regulation of IR and IGF1-R activity by 
KLOTHO have arisen relatively recently in vertebrate evolution (Forsyth and Wallis, 2002; 
Mian,  1998). Genetic variance in these genes has been associated with lower IIS signaling and 
with increased lifespan, corroborating the findings from invertebrates. However, in these organ-
isms this phenotype was attained by modifying the “shared” genes. This demonstrates that in 
humans, we should not limit ourselves to studying the evolutionarily conserved genes that have 
been implicated in lifespan regulation in invertebrates, but also include, and maybe even focus 
on, “add-ons” that regulate their activity. Taken together, the increased complexity of signaling 
systems in vertebrates adds robustness to the signaling pathways, which is the ability to maintain 
its functions despite changes in its components or environment (Lenski et al., 2003; Soyer and 
Bonhoeffer, 2006). In that respect, lifespan regulation can be regarded as a complex genetic trait, 
for which it is unlikely that single alterations in the genetic machinery will have dramatic effects. 
Furthermore, genes that have appeared later in evolution, “add-ons” are interesting candidates 
to determine longevity in vertebrate organisms.
Environmental influences
Environmental influences have played a major role in shaping and patterning the genomes of 
all organisms throughout evolutionary history. Changes in environment can lead to different ex-
pression of genotypic information, and thereby complicate the comparability of results between 
model organisms and humans. Most research on model organism has been performed under 
laboratory conditions, where temperature, presence of pathogens, food availability and popula-
tion density are tightly controlled. In most cases these conditions poorly mimic the evolutionary 
niche in which the genes come to expression and it may therefore be questioned how well the 
results obtained in these condition are applicable to species under “natural” conditions (Clancy 
et al., 2001; Marden et al., 2003; Walker et al., 2000). 
Even for humans, the environment in which the genome effectively evolved has changed. 
The genes that were originally selected for survival in adverse environments are now expressed 
under completely new, affluent conditions. For instance, the IIS system was selected and fine-
tuned in times when food abundance and famine alternated. The genotypes that increased the 
efficiency to store energy in times of abundance and use these storages in times of famine had 
a survival advantage. In modern Western societies, where food is constantly abundant these 
“thrifty genotypes” lead to increased prevalence of storage diseases, such as obesity and diabe-
tes (Neel,  1962). This reinforces the idea that our population genome has been optimized to 
increase fitness under adverse conditions whereas this need not to be the case under modern 
affluent conditions, the outcome of these new interactions are both unknown and unpredictable. 
Taken together, caution should be taken in extrapolating results on genetic variation obtained 
in model organisms to the human situation, since the environments in which the genes come to 
expression are often markedly different. Moreover, research into human ageing should include 
various environmental conditions that can explain for different phenotypes despite an equal 
genetic background
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Mutants versus natural genetic variants
The majority of candidate genes of longevity have been identified by studies with mutant 
model organisms, such the worm, fruit fly and mouse models. These approaches are extremely 
powerful to disentangle biological pathways. However, to date it is largely unknown to what 
extent these mutations affect fitness in natural environments and whether these candidate loci 
contain genetic variation, which would contribute to phenotypic variance for lifespan in natural 
populations (Figure 1). These questions are of importance since not all candidate loci with major 
effects on longevity in laboratory conditions may exhibit variation in natural populations. Cur-
rently, only few studies have tried to disentangle this question. For instance, it has been shown 
that the long-lived mutant fruit fly methuselah (mth) underperforms in most cases under condi-
tions that resemble more a natural situation (Baldal et al., 2006). This illustrates that the mth 
locus would never have been identified to influence lifespan if natural populations of the fruit fly 
would have been analyzed. A similar observation is obtained for the Chico variant that outlives 
the wild type under food affluence but becomes short lived when exposed to food restricted 
conditions (Clancy et al., 2002). In case of humans, most information on the effect of genetic 
variation on longevity is being obtained by studying naturally occurring variants in candidate 
genes identified in mutant model organisms. Hence, the discrepancy between the data from 
Figure 1. The amount of information obtained from different organisms on genetic mechanisms on 
ageing and longevity. The amount of available information on the effect of genetic variation on life 
span in organisms of different complexity is indicated by the size of the four quadrants. As can be seen, 
in humans most information on the effect of genetic variation on longevity is being obtained by study-
ing naturally occurring variants, while in model organisms, most information on the effect of genetic 
variation on longevity has been obtained by studying the effect of mutations in invertebrate models, 
and, to a lesser extent, in vertebrate models. In contrast, only few studies have analyzed the contribu-
tion of standing natural genetic variation on lifespan in model organisms. The direct translation of 
the importance of candidate genes identified in mutant invertebrate models for variation in human life 
span is complicated by two possible discrepancies. The first includes the influences of mutations and 
standing (subtle) genetic variations in the candidate loci and the second possible discrepancy includes 
the differences in genome complexity between the organisms. 
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mutant model organism and standing genetic variance in natural populations contributes to the 
difficulty of translating results from model organisms to humans (Figure 1). Therefore, to facili-
tate translation of the results from mutant model organisms to humans, the analysis of standing 
variation in the same loci in natural populations of model organisms should be encouraged.
Methodological considerations
The lack of very strong effects of the evolutionarily conserved genes in humans can have 
other reasons than those suggested above. Some of these include study design and methodol-
ogy in human studies. Most of the genetic association studies of longevity have been performed 
in case-control settings, where genotype- or allele frequencies between elderly and a younger 
population are compared. The main advantage of case-control study design is that cases are 
readily obtainable and can be efficiently genotyped and compared with control populations. 
Cases can be nonagenarians, centenarians or long-lived sibpairs. By collecting long-lived sib-
pairs instead of long-lived singletons, an enrichment of genetic factors contributing to longevity 
in this population can be expected, while the likelihood of having reached a long life because 
of exceptional environmental conditions or chance is lower. The difficulty of case-control stud-
ies is in selecting controls. In longevity studies, the ideal control group should be composed of 
participants from the same birth cohort who were not long-lived, to minimize the effect of en-
vironmental differences caused by cohort differences.  However, obtaining such a control group 
is impossible in a retrospective study design. Such case-control studies are only possible if one 
is studying in long-lasting population surveys. The longest ongoing studies (e.g. Framingham 
Heart Study) now allow a difference of 30 years between subjects that survived and those that 
did not. However, in most studies so far, controls have been selected from the general popula-
tion of younger generations. This, can lead to biases where allele frequency differences between 
cases and controls can appear as an association, even if they only reflect the results of changes 
to the source population due to changes in environment, migratory history, gender differences, 
or other independent processes (Cardon and Palmer, 2003; Manolio et al., 2006). An alternative 
approach would be prospective cohort studies, which suffer less from population stratification 
but are more expensive and time-consuming (Manolio et al., 2006).
Another consideration for the methodology includes the selection and analysis of genetic 
variants in the candidate genes. Commonly, a selected number of polymorphisms from the 
coding region of candidate genes are analyzed, leaving aside genetic variants in regulatory re-
gions. In addition, besides analyzing the individual polymorphisms only few studies have under-
taken haplotype analyses. Given the amount of information that has recently become available 
through the International HapMap project, polymorphisms that tag common haplotypes can 
easily be identified. The analysis of haplotypes can be more powerful since this analysis captures 
the joint effect of all unknown gene variants that are in linkage disequilibrium with the markers 
forming the haplotype ( Johnson et al., 2001). 
Finally, similar to other association studies, also the results from longevity association stud-
ies have been rarely replicated. Explanations for lack of reproducibility include poor study de-
sign, small sample size, incorrect assumptions about the underlying genetic architecture, and 
over interpretation of the data. In addition, for a number of associations (mainly negative) no 
replication has been undertaken, leaving open the reproducibility. Replication of even negative 
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results is necessary, since the lack of associations in the first study could likewise have been due 
to poor study design, population stratification or other reasons. Therefore, before discarding a 
candidate gene from the list of possible candidates, replication in different cohorts with more 
thorough genetic analysis is necessary.  
Future directions
Pathway analyses and epigenetic variation
Given the current feasibility of high throughput genotyping and increasing knowledge on 
cellular mechanisms, pathway analyses instead of analyzing individual loci separately could be 
performed. The appropriate tools are likely to be available soon, since the analysis of complex 
traits, which are under the influence of multiple and possibly interacting genes, has become a 
subject of new statistical methodological research (Kristensen et al., 2006). However, besides 
genetic variation, other mechanisms influence the expression of genomic information. For in-
stance, epigenetic modifications, which are differences in gene expression that cannot be ac-
counted for by changes in the primary DNA sequence, have a significant impact on gene func-
tion, and may explain how iso-genetic organisms are phenotypically very distinct. Likewise, a 
different level of transcriptional and post-transcriptional control through RNA interference, or 
other mechanisms, can account for phenotypic differences. These and other modifications con-
tribute to the differences in lifespan between and within species, and this type of information 
from model organisms and humans is essential for the extrapolation of results.
Genes and pathways for future
A number of interesting candidate genes, with or without homologues in model organisms 
remain to be investigated in humans. The most interesting and so far not very thoroughly ana-
lyzed genes in respect to longevity include those involved in fertility. In model organisms, fer-
tility and lifespan are closely linked (Partridge et al., 2005). In C. elegans, ablation of germline 
precursor cells of the gonad abolishes reproduction and extends lifespan (Hsin and Kenyon, 
1999), as do mutations that reduce germline proliferation (Arantes-Oliveira et al., 2002). In D. 
melanogaster, a reduction in fecundity extends lifespan in females (Sgro and Partridge, 1999) and 
long-lived heterozygous chico mutant females exhibit reduced fecundity, with the homozygotes 
being almost sterile (Clancy et al., 2001). In mice, Ames and Snell dwarfs are long-lived and 
sterile (Bartke,  2005). The observational studies in historical human populations living under 
pre-affluent conditions have provided similar evidence. In the English and Finnish aristocracy, 
women with the longest lifespan had the smallest number of offspring (Korpelainen,  2000; 
Westendorp and Kirkwood, 1998). Despite this evidence, the genetic determinants for the trade 
off between fertility and lifespan are unknown.
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Samenvatting
Genetische factoren spelen een belangrijke rol bij variatie in de levensduur van mensen. In de 
afgelopen jaren zijn, vooral in modelorganismen, een aantal genen geïdentificeerd die betrokken 
zijn bij langlevendheid. Een aantal van de geïdentificeerde genen zijn interessante kandidaten 
voor studie naar de snelheid van veroudering en langlevendheid bij de mens.
Hoofdstuk 1 bevat een algemene inleiding met een overzicht van de kandidaatgenen die in 
dit proefschrift zijn onderzocht in relatie met aan leeftijds gerelateerde ziekten en langlevend-
heid. Alle onderzoeken die in dit proefschrift worden beschreven zijn uitgevoerd binnen de 
Leiden 85-plus Studie, een prospectief bevolkingsonderzoek onder de oudste ouderen in de stad 
Leiden. 
Hoofdstuk 2 beschrijft het onderzoek naar de effecten van genetische variatie in de evolu-
tionair geconserveerde genen FOXO1 en FOXO3a op de prevalentie van aan leeftijd gerelateerde 
ziekten en langlevendheid. De humane FOXO1a en FOXO3a genen zijn homoloog aan het daf-
16 gen in Caenorhabditis elegans. Deze genen coderen voor transcriptiefactoren die zowel bij de 
mens als bij C. elegans het belangrijkste doelwit zijn van een door insuline/IGF-1 aangestuurd 
signaaltransductie-systeem. Eerder onderzoek heeft uitgewezen deze signaalroute de activiteit 
van Daf-16 negatief beïnvloeden. Een lager signaal en hogere Daf-16 activiteit zijn geassocieerd 
met een langer leven in verschillende modelorganismen. Bij de mens zijn zowel FOXO1 als 
FOXO3a betrokken bij verschillende cellulaire functies, zoals metabolisme, cel differentiatie en 
reparatie van DNA. Bovendien speelt FOXO1a een specifieke rol bij het effect van insuline op 
de glucoseproductie in de lever. FOXO3a speelt een rol bij de vruchtbaarheid in vrouwen. De 
analyses van genetische variatie in de FOXO1a en FOXO3a genen lieten zien dat deze genen ook 
in de mens bij het reguleren van levensduur betrokken zijn. De genvariaties in FOXO1a bleken 
geassocieerd met een hoger risico op mortaliteit, dat verklaard kon worden door een verhoogde 
sterfte door diabetes. De ouderen die drager waren van een van deze genvariaties hadden ook 
verhoogde HbA1C concentraties, een uiting van een slechtere glucose huishouding en diabetes 
mellitus. Tevens bleken dragers van een variant in het FOXO3a gen een verhoogd sterfterisico te 
hebben, in het bijzonder aan hart- en vaatziekten. Ook het risico op een hartinfarct was groter. 
Anders dan verwacht werd er géén relatie gevonden tussen varianten van het FOXO3a gen en 
metabole parameters of vruchtbaarheid. Deze bevindingen tonen aan dat genetische variatie in 
FOXO1a en FOXO3a invloed heeft op levensduur.
In hoofdstuk 3 en 4 wordt respectievelijk de rol van LXRA en die van VDR op de levens-
duur onderzocht. Beide genen zijn humane homologen van het daf-12 gen in C. elegans. In C. 
elegans is Daf-12 betrokken bij de regulatie van de overgang naar het stress-resistente “dauer” 
stadium, dat wordt geïnduceerd in reactie op nadelige omgevingsinvloeden, zoals voedseltekort. 
Mutaties in het daf-12 gen kunnen leiden tot de vorming van wormen die geen “dauer” stadium 
meer kennen en wormen die permanent in het “dauer” stadium verblijven. Deze wormen zijn 
respectievelijk lang- en kortlevend. Onze genetische analyses van het LXRA gen in de mens 
toonden aan dat een variant van dit gen met een lager risico op mortaliteit is geassocieerd, ge-
kenmerkt door een verminderde sterfte aan infectieziekten. Dragers van deze genvariant had-
den ook hogere concentraties van het apolipoproteine E, waarvan de transcriptie (deels) wordt 
gereguleerd door LXRA, en ook door hogere concentraties van triglyceriden. Deze resultaten 
wijzen erop dat genetische variatie in het LXRA gen via metabole processen invloed heeft op de 
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levensduur van de mens. In hoofdstuk 4 laten we zien dat we géén associaties tussen genetische 
variatie in het VDR gen en levensduur konden aantonen. Variaties in dit gen bleken wel geas-
socieerd met cognitieve functies en met symptomen van depressie, hetgeen suggereert dat het 
VDR gen een rol speelt in cognitieve achteruitgang.
In hoofdstuk 5 worden de resultaten beschreven van onderzoek aan het SIRT1 gen. Dit gen 
is een van de humane homologen van het Sir2 gen van de gist Saccharomyces cerevisiae. Eerder 
onderzoek aan modelorganismen heeft aangetoond dat overexpressie van het Sir2 gen leidt tot 
een langer leven. In zoogdieren is SIRT1 betrokken bij het behoud van neuronen, bij metabo-
lisme, en bij de resistentie van cellen tegen stress. Wij hebben onderzocht of genetische variatie 
in SIRT1 in de mens invloed heeft op sterfte, cognitieve functies en aan leeftijd gerelateerde 
ziekten. De resultaten lieten zien dat een variant van dit gen geassocieerd is met een lager risico 
op mortaliteit als gevolg van hart- en vaatziekten en met cognitieve functies. Ondanks deze 
relaties met het optreden van aan leeftijd gerelateerde ziekte werd géén relatie gevonden met de 
verschillende parameters van het metabole profiel. Deze resultaten kunnen wijzen op een rol van 
SIRT1 in cognitieve functies, maar omdat een associatie met het metabole profiel ontbrak is de 
relatie met langlevendheid onzeker. 
In hoofdstuk 6 hebben we de invloed van het stresshormoon cortisol en van genetische vari-
aties in de mineralocorticoid receptor (MR) en de glucocorticoid receptor (GR) genen op cog-
nitief functioneren en depressieve symptomen bij ouderen geanalyseerd. Cortisol speelt, via de 
MR en GR, een belangrijke rol in de coördinatie van reacties op stress. Aan stress gerelateerde 
ziekten zoals depressie gaan vaak samen met overmatige secretie van cortisol. Verder beïnvloedt 
cortisol ook het cognitief functioneren. Het vermogen om adequaat met stress om te gaan en 
een behoud van een goede geestelijke gezondheid zijn essentieel voor een lang leven. In onze 
studies waren hogere cortisol concentraties geassocieerd met een achteruitgang van globale cog-
nitieve functies bij aanvang van de studie en gedurende de follow-up. De achteruitgang van de 
cognitieve functies kon met name worden toegewezen aan een verminderde concentratie, en aan 
een verlaagde cognitieve snelheid. Er werd echter geen invloed van MR en GR gen varianten op 
cognitieve functies geobserveerd. In tegenstelling tot de cognitieve functies was de prevalentie 
van depressie symptomen van verschillend bij dragers van een of meerdere MR gen varianten. 
Deze resultaten tonen aan dat cortisol een belangrijke rol speelt in cognitief functioneren en dat 
genetische variatie in het MR gen het voorkomen van symptomen van depressie beïnvloedt. 
Eerder onderzoek heeft uitgewezen dat veranderingen in het cortisol signaal ook het risico 
op hart- en vaatziekten beïnvloeden. Hart- en vaatziekten zijn de voornaamste doodsoorzaak 
onder ouderen. In hoofdstuk 7 wordt de invloed geanalyseerd van GR gen varianten op het risico 
op hart- en vaatziekten en op mortaliteit. De resultaten lieten zien dat varianten van het GR gen 
het metabole profiel beïnvloeden, maar niet het risico op hart- en vaatziekten en sterfte op hoge 
leeftijd. De invloed van genetische variaties in het MR gen op het optreden van aan leeftijds 
gerelateerde ziekte en mortaliteit moet nog onderzocht worden.
In 1996 werd het WRN gen geïdentificeerd, dat gemuteerd is bij het Werner syndroom. Het 
Werner syndroom is een zeldzame aandoening, die gepaard gaat met een versnelde, vroegtijdig 
optredende veroudering. De vraag is of subtielere variatie in het WRN gen zou kunnen leiden 
tot een versnelde en/of vroegtijdig optredende veroudering. Daarom hebben we in hoofdstuk 8 
de invloed van veel voorkomende varianten in het WRN gen op veroudering en langlevendheid 
in de algemene populatie onderzocht. Onze analyses toonden géén verschillen in het risico 
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op hart- en vaatziekten, niet in cognitieve functies en niet in het risico op sterfte. In onze stu-
diepopulatie vonden wij dus géén aanwijzingen dat het WRN gen invloed heeft op variatie in 
levensduur.
In Hoofdstuk 9 worden de resultaten van al deze onderzoeken samengevat en in een breder 
perspectief besproken. De studies laten zien dat kandidaatgenen uit experimentele modellen in 
de meeste gevallen aantoonbaar het metabolisme en of het optreden van aan leeftijdsgerelateerde 
ziekten en levensduur bij de mens beïnvloeden. Echter, in vergelijking met de modelorganismen 
zijn de effecten bij de mens veel kleiner. Dit zou verklaard kunnen worden door de grotere 
complexiteit van het humane genoom, of omdat de interacties tussen genen en de omgeving bij 
de mens complexer zijn. Desalniettemin blijkt een strategie waarbij kandidaatgenen uit experi-
mentele modellen voor langlevendheid in de mens worden geanalyseerd een belangrijke bijdrage 
te kunnen leveren aan de identificatie van biologische mechanismen die belangrijk zijn voor het 
optreden van aan leeftijd gerelateerde ziekten en een lange levensduur.
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